Methods
in
Molecular Biology™
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfi...
68 downloads
1639 Views
16MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Methods
in
Molecular Biology™
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For other titles published in this series, go to www.springer.com/series/7651
Chemogenomics Methods and Applications
Edited by
Edgar Jacoby Novartis Institute for Biomedical Research, Basel, Switzerland
Editor Edgar Jacoby Novartis Institute for Biomedical Research Basel, Switzerland
ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-60761-273-5 e-ISBN 978-1-60761-274-2 DOI 10.1007/978-1-60761-274-2 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2009932720 © Humana Press, a part of Springer Science+Business Media, LLC 2009 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Cover illustration: Background art derived from Figure 3 in Chapter 11 Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface Chemogenomics aims toward the systematic identification of small molecules that interact with the products of the genome and modulate their biological function. The establishment, analysis, prediction, and expansion of a comprehensive ligand–target SAR (structure–activity relationship) matrix has followed the elucidation of the human genome and presents a key scientific challenge for the twenty-first century. The annotation and knowledge-based exploration of the ligand–target SAR matrix is then expected to impact science greatly. Progress alongside this challenge without a doubt will contribute to further the fundamental understanding of the biological function of the individual proteins and ultimately provide a basis for the discovery of new and better therapies for diseases. While historically the chemogenomics approach is based on efforts that systematically explore target gene families, today broader in vitro and in silico approaches are available to encompass wider genomes. In this book, experts from academia and industry outline relevant aspects of chemistry, biology, and molecular informatics which are the cornerstones of chemogenomics. General introductory chapters are combined with chapters describing methods and protocols, which are the gold standard of the Methods in Molecular Biology book series. In Chapter 1, Dr. Hans-Peter Nestler from Sanofi-Aventis outlines the concept and advantages of organizing drug discovery in target families. In Chapter 2, Dr. Konstantin Balakin from ChemDiv describes the methods and application of target family-oriented compound library design. In Chapters 3 and 4, Dr. Dirksen Bussiere from Novartis and Prof. Andrea Mozzarelli from the University of Parma, respectively, outline the concepts of drug discovery targeting the purinome and cofactor binding sites in general. In Chapter 5, Prof. Garland Marshall from the Washington University School of Medicine outlines chemogenomics with peptide secondary structure mimetics. In Chapter 6, Dr. Sarma Jagarlapudi from GVK Biosciences describes molecular information systems for knowledge-based discovery. In Chapter 7, our group demonstrates knowledge-based virtual screening approaches with the application to the P53-MDM4 protein–protein interaction. In Chapters 8 and 9, Dr. Michael Keiser from the University of California at San Francisco and Dr. Josef Scheiber from Novartis, respectively, describe the analysis and prediction of the SAR matrix of the comprehensive chemogenomics knowledge space and of the safety profiling knowledge space. In Chapter 10, Dr. Richard Brennan shows the mining of biological pathway data with emphasis on compound protein networks. In Chapters 11 and 12, Prof. Ruben Abagyan from the Scripps Institute and Dr. Bernard Pirard from Novartis, respectively, describe the pocketome engine and molecular interaction field approaches which aim to analyze the target binding sites and the binding modes of the ligands. Finally, in Chapter 13, Dr. Ulrich Schopfer from Novartis describes the logistics of compound management and screening in action, which are essential elements for the experimental generation of the SAR data. While there are many obvious advantages to the herein described approaches, like the emphasis on systematization, a key limitation to the success of chemogenomics approaches is
v
vi
Preface
recognized by the fact that drug discovery is not a totally structured and predictable science. Diversity and serendipity, both in chemistry and in biology, are drivers of many important discoveries. Conversely, the chemogenomics approaches described in this book are today part of the portfolio of the major pharmaceutical companies, and important contributions to drug discovery have been reached in the design of protein kinase inhibitors. All chapter authors are very much acknowledged for their excellent scientific contributions and their willingness to share their insights and strategic viewpoints on chemogenomics which make this book especially interesting to read. I also thank Prof. John M. Walker, the Series Editor, and David Casey from Humana Press, for the invitation to edit this book and for their commitment to dealing with the production work. I am convinced that the content of this book will help to broaden the practical application of chemogenomics concepts in drug discovery, and I hope that you, the reader, will find the book both informative and enjoyable. Basel, Switzerland
Edgar Jacoby
Contents Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
v ix
1 Organizing Bioactive Compound Discovery in Target Families . . . . . . . . . . . . . . H. Peter Nestler 2 Compound Library Design for Target Families . . . . . . . . . . . . . . . . . . . . . . . . . . K.V. Balakin, Y.A. Ivanenkov, and N.P. Savchuk 3 Targeting the Purinome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jeremy M. Murray and Dirksen E. Bussiere 4 Cofactor Chemogenomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ratna Singh and Andrea Mozzarelli 5 Chemogenomics with Protein Secondary-Structure Mimetics . . . . . . . . . . . . . . . Garland R. Marshall, Daniel J. Kuster, and Ye Che 6 Database Systems for Knowledge-Based Discovery . . . . . . . . . . . . . . . . . . . . . . . . Sarma A.R.P. Jagarlapudi and K.V. Radha Kishan 7 Knowledge-Based Virtual Screening: Application to the MDM4/p53 Protein–Protein Interaction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Edgar Jacoby, Andreas Boettcher, Lorenz M. Mayr, Nathan Brown, Jeremy L. Jenkins, Joerg Kallen, Caroline Engeloch, Ulrich Schopfer, Pascal Furet, Keiichi Masuya, and Joanna Lisztwan 8 Off-Target Networks Derived from Ligand Set Similarity . . . . . . . . . . . . . . . . . . . Michael J. Keiser and Jérôme Hert 9 Chemogenomic Analysis of Safety Profiling Data . . . . . . . . . . . . . . . . . . . . . . . . . Josef Scheiber and Jeremy L. Jenkins 10 Network and Pathway Analysis of Compound–Protein Interactions . . . . . . . . . . . Richard J. Brennan, Tatiana Nikolskya, and Svetlana Bureeva 11 The Flexible Pocketome Engine for Structural Chemogenomics . . . . . . . . . . . . . Ruben Abagyan and Irina Kufareva 12 Structure-Based Chemogenomics: Analysis of Protein Family Landscapes . . . . . . Bernard Pirard 13 Hypothesis-Driven Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ulrich Schopfer, Caroline Engeloch, Frank Höhn, Hervé Mees, Jennifer Leeds, Fraser Glickman, Günther Scheel, Sandrine Ferrand, Peter Fekkes, and Martin Pfeifer Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1
vii
21 47 93 123 159
173
195 207 225 249 281 297
317
Contributors Ruben Abagyan • Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA K.V. Balakin • ChemDiv, Inc., San Diego, CA, USA Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Noginsk Area, Moscow Region, Russia Andreas Boettcher • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Richard J. Brennan • GeneGo Inc., Encinitas, CA, USA Nathan Brown • The Institute of Cancer Research, Royal Cancer Hospital, Belmont, Sutton, Surrey, UK Svetlana Bureeva • GeneGo Inc., Encinitas, CA, USA Dirksen E. Bussiere • Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Emeryville, CA, USA Ye Che • Exploratory Medicinal Sciences, Pfizer Global Research & Development, Groton, CT, USA Caroline Engeloch • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Peter Fekkes • Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA Sandrine Ferrand • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Pascal Furet • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Fraser Glickman • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Jérôme Hert • Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA Frank Höhn • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Y.A. Ivanenkov • ChemDiv, Inc., San Diego, CA, USA Chemical Diversity Research Institute (IIHR), Khimki, Moscow Region, Russia Edgar Jacoby • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Sarma A.R.P. Jagarlapudi • GVK Biosciences Pvt. Ltd. S-1, Phase-1, TIE, Balanagar, Hyderabad, India Jeremy L. Jenkins • Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA
ix
x
Contributors
Joerg Kallen • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Michael J. Keiser • Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA K.V. Radha Kishan • GVK Biosciences Pvt. Ltd. S-1, Phase-1, TIE, Balanagar, Hyderabad, India Irina Kufareva • Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA Daniel J. Kuster • Biomedical Engineering, Washington University, St. Louis, MO, USA Jennifer Leeds • Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA Joanna Lisztwan • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Garland R. Marshall • Departments of Biochemistry and Molecular Biophysics and Biomedical Engineering, Washington University, St. Louis, MO, USA Keiichi Masuya • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Lorenz M. Mayr • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Hervé Mees • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Andrea Mozzarelli • Department of Biochemistry and Molecular Biology, University of Parma, Parma, Italy Italian Institute of Biostructures and Biosystems, Parma, Italy Jeremy M. Murray • Department of Protein Engineering, Genentech, Inc., South San Francisco, CA, USA H. Peter Nestler • Sanofi-Aventis Combinatorial Technologies Center, Tucson, AZ, USA Martin Pfeifer • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Bernard Pirard • Computer-Aided Drug Discovery, Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, Switzerland N.P. Savchuk • ChemDiv, Inc., San Diego, CA, USA Günther Scheel • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Josef Scheiber • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Ulrich Schopfer • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland Ratna Singh • Department of Biochemistry and Molecular Biology, University of Parma, Parma, Italy Italian Institute of Biostructures and Biosystems, Parma, Italy
Chapter 1 Organizing Bioactive Compound Discovery in Target Families H. Peter Nestler Summary The sequencing of genomes gave access to the complete set of building blocks for organisms of various species. A plethora of “-omics”-technologies has been developed to investigate the dynamic interactions of the building blocks in order to understand the functioning of living organisms. This has given rise to the clustering of proteins into target families based on the phylogenetic and structural similarities. In this chapter we will discuss how the concept of target families enables to investigate and modulate biochemical function in the quest to chart Chemical and Biological Spaces. Key words: Chemical space, Drug discovery technologies, Privileged motifs, Target families, Fragment screening
1. Introduction Over the last 3 decades, pharmaceutical compound discovery has undergone a dramatic evolution with several paradigm shifts. Originally drug discovery and development were based on pharmacological observation for a small number of compounds. While this process was slow and tedious and limited the numbers of substances that could be evaluated, the relevance of the studies allowed a fast transfer of efficacious compounds to the clinic. The increased understanding of molecular biology and the access to purified proteins triggered the paradigm of target-based drug discovery. The approach took biological reductionism to the extreme in stipulating that the modulation of individual protein activities would allow controlling physiological events and thus exerting a therapeutic effect. The focus on individual proteins Edgar Jacoby (ed.), Chemogenomics, Methods in Molecular Biology, vol. 575 DOI 10.1007/978-1-60761-274-2_1, © Humana Press, a part of Springer Science + Business Media, LLC 2009
1
2
Nestler
simplified the initial testing of compounds and allowed the highthroughput screening of vast compound collections. It was soon realized that the success rate per tested compound was lower than in the original paradigm as these high-throughput screening assays have a high degree of abstraction to the physiological setting. To feed the screening machinery and to respond to increased crowding of intellectual property space, chemists devised combinatorial synthesis methods to quickly populate diverse chemical spaces. Even though the size of the screening collections grew quickly, the number of compounds entering clinical development stagnated. It was soon discovered that the majority of chemical structures present in the screening collections were incompatible with the requirements for successful physiological applications. Studies focused on the property analysis of successful drugs to define the “drug-like” chemical space and thus guide library and compound design (1, 2). In the beginning of the millennium the completion of the sequencing of the human genome constituted a landmark achievement in biological sciences (3). For the first time the complete set of protein building blocks for the human organism was available for pharmacological studies. Early analysis focused on establishing the number of druggable proteins, based on the correlation of binding sites with the guidelines for drug-like chemical space (4–6). While the actual number of druggable targets maybe not clearly defined and estimates range from 1,500 to 10,000 out of 30,000 human genes, the studies revealed the clustering of targets within various protein families (7–9). These insights triggered the concepts of organizing drug discovery aligned along the boundaries of these protein families to find chemical structures that address the structural space offered by biology on a more rational basis. From a managerial standpoint, corporations chose various models for implementation ranging from virtual knowledge networks to dedicated departments to improve the efficiency of their drug discovery efforts (10, 11). In this chapter, the scientific concepts of target-family-oriented drug discovery, also called Chemogenomics, will be discussed and exemplified, focusing more on their general technological applicability than on individual chemical structures.
2. Understanding Biological Space After the sequencing of the human genome, many questions started to be addressed: Which proteins cluster into families and are related on a structural level to each other? Which genes are expressed under which physiological setting and how do their
Organizing Bioactive Compound Discovery in Target Families
3
levels respond to challenges of the system? Are the expressed proteins functionally active, on which ligands do they exert their actions, and is their functioning dependent on their subcellular distribution? Having the blueprint of human physiology available allowed using the repertoire of bioinformatic tools to classify and cluster proteins based on their sequence homology (3). Although this comfortable straightforward picture is complicated by the fact that genes can be expressed in various forms, the target family classifications hold up in a first approximation especially if searching for structural information that helps to address the binding sites crucial for the protein activity. In the initial phase of mining the human proteome for new targets, the bioinformatic efforts took a rather static look at the genomic information. The analysis was based on sequence and structural homology, thereby ignoring the dynamics of biological systems. Proteins do not act as isolated entities but as complexes in an almost overcrowded environment. To exert their biological effect, the individual entities enter dynamic physical interactions with each other, and our textbook knowledge about kinetics and thermodynamics does not necessarily stand up to the task because of the high concentration and high viscosity of the cytoplasmic space. Furthermore, the monitoring of gene expression and protein analysis does not reveal the complete picture about their respective binding partners. Finally, protein actions are coupled and networked with each other in pathways that can either lead to an avalanche-like amplification of signals or feedback-triggered attenuation. One of the prototype cascades is the coagulation of blood, where one protease cleaves multiple molecules of the next downstream protease thus leading to an exponential increase in proteolytic potential and fibrin formation. “Systems Biology” makes an attempt at investigating and modeling these protein pathways and networks. Nonetheless, we are still ignorant about the intricate details of many protein/protein- and protein/ ligand-complexes, such as GPCR-agonist, ion-channel-modulator, or protease-substrate pairs that associate and dissociate in a cell and are responsible for biological activity. Even in cases where we know the respective binding partners, we are a long way from understanding the structural basis and dynamics of these interactions. Structural biology methods such as crystallography and NMR have taught us a lot for soluble proteins such as kinases and proteases, but gaining structural insights on membranebound proteins such as GPCRs and ion channels remains difficult, and the first structures in these protein families only could be determined at the turn of this millennium (12–14). Many of the pathway related challenges are addressed by “Systems Biology,” a concerted effort of informatics, chemistry, and biology. Although the dynamic aspects are crucial for the understanding of biological function, we will focus in this section on the approaches
4
Nestler
to identify physiological and artificial ligands for proteins as well as gaining structural knowledge about their interactions within the target-families.
3. Exploring Chemical Space One of the key aspects of Chemogenomics is to discover small bioactive molecules that allow to selectively modulate the activity of proteins. The expedition through biological space with small molecules has gone through several stages, swiveling between post- and presynthesis selection of chemical structures (15). From a purely empirical level led by phenomenological studies without guidance from structural information, through a phase of strong desire to rationally design drugs, via the high-number trial-and-error games of high-throughput screening and combinatorial chemistry, we have reached today a stage where we believe that organizing the biological space in target families will help us to integrate knowledge and technologies to chart the Chemical Space in an effective manner. One of today’s cornerstones of the synthetic strategies is the preparation of compounds in a libraries’ setting. Historically, the art of chemical synthesis demanded that individual molecules are prepared efficiently with high yield and are extensively characterized. Over decades, more and more complex molecules were prepared by dissecting the target molecule at key reactive bonds, devising strategic options for the assembly, and developing novel reactions to address the synthetic needs (16, 17). While this “Logic of Synthesis” laid the foundation for today’s capabilities to prepare a wide variety of conceivable target structures, it did not provide the numbers of molecules necessary for an efficient investigation of the “biological space.” The resolution of this conundrum required a conceptual rethinking by chemists: Instead of preparing individual “hypothesis-driven” structures with the hope of hitting the jackpot, libraries are based on the assumption of being “biologically naïve” but represent sufficient diversity to allow for the selection of compounds with desired activity. Combinatorial chemistry had raised expectations to solve the challenge of making the complete chemical space available for testing. Yet, it fast quickly realized that this hope was futile. Calculating the numbers of possible chemical structures that would be considered drug-like, e.g., based on carbon, hydrogen, nitrogen, oxygen, sulfur, and phosphorus with molecular weights below 500, estimates reached ballpark figures of 1060(18). Even if we assume that we could represent this space through 1% of the structures, an estimate that is made often for representative
Organizing Bioactive Compound Discovery in Target Families
5
selections from compound sets, we are still looking at 1058 structures. The material requirements for single representation of each structure go beyond the resources available in the known universe. Besides being disillusioned by the numbers, chemists soon recognized that compounds from combinatorial libraries were often inactive or poorly active on biological molecules unless they were derived from known active compounds. The structures were based on chemical feasibility and therefore densely populated the regions of chemical space offered by the scaffolds. With the insight that combinatorial libraries would not be capable of addressing the biological space and would even fall way short of filling the chemical space even within the boundary of molecular weights below 500, the utilization of combinatorial chemistry and parallel synthesis shifted from a diversity approach to densely populating chemical space around proven starting points, compounds with documented biological activity. One approach to solving conundrum is to use existing know ledge of bioactive structural motifs. Literature and databases on marketed drugs provide many of these starting points. Analysis of drugs on the market and development revealed that a limited set of 32 frameworks form the basis of more than 50% of marketed drugs (19). Although this analysis, like all retrospective studies, may be biased toward GPCR activity modulators that represent a significant fraction of drugs on the market, the study underlines two aspects. First, through one and a half centuries of organic synthesis we have explored only a very limited subset of chemical space in our drug discovery efforts, but remaining within this space makes us quite successful. Second, nature may not be as structurally creative and tolerant as could have been assumed and therefore biological space may be not as diverse as envisioned. Beyond these points, the bias toward GPCR ligands may not be as limiting as it may seem as GPCR through their subfamilies are binding a variety of structural motifs, such as nucleotides, lipids, peptides, and small molecule ligands like nicotinic acid or dopamine (20). These ligand types are actually shared with other target families, and therefore the structural motifs from drugs on the market can be transferred to drug discovery of other target families that may seem unrelated at first glance such as nucleotide mimics for kinases and peptide mimics for proteases. Thus molecular frameworks may be the uniting concept between and within target families, and recently studies have reported the clustering of proteins by their small molecule ligands (9, 21). The clustering along binding sites is nothing unique to small molecule ligands. Throughout evolution substrate core motifs have been conserved and thus driven the development of the respective protein family (22). To establish a more detailed analysis of ligand types and target families, so called biospectra have gained importance. To derive biospectra, a defined set of compounds is tested against a set of
6
Nestler
targets in a “full-matrix” layout. These biospectra allow several types of analysis as demonstrated by Fliri et al. on a set of 1,500 compounds and 92 assays. First, proteins can be clustered on the similarity of responses to the compounds (23). As mentioned earlier this may lead to new insights on how to group proteins for accelerating the discovery of bioactive compounds (vide infra). Second, the reactivity patterns can be used to establish similarity relationships between compounds (24). The outcome of the studies underline today’s paradigm that similar ligands bind to proteins with similar binding sites. Taking the data from these experiments opens the way to predict or design new ligands to predefined proteins (25, 26). In the following part of this chapter, several examples of target-family-oriented studies are highlighted in an attempt to emphasize the particular challenges of each target family in the discovery and profiling of bioactive compounds. As the field of Chemogenomics has expanded over the last 5 years, an exhaustive overview of research is beyond the scope of this contribution.
4. Examples of Target Families 4.1. G-Protein-Coupled Receptors (GPCRs)
GPCRs are the target family probably most frequently targeted by drugs on the market, albeit historically based on pharmacological observations without target knowledge. The human genome features several hundred GPCRs, thus making them today favorite targets for drug discovery. Two aspects distinguish GPCRs from other target families, especially the kinases or proteases. First, GPCRs do not possess enzymatic activity by themselves and the availability of structural information is limited. Second, unlike proteases and kinases which affect their enzymatic actions on proteins, many GPCRs bind ligands of small molecular weight. Because of the limited availability of crystal structures of membrane-bound proteins such as GPCRs, the rational design of GPCR-targeting agents relies heavily on design derived from known ligands (12, 13). Structure-based design is dependent on deducing structural information through sequence homologies. For families of soluble protein targets the situation for gaining structural knowledge is quite comfortable. A wealth of crystal structures in free as well as inhibitor-bound forms is available for proteases and kinases, very often for a variety of ligands to each protein. This information is used intensely for inhibitor optimization purposes and allows as well for structural comparisons on a target family level. These analyses are based on structural overlays of the protein structures within the target families, respectively, the subfamilies of proteases, and probing the affinity and repulsion
Organizing Bioactive Compound Discovery in Target Families
7
of various small molecular probes, such as water or methanol, with the active sites surface. The studies provide “target family landscapes” that show the relationships of the target family members on a structural level (21, 27–30). The landscapes provide the tools necessary to understand cross-reactivities of inhibitors with closely related proteins or to assess the likelihood of success for transforming an inhibitor for a particular target into an inhibitor for another family target. Furthermore, they allow selecting closely related proteins as structural surrogates for those family members, where crystallographic information is not available. This so-called homology modeling is of crucial importance for understanding the structural space covered by membrane-bound proteins, such as GPCRs or ion channels (31). Using the rhodopsin GPCR structure (12) as a template and combining it with target family homology knowledge, it has been possible get topological information about the binding sites for many GPCRs to foster understanding of the binding modes of ligands (12). At a resolution of about 3.5 Å which can usually be achieved, it is possible to understand differential binding of ligands to the receptors and to rationalize their activation, as demonstrated by Goddard et al. on a homologous series of ketones activating the olfactory receptor 912–93. Furthermore the differences in activation between mouse and human orthologs could be assigned to a Ser105Gly mutation (32). This study points also to an instrumental aspect for the structural modeling of membrane proteins. In addition to sequence homologies, ligand-binding strengths are used to refine the topologies and interactions. If combined with molecular dynamics refinements of the loops connecting the transmembrane helices as demonstrated by the program PREDICT (33), the accuracy of the models becomes powerful enough to perform virtual screening and to discriminate between ligands and their binding modes (29, 30, 34). Recently the high-resolution crystal structure of the b2-Adrenergic GPCR was reported (35–37). As the receptor is complexed with the partial inverse agonist carazolol, it gives new insights in possible binding interactions and modes of function thus enabling a more refined design of compound libraries targeted as against GPCRs (29, 38). Orphan GPCRs are receptors without known agonistic or antagonistic ligands. As GPCRs are usually identified based on sequence homologies, most of the GPCRs have no pharmacologic function or ligands associated at the time of their identification. To find such ligands and later on elicit a biological response, GPCRs are cloned and overexpressed with linkage to easily detectable reporter genes and screened against collection of known signal transmitters or dedicated libraries. Especially with the evolution of screening technology for GPCRs, it is possible today to deorphan many GPCRs, either with their endogenous ligands or synthetic analogues. The identified ligands give insights
8
Nestler
into the structural requirements for binding, information that can be used to refine aforementioned homology models, and can be used as tools to elucidate the biological functions. The endeavor of deorphaning GPCRs is supported by the existence of many GPCR-targeted drugs and the deorphaning efforts lead often to discovery of GPCRs that are the target for drugs with hitherto unknown mode of action (39–41). As mentioned earlier many of the GPCR-targeted compound discovery efforts are based on cell-based assays with the target GPCR coupled to a gene-expression read-out system. Unfortunately the readout of these systems can be influenced by many factors which are independent of the target action. Consequently, efforts to develop direct affinity screens have attracted some interest for GPCRs. One of the most elegant approaches has focused on size-exclusion chromatography. GPCR-micelle preparations are equilibrated with compound libraries and passed through a size-exclusion column. As the removal of unbound compounds relies on the size difference between small molecules and proteins, this approach was assumed to be quite powerful for screening membrane-bound proteins that are captured in micelles. GPCR/ ligand complexes provide a high molecular size during separation from the small unbound ligands and allowed identifying ligands to the M2-receptor (42). Despite the intellectual appeal of this affinity screen, the elegance of selecting compounds based on a cellular response still tilts the scale toward gene-expression linked cellular screens and allows to progress selected GPCR-ligand comparatively fast through the early stages of drug development. 4.2. Kinases
The insights into structural relationship within target families have reshaped our thinking about library synthesis and high-throughput screening and lead to the concept of focused target family libraries to improve screening efficiency. The concept has been especially valuable in the family of kinases that provide a high structural homogeneity in their ATP-binding pocket. The use of focused screening sets provides – assuming they are properly constructed or selected – multiple advantages. First, the lower numbers of compounds reduce the cost and efforts of screening campaigns and address the throughput limitations of some assay types. Second, high-quality activity data can be gathered from the beginning as the smaller compound numbers allow measuring multiple data points per compound and thus reducing false-positive and -negative occurrence. Third, they provide higher hit rates and thus SAR from the initial screening and thus can give immediate guidance for chemical programs. However, a delicate balance between focused screening and chance for serendipity has to be maintained, especially to address the challenge of discovering novel chemotypes to secure an intellectual property position and to explore novel interfaces of chemical and biological spaces.
Organizing Bioactive Compound Discovery in Target Families
9
Furthermore, the heavy use of privileged scaffolds may lead to an incestuous reinvestigation of established structures. While these privileged scaffolds may be advantageous for the efficiency of optimizing lead structures toward drug candidates as we are moving on known terrain, it also limits our ability to resolve old issues or to find new activities. The paradigm of target families stipulates that similar chemical structures elicit similar biological response, and we base our optimization strategies on this concept (43). On the flipside of the coin we have to take into account that the reverse assumption also will hold true: If two similar molecules cause a similar response on the target, then we have to assume that two structural similar targets respond to a molecule in a similar way. Especially for kinases, the prototypic target family, we observe this phenomenon with significant activities of one compound on several kinases. Most known kinase inhibitors act as competitors of ATP, the universal cosubstrate for all kinases, and therefore frequent hitters are quite common in high-throughput screening of kinase inhibitors (44, 45). In a recent investigation the binding affinities of 20 structurally diverse kinase inhibitors that are in clinical trials or marketed drugs were investigated against a panel of 113 kinases distributed across the kinome. The study highlights that even “selectivity”-optimized kinase inhibitors are a long way from being selective and hit targets across the kinome (46). The kinome maps are phylogenetic trees based on sequence similarities, and we discussed the shortcomings of phylogenetic analysis for high-resolution structural grouping before. Inhibition profiles of series of compounds can give us guidance for structural clustering of kinases that is necessary to devise selective and potent inhibitors (21). Because of their prototypic characteristics and structural homogeneity, kinases serve also as the workhorses for developing or revisiting predictive approaches. In a recent example, 700 compounds from two libraries with different chemotypes were tested against a panel of 45 kinases. Neither the combinatorial matrices in the libraries nor the testing on the kinase panel was exhaustive. Nonetheless the available data allowed to successfully build refined increment systems for the prediction of activities and specificities on each of the kinases and missing compounds using Free-Wilson analysis (47), a methodology developed 40 years ago for the QSAR of small medicinal chemistry series (48). Beyond the problems that may arise through the polyenzymology of kinase inhibitors, we also have to take into consideration that privileged motifs may also lead to “privileged problems” for drug development in pharmacological and toxicological studies. As the compounds derived from focused screening set share high structural similarities, the different substitutions may not sufficiently modulate the metabolic lability of the scaffolds or suppress unwanted interactions with proteins even from unrelated families. For kinases, the ensemble of active sites provides an enveloping shape for the ATP-binding pocket that can be addressed through
10
Nestler
screening (27). To address the differences of the binding pockets in various kinases, affinity screens with small molecular probes have gained considerable attention. Because of the very compact binding site in kinases, fragment-based assays have been quite successful in exploiting the differences of the binding sites. As described for the GPCRs earlier, one of the promising concepts couples the equilibration of molecular fragments and proteins with a size-exclusion filtration to remove unbound library members before determining the ligands bound to target proteins by mass spectrometry (49). A family experiment using several JNK-kinases thus provided selective inhibitors with nanomolar activities and molecular weights starting at around 350 Da (50). Unlike the GPCRs, kinases are soluble proteins and usually can be cocrystallized with ligands. Even low affinity molecules may yield crystals of the kinase/ligand complex. As the information content of such cocrystal structures is very high, they have been used commonly in the optimization of inhibitors and recently found a new application in the screening for kinases inhibitors. Starting from privileged scaffolds for the ATP pocket of kinases, fragments binding to p38 MAP kinase and CDK2 were discovered, that can serve as novel central building blocks for kinase inhibitors (51). As the throughput of crystallography is still limited compared to biochemical screenings, collection sizes have to be small or as in the previous example, mixtures of fragments have to be screened. To expand the size of collections that can be screened by crystallography, Congreve et al. devised a dynamic combinatorial library system using cyclin-dependent kinase 2 (“CDK2”). Protein crystals act as selectors for the tightest binding ligands which are formed from the condensation of isatin and hydrazines. Instead of equilibrating with a large amount of template protein, the reaction mixture is exposed to individual crystals of CDK2 guiding the selective formation of imino-indolones. The structures of selected reaction products are determined by crystallography, immediately establishing a binding mode for the nanomolar inhibitors of CDK2 (52). Using the information gained on the fragments, they can be extended from a central scaffold (usually one that has shown its suitability to yield kinase inhibitors) into the side pockets of the ATP-binding site to improve selectivity and activity. The growth of inhibitors has been demonstrated in the case of growing nonnucleotide binders into the nucleotide-binding pocket of adenosine kinase (53, 54). Because of the low molecular weight of the fragments which allow the addition of structural elements to tune activity and specificity, fragment-based screenings have found their way into many areas of bioactive compound discovery across target families (55–57). 4.3. Proteases
Tracking protease activity remains one of the major challenges as gene expression levels do not correlate tightly with the activity of a protease. Even monitoring tools like in situ hybridization
Organizing Bioactive Compound Discovery in Target Families
11
cannot elucidate the protease activity in tissues or cellular systems, because the antibodies employed for the studies often do not discriminate between the proenzyme and active protease. Efforts to image protease activity in cells yielded to activity labeling probes, which act as suicide substrates and provide a fluorescent tagging of the active site of active proteases (58, 59). Originally it was believed that this technology would be limited to proteases that allow for covalent attachment of the probes, i.e., serine and cysteine proteases that act through a nucleophilic substitution, to limit the diffusion of the fluorescent molecule in the cells or organisms in order to achieve a sufficient signal for imaging (60). Some recent papers support however the knowledge that covalent attachment to the protease is not needed, but linking the fluorophor to a carrier may give sufficient signal intensity for in vivo imaging purposes (61–63). Most recently Watzke et al. could show that even small diffusible fluorophores provide sufficient intensity for detecting protease activity in living systems (64). In an interesting twist to the traditional design of the probes starting from the substrate peptide, they utilize a “reverse design” to derive the probes from known highly selective Cathpesin inhibitors by introducing a cleavable bond in the center of the scaffold to achieve higher specificity of detection. Unfortunately, none of these probes addresses the other problem of protease-directed pharmacology: revealing the proteins that are cleaved by the protease. Straightforward labeling approaches as utilized to discover kinase substrates are not feasible because no additional moieties are introduced. Therefore, alternate approaches based on two-dimensional gel electrophoresis have been devised that allow either the differential labeling of substrates or utilize the differential mobility of substrates and cleavage products after digestion. The identities of the proteins are determined by mass spectrometry and sequence analyses, although these technologies do not reach a resolution that would allow determining the characteristics of the protease selectivity pockets. For the first approach, cell extracts are divided into two parts and in each portion the proteins are labeled with a fluorescent dye, using different dyes for the portions. One fraction is subjected to proteolytic digestion, while the other fraction remains untreated. After mixing of the portions and electrophoretic separation, substrates can be identified through the varying color of the spots (65). In the second approach, a cellular extract is separated by electrophoresis in one dimension. After proteolytic digestion in the gel, the protein mixture is separated in the second dimension where the cleavage products show a different mobility from the parent proteins (66). While the first approach allows for analysis on a proteomic level and under various conditions, the latter allows a direct correlation of the cleavage peptides to the parent proteins. We use the insights into the biological space
12
Nestler
of the target families to select screening collections as well as to define specificity requirements for target family members to build appropriate profiling panels. To gain a more detailed insight into the structural parameters controlling substrate selections, peptide libraries have been used intensely. Proteolytic digestion of such libraries that commonly contain hexa- to octapeptides returns ensembles of peptide substrates (67, 68). These substrate ensembles carry pharmacophoric information of the substrate pockets as well as on specificity of these pockets. Together with the knowledge about the preferred ß-strand geometry of protease inhibitors (69) and the ensuing privileged scaffolds this information can guide protease inhibitor design (70). Peptidomimetic approaches are heavily used to build protease inhibitor scaffolds. Selective protease inhibitors are quite straightforward to be obtained because of the substrate variety and specificity of the proteases. However, the concept of privileged scaffolds does not carry far for proteases. The unifying element in protease substrates is the extended beta-strand conformation that allows interactions with four to six subpockets in the protease active site (69). Mimics for this conformation have been developed but they still lack universal applicability for the transfer into clinical application (70). Unlike the scaffolds for kinase or GPCR ligands, the cores of protease inhibitors, such as the peptidic backbone in the substrate, do not contribute the majority of binding energy and are therefore not crucial for affinity to the target (although they may severely affect the pharmacokinetic properties of the inhibitors). The energetic drivers of protease/inhibitor binding are the interactions in the subpockets, determining activity and selectivity of the inhibitors. Recently, these pockets are probed directly with molecular fragments that are conjugated to each other upon showing affinity to the targets. The structure-focused concept for fragment screening tries to extract as much structural information from the initial interaction experiment and relies on either NMR or crystallography, paying for the increased information content with a limitation in throughput. The door to these experiments was pushed wide open when Fesik and colleagues reported the successful screening of small molecular fragments against the S1¢ pocket of stromelysin (matrix metalloprotease 3). Using biaryl systems, they could show that the resonances in NMR spectra shifted when the molecule fragments bound to the protein. Conjugating these fragments with hydroxamic acid, a potent zinc chelator, provided compounds with nanomolar affinities (71). The elegance and potential of fragment-based screening approaches was underlined by a detailed investigation of the thermodynamics of the interactions (72). Using the NMR-fragment screening but another fragment set, high affinity inhibitors with novel structural motifs were discovered from a small set of fragments for urokinase, wherein the deep S1-specificity pocket served as anchoring point for the ligands (73).
Organizing Bioactive Compound Discovery in Target Families
13
Starting from these anchors the ligands were grown into the S2, S3, and S4 pockets of the enzyme. Biochemical data as well as structural information from NMR experiments guided the optimization toward selective and nanomolar inhibitors (74). The structural-based fragment screenings are a powerful way for the design of compounds and the evaluation of small compound sets. High-throughput screening of large collections depends on faster – less information-rich – readouts. Although the affinity of small fragments is sufficient for detection and quantification, the interaction strengths are usually too weak to be reliably detected in the high-throughput enzymatic assays, which depend on the competition of inhibitors with the substrate. Therefore a high-throughput affinity detection technology is required for the screening of larger fragment collections. Surface Plasmon Resonance (“SPR”) offers the advantage of fast and label-free affinity detection, meaning that no additional modification of the analyte is needed. Attaching the fragments on an SPR array allows the simultaneous testing of thousands of fragments and the ability to combinatorially synthesize small ligands conjugated to surface attachment tags allow the convenient preparation of such arrays (75). As the strength of SPR response depends on the changes of molecular weight on the resonance surface, capturing a protein with a small ligand provides a favorable signal-to-background ratio. Recently, the search for fragments binding to the S1-specificity pocket of the serine protease Factor VIIa yielded haloaromatic moieties that can substitute for the well-known but undesired benzamidine as anchor. Haloaromatic moieties had been known as ligands to the benzamidine-binding S1-pockets of the S1-clan serine proteases, such as Factor Xa or thrombin. This knowledge guided the design for a library of approximately 1,500 small-size fragments, which were immobilized on a microarray. Affinity screening with Factor VIIa identified several small ligands and their interaction in the S1-pocket could be confirmed by crystallography using trypsin as a surrogate for faster crystallographic screening and reconfirmation of the binding in Factor VIIa (76).
5. Beyond the Original Target Families: Addressing Toxicology and ADME
The discovery and optimization of compounds against therapeutical target is the obvious application of target family knowledge. Nonetheless, the discovery and development of pharmacological agents is more often than not challenged by unwanted side effects of the compounds. The methods described earlier can as well be utilized to optimize compounds to be nonreactive against unwanted targets. One of the prime “antitargets” is the hERG channel. The hERG channel, a voltage-gated potassium ion channel located in cardiac
14
Nestler
tissue, is responsible for membrane depolarization and is of general pharmacological interest because blocking this channel can induce fatal atrial fibrillation through prolongation of the QT-cardiac interval (77, 78). In the ion channel field, homology models can be based on three crystal structures of various potassium channels, two of which show the channel in the open (13, 14) and one in the closed state (79). Although ion channels are multimeric proteins and structurally more diverse than GPCRs, good models have become available using the three structures and ligand-activity information, as highlighted by the possibility of predicting hERG blocking activity of ligands (77, 80). Because of the importance of the hERG channel, a lot of biological data are available and the homology-based models, even though they are built on the bacterial MthK channel (13), have meanwhile reached the same accuracy as models derived from structure– activity relationship data (81) and can guide chemical optimization to achieve specificity of ligands. Beyond the prediction of ligand binding, homology models help in the functional analysis of ion channels. In a recent example, the gating of the Kir6.2 channel by ATP could be explained at atomic level (82) utilizing the structures of the open Kir3.1 channel (14) and the closed KirBac1.1 channel (79). Another major class of undesired targets is the Cytochrome P450 family (“CYP”). CYPs are mitochondrial proteins responsible for the oxidative metabolism of compounds. Their activity is dependent on a heme molecule bound to the active site. Even though the human genome contains about 60 P450s, about than 90% of all drugs are metabolized via five main CYP isoforms: CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, the latter often being the main route of initial oxidation. Inhibition and/or induction of CYP isoforms by one drug can cause major changes in the metabolism rates of other drugs thus causing various adverse drug interactions, e.g., loss in therapeutic efficacy through faster degradation or drug toxicity by route of unexpected accumulation of drugs. Based on crystal structures of the isoforms complex to various drugs, models have been developed to allow the rationalization of drug interactions with CYPs (83, 84). Starting from these insights efforts are underway to develop general structural descriptors to predict metabolism as well as those parameters of pharmacokinetics that we cannot yet explain on a structural level (85).
6. Epilogue Over the last decade Chemogenomics and its subaspect of target families have reshaped our ways of doing drug discovery and medicinal chemistry (86–88). The rationalization of small molecules acting
Organizing Bioactive Compound Discovery in Target Families
15
as the keys to unlock the activity of proteins served as a starting point into molecular biology (89, 90). The investigations of the structural characteristics of target families allow us today to take a more rational approach toward selecting appropriate compounds for synthesis and testing. Through the sequencing of the human genome, we have the blueprint of the building blocks of life that we can modulate in their interactions through therapeutics (3). Our learning about molecular characteristic that provide favorable pharmacokinetic characteristics of molecules in the human body has established guidelines and boundaries for molecules that help us to navigate the chemical space in regions that offer a higher population of structures that may be suitable as drugs (1). While many of the concepts of the target family approach may not be novel to a medicinal chemist if considered in isolation, their conscious combination adds another dimension: “Chemical Biology” is based on a thorough structural knowledge of similarities and differences within a target family. Today’s structural understanding also allows us to make more sophisticated choices about investigations to prevent side effects, and the increasing biological knowledge helps us to rationalize side effects of drugs and to modify affected drugs accordingly. However, we still run into the trap of building assay schemes for drug discovery that allow high throughput and are self-consistent. The high-throughput design sacrifices the biochemical mimicking of the cellular environment, such as the mentioned high concentration and viscosity, for technical feasibility. The self-consistency leads often to the risk of losing the relevance for the pathophysiological phenomenology and thus jeopardizes the predictivity for the therapeutic setting, being detached from reality like the “Hessian glass bead game” (91). Eventually “Systems Biology” will elucidate how the building blocks of life work together in networks and pathways and which results can be expected by tweaking one dial in the systems, leading to novel and powerful assay setups. Once we have established the tools for highcontent screening, we may be set to tackle the challenge to address complex organisms in a rational manner. To date the interplay of various organs and cell types combined with the ever-changing concentrations of compounds at the locus of action is not understood. The challenge for drug discovery will be the discovery of bioactive compounds for application in the dynamic universe of Chemical and Biological Spaces and Networks. References 1. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23, 3–25. 2. Veber, D.F., Johnson, S.R., Cheng, H.-Y., Smith, B.R., Ward, K.W., and Kopple, K.D.
(2002) Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615–2623. 3. Venter, J.C., Adams, M.D., Myers, E.W., et al. (2001) The sequence of the human genome. Science 291, 1304–1351. 4. Drews, J. (2000) Drug discovery: A historical perspective. Science 287, 1960–1963.
16
Nestler
5. Hopkins, A.L, and Groom, C.R. (2002) The druggable genome. Nat. Rev. Drug Discov. 1, 727–730. 6. Overington, J.P., Al-Lazikani, B., and Hopkins, A.L. (2006) How many drug targets are there? Nat. Rev. Drug. Discov. 5, 993–996. 7. Russ, A.P., and Lampel, S. (2005) The druggable genome: An update. Drug. Discov. Today 10, 1607–1610. 8. Hajduk, P.J., Huth, J.R., and Tse, C. (2005) Predicting protein druggability. Drug Discov. Today 10, 1675–1682. 9. Paolini, G.V., Shapland, R.H.B., van Hoorn, W.P., Mason, J.S., and Hopkins, A.L. (2006) Global mapping of pharmacological space. Nat. Biotechnol. 24, 805–815. 10. Narayanan, V.K., Douglas, F., Schirlin, D., Wess, G., and Giesing, D. (2004) Virtual communities as an organizational mechanism for embedding knowledge in drug discovery: The case of chemical biology platform. J. Business Chem. 1, 37–47. 11. Douglas, F.L. (2007) Managerial challenges in implementing chemical biology platforms. In: Schreiber, S.L., Kapoor, T.M., and Wess, G. (eds.) Chemical Biology: From Small Molecules to Systems Biology and Drug Design. Wiley-VCH, Weinheim, pp. 789–803. 12. Palczewski, K., Kumasaka, T., Hori, T., et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739–745. 13. Jiang, Y., Lee, A., Chen, J., Cadene, M., Chait, B.T., and MacKinnon, R. (2002) Crystal structure and mechanism of a calcium-gated potassium channel. Nature 417, 515–522. 14. Nishida, M., and MacKinnon, R. (2002) Structural basis of inward rectification: Cytoplasmic pore of the G protein-gated inward rectifier GIRK1 at 1.8.ANG. resolution. Cell 111, 957–965. 15. Eschenmoser, A. (1994) One hundred years of the lock-and-key principle. Angew. Chem. Int. Ed. Engl. 33, 2363. 16. Woodward, R.B. (1972) Recent advances in the chemistry of natural products (Nobel Lecture, December 11, 1965). In: Nobel Foundation (ed.) Nobel Lectures, Chemistry 1963–1970. Elsevier, Amsterdam, pp. 100–121. 17. Corey, E.J. (1991) The logic of chemical synthesis: Multistep synthesis of complex carbogenic molecules. (Nobel lecture). Angew. Chem. Int. Ed. Engl. 30, 455–465. 18. Bohacek, R.S., McMartin, C., and Guida, W.C. (1996) The art and practice of struc-
19.
20.
21.
22.
23.
24.
25.
26. 27.
28.
29. 30.
ture-based drug design: A molecular modeling perspective. Med. Res. Rev. 16, 3–50. Bemis, G.W., and Murcko, M.A. (1996) The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887– 2893. Bondensgaard, K., Ankersen, M., Thogersen, H., Hansen, B.S., Wulff, B.S., and Bywater, R.P. (2004) Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem. 47, 888–899. Vieth, M., Higgs, R.E., Robertson, D.H., Shapiro, M., Gragg, E.A., and Hemmerle, H. (2004) Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697, 243–257. Chiang, R.A., Sali, A., and Babbitt, P.C. (2008) Evolutionarily conserved substrate substructures for automated annotation of enzyme superfamilies. PLoS Comput. Biol. 4, e1000142. Fliri, A.F., Loging, W.T., Thadeio, P.F., and Volkmann, R.A. (2005) Biospectra analysis: Model proteome characterizations for linking molecular structure and biological response. J. Med. Chem. 48, 6918–6925. Fliri, A.F., Loging, W.T., Thadelo, P.F., and Volkmann, R.A. (2005) Biological spectra analysis: Linking biological activity profile to molecular structure. Proc. Natl. Acad. Sci. U.S.A. 102, 261–265. Bender, A., Young, D.W., Jenkins, J.L., Serrano, M., Mikhailov, D., Clemons, P.A., and Davies, J.W. (2007) Chemogenomic data analysis: Prediction of small-molecule targets and the advent of biological fingerprints. Comb. Chem. High Throughput Screen. 10, 719–731. Bajorath, J. (2008) Computational analysis of ligand relationships within target families. Curr. Opin. Chem. Biol. 12, 352–358. Naumann, T., and Matter, H. (2002) Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: Target family landscapes. J. Med. Chem. 45, 2366–2378. Matter, H., and Schwab, W. (1999) Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins. J. Med. Chem. 42, 4506–4523. Klabunde, T. (2007) Chemogenomic appro aches to drug discovery: Similar receptors bind similar ligands. Br. J. Pharmacol. 152, 5–7. Klabunde, T., and Hessler, G. (2002) Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 3, 928–944.
Organizing Bioactive Compound Discovery in Target Families
31. Radestock, S., Weil, T., and Renner, S. (2008) Homology model-based virtual screening for GPCR ligands using docking and targetbiased scoring. J. Chem. Inf. Model. 48, 1104–1117. 32. Hummel, P., Vaidehi, N., Floriano, W.B., Hall, S.E., and Goddard, W.A. III. (2005) Test of the binding threshold hypothesis for olfactory receptors: Explanation of the differential binding of ketones to the mouse and human orthologs of olfactory receptor 912–93. Protein Sci. 14, 703–710. 33. Shacham, S., Marantz, Y., Bar-Haim, S., Kalid, O., Warshaviak, D., Avisar, N., Inbal, B., Heifetz, A., Fichman, M., Topf, M., Naor, Z., Noiman, S., and Becker, O.M. (2004) PREDICT modeling and in-silico screening for G-protein coupled receptors. Proteins 57, 51–86. 34. Becker, O.M., Marantz, Y., Shacham, S., Inbal, B., Heifetz, A., Kalid, O., Bar-Haim, S., Warshaviak, D., Fichman, M., and Noiman, S. (2004) G protein-coupled receptors: In silico drug discovery in 3D. Proc. Natl. Acad. Sci. U.S.A. 101, 11304–11309. 35. Rosenbaum, D.M., Cherezov, V., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Yao, X.J., Weis, W.I., Stevens, R.C., and Kobilka, B.K. (2007) GPCR engineering yields high-resolution structural insights into beta 2-adrenergic receptor function. Science 318, 1266–1273. 36. Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Kuhn, P., Weis, W.I., Kobilka, B.K., and Stevens, R.C. (2007) High-resolution crystal structure of an engineered human beta 2-adrenergic G proteincoupled receptor. Science 318, 1258–1265. 37. Rasmussen, S.G., Choi, H.J., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., Edwards, P.C., Burghammer, M., Ratnala, V.R., Sanishvili, R., Fischetti, R.F., Schertler, G.F., Weis, W.I., and Kobilka, B.K. (2007) Crystal structure of the human beta 2 adrenergic G-protein-coupled receptor. Nature 450, 383–387. 38. Jacoby, E., Bouhelal, R., Gerspacher, M., and Seuwen, K. (2006) The 7 TM G-proteincoupled receptor target family. ChemMedChem 1, 760–82. 39. Civelli, O. (2005) GPCR deorphanizations: The novel, the known and the unexpected transmitters. Trends Pharmacol. Sci. 26, 15–19. 40. Chung, S., Funakoshi, T., and Civelli, O. (2007) Orphan GPCR research. Br. J. Pharmacol. 153(S1), S339–S346.
17
41. Levoye, A., and Jockers, R. (2008) Alternative drug discovery approaches for orphan GPCRs. Drug Discov. Today 13, 52–58. 42. Hou, Y., Felsch, J., Annis, A., et al. (2002) Identification of Small Molecule Ligands for G Protein Coupled Receptor Using Affinity Selection Screening. GPCR IBC Conference 2002. 43. Martin, Y.C., Kofron, J.L., and Traphagen, L.M. (2002) Do structurally similar molecules have similar biological activity? J. Med. Chem. 45, 4350–4358. 44. Aronov, A.M., McClain, B., Moody, C.S., and Murcko, M.A. (2008) Kinase-likeness and kinase-privileged fragments: Toward virtual polypharmacology. J. Med. Chem. 51, 1214–1222. 45. Aronov, A.M., and Murcko, M.A. (2004) Toward a pharmacophore for kinase frequent hitters. J. Med. Chem. 47, 5616–5619. 46. Fabian, M.A., Biggs, W.H., Treiber, D.K., et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329–336. 47. Free, S.M., and Wilson, J.W. (1964) A mathematical contribution to structure-activity relationships. J. Med. Chem. 7, 395–399. 48. Sciabola, S., Stanton, R.V., Wittkopp, S., et al. (2008) Predicting kinase selectivity profiles using Free-Wilson QSAR analysis. J. Chem. Inf. Model. 48, 1851–1867. 49. Dunayevskiy, Y.M., Vouros, P., Wintner, E.A., Shipps, G.W., Carell, T., and Rebek, J. Jr. (1996) Application of capillary electrophoresis-electrospray ionization mass spectrometry in the determination of molecular diversity. Proc. Natl. Acad. Sci. U.S.A. 93, 6152–6157. 50. Agnihotri, G., Scott, M.P., Alaoui-Ismaili, M.H., et al. (2004) Identification of Potent Inhibitors of c-Jun N-terminal Kinase-1 (JNK1) using Ultra High-Throughput Affinity Based Screening. 12th Symposium on Second Messengers and Phospho-proteins (SMP-2004). 51. Hartshorn, M.J., Murray, C.W., Cleasby, A., Frederickson, M., Tickle, I.J., and Jhoti, H. (2005) Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 48, 403–413. 52. Congreve, M.S., Davis, D.J., Devine, L., et al. (2003) Detection of ligands from a dynamic combinatorial library by X-ray crystallography. Angew. Chem. Int. Ed. Engl. 42, 4479–4482. 53. Hajduk, P.J., Bures, M., Praestgaard, J., and Fesik, S.W. (2000) Privileged molecules for
18
54.
55. 56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
Nestler protein binding identified from NMR-based screening. J. Med. Chem. 43, 3443–3447. Hajduk, P.J., Gomtsyan, A., Didomenico, S., et al. (2000) Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 43, 4781–4786. Nestler, H.P. (2005) Combinatorial chemistry and fragment screening - two unlike siblings? Curr. Drug Discov. Technol. 2, 1–12. Congreve, M., Chessari, G., Tisi, D., and Woodhead, A.J. Recent developments in fragment-based drug discovery. J. Med. Chem. 51, 3661–3680. Degen, J., Wegscheid-Gerlach, C., Zaliani, A., and Rarey, M. (2008) On the art of compiling and using ‘drug-like’ chemical fragment spaces. ChemMedChem. 3, 1503–1507. Greenbaum, D.C., Arnold, W.D., Lu, F., et al. (2002) Small molecule affinity fingerprinting a tool for enzyme family subclassification, target identification, and inhibitor design. Chem. Biol. 9, 1085–1094. Greenbaum, D., Baruch, A., Hayrapetian, L., Darula, Z., Burlingame, A., Medzihradszky, K.F., and Bogyo, M. (2002) Chemical approaches for functionally probing the proteome. Mol. Cell. Proteomics 1, 60–68. Blum, G., Degenfeld, G.V., Merchant, M.J., Blau, H.M., and Bogyo, M. (2007) Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3, 668–677. Zacharakis, G., Kambara, H., Shih, H., Ripoll, J., Grimm, J., Saeki, Y., Weissleder, R., and Ntziachristos, V. (2005) Volumetric tomography of fluorescent proteins through small animals in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 18252–18257. Jaffer, F.A., Tung, C.H., Gerszten, R.E., and Weissleder, R. (2002) In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler. Thromb. Vasc. Biol. 22, 1929–1935. Mahmood, U., Tung, C.H., Bogdanov, A. Jr., and Weissleder, R. (1999) Near-infrared optical imaging of protease activity for tumor detection. Radiology 213, 866–870. Watzke, A., Kosec, G., Kindermann, M., et al. (2008) Selective activity-based probes for cysteine cathepsins. Angew. Chem. Int. Ed. Engl. 47, 406–409. Bredemeyer, A.J., Lewis, R.M., Malone, J.P., et al. (2004) A proteomic approach for the discovery of protease substrates. Proc. Natl. Acad. Sci. U.S.A. 101, 11785–11790.
66. Nestler, H.P. and Doseff, A. (1997) A two-dimensional, diagonal sodium dodecyl sulfate polyacrylamide gel electrophoresis technique to screen for protease substrates in protein mixtures. Anal. Biochem. 251, 122–125. 67. St. Hilaire, P.M., Willert, M., Juliano, M.A., Juliano, L., and Meldal, M. (1999) Fluorescence-quenched solid phase combinatorial libraries in the characterization of cysteine protease substrate specificity. J. Comb. Chem. 1, 509–523. 68. Meldal, M. (2002) The one-bead two-compound assay for solid phase screening of combinatorial libraries. Biopolymers 66, 93–100. 69. Tyndall, J.D.A., Nall, T., and Fairlie, D.P. (2005) Proteases universally recognize beta strands in their active sites. Chem. Rev. 105, 973–999. 70. Leung, D., Abbenante, G., and Fairlie, D.P. (2000) Protease inhibitors: Current status and future prospects. J. Med. Chem. 43, 305–341. 71. Hajduk, P.J., Sheppard, G., Nettesheim, D.G., et al. (1997) Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 119, 5818–5827. 72. Olejniczak, E.T., Hajduk, P.J., Marcotte, P.A., et al. (1997) Stromelysin inhibitors designed from weakly bound fragments: Effects of linking and cooperativity. J. Am. Chem. Soc. 119, 5828–5832. 73. Hajduk, P.J., Boyd, S., Nettesheim, D., et al. (2000) Identification of novel inhibitors of urokinase via NMR-based screening. J. Med. Chem. 43, 3862–3866. 74. Wendt, M.D., Rockway, T.W., Geyer, A., et al. (2004) Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. J. Med. Chem. 47, 303–324. 75. Metz, G., Ottleben, H., and Vetter, D. (2003) Small molecule screening on chemical microarrays. In: Böhm, H.J., and Schneider, G. (eds.) Protein-Ligand Interactions, From Molecular Recognition to Drug Design. Wiley-VCH, Weinheim, pp. 213–236. 76. Dickopf, S., Frank, M., Junker, H.D., et al. (2004) Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa. Anal. Biochem. 335, 50–57. 77. Mitcheson, J.S., Chen, J., Lin, M., Culberson, C., and Sanguinetti, M.C. (2000) A structural basis for drug-induced long QTsyndrome. Proc. Natl. Acad. Sci. U.S.A. 97, 12329–12333.
Organizing Bioactive Compound Discovery in Target Families
78. Haverkamp, W., Breithardt, G., Camm, A.J., et al. (2000) The potential for QT prolongation and proarrhythmia by nonantiarrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur. Heart J. 21, 1216–1231. 79. Kuo, A., Gulbis, J.M., Antcliff, J.F., et al. (2003) Crystal structure of the potassium channel KirBac1.1 in the closed state. Science 300, 1922–1926. 80. Pearlstein, R.A., Vaz, R.J., Kang, J., et al. (2003) Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 13, 1829–1835. 81. Aronov, A.M. (2005) Predictive in silico modeling for hERG channel blockers. Drug Discov. Today 10, 149–155. 82. Antcliff, J.F., Haider, S., Proks, P., Sansom, M.S.P., and Ashcroft, F.M. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. EMBO J. 24, 229–239. 83. Jensen, B.F., Vind, C., Padkjar, S.B., Brockhoff, P.B., and Refsgaard, H.H.F. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J. Med. Chem. 50, 501–511.
19
84. Kontijevskis, A., Komorowski, J., and Wikberg, J.E. (2008) Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors. J. Chem. Inf. Model. 48, 1840–1850; PMID: 18693719. 85. Gleeson, M.P. (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51, 817–834. 86. Wess, G., Urmann, M., and Sickenberger, B. (2001) Medicinal chemistry: Challenges and opportunities. Angew. Chem. Int. Ed. Engl. 40, 3341–3350. 87. Mueller, G. (2003) Medicinal chemistry of target family-directed masterkeys. Drug Discov. Today 8, 681–691. 88. Nestler, H.P. (2007) The target family approach. In: Schreiber, S.L., Kapoor, T., Wess, G. (eds.) Chemical Biology: From Small Molecules to Systems Biology and Drug Design. 1. Wiley-VCH, Weinheim, pp. 825–851. 89. Fischer, E. (1894) Effekt der Zuckerkonfiguration auf die Enzymwirkung. Berichte 27, 2984–2993. 90. Koshland, D.E. Jr. (1994) The lock-and-key principle and the induced-fit theory. Angew. Chem. Int. Ed. Engl. 33, 2475–2478. 91. Horrobin, D.F. (2003) Opinion: Modern biomedical research: An internally selfconsistent universe with little contact with medical reality? Nat. Rev. Drug Discov. 2, 151–154.
Chapter 2 Compound Library Design for Target Families K.V. Balakin, Y.A. Ivanenkov, and N.P. Savchuk Summary Chemogenomics is a modern approach to analysis of the biological effect of a wide array of small molecule compounds on a large set of homologous receptors or other macromolecular drug targets. However, the relative productivity of the method and the extremely high-cost procedure jointly force the scientist to use additional computational tools for rational compound library design and selection. The present chapter will focus specifically on application of a predictive mapping computational technology in the context of the fundamental principles of chemogenomic approach to foster rational drug design and derive information from the simultaneous biological evaluation of multiple compounds on a set of coherent biological targets. Key words: Chemogenomics, Biological target, Neural modeling, Kohonen self-organized maps, GPCR, Compound library, Chemokine, Receptor
1. Introduction Among the methodological approaches currently described as promising strategies toward drug design and development, chemogenomics comprises a special discipline targeted particularly at systematically studying the biological effect of a vast number of small-molecular compounds on a wide spectrum of principal biological targets. Considering an extremely large quantity of existing data (compounds, targets, and assays) and corresponding information flows (gene/protein expression levels and binding constants) a throughput analysis and an effective searching within the data obtained are too complex for manual manipulations, immediate representation, and a clear understanding of the phenomena observed. From this point of view information technologies and methods play a crucial role in modern drug design and Edgar Jacoby (ed.), Chemogenomics, Methods in Molecular Biology, vol. 575 DOI 10.1007/978-1-60761-274-2_2, © Humana Press, a part of Springer Science + Business Media, LLC 2009
21
22
Balakin, Ivanenkov, and Savchuk
chemogenomics. In addition, it becomes quite obvious that the current drug discovery paradigm states that mass random synthesis and screening do not necessarily provide a sufficiently large number of high-quality leads; therefore chemogenomics, as an effective tool for rational drug design and development, as well as related computational technologies are of great industrial demand. Currently, insights from chemogenomics are increasingly used for the rational compilation of screening sets and for the rational design and synthesis of directed chemical libraries to accelerate drug discovery. In this chapter, we will focus on the application of an advanced knowledge-based neural-net method belonging to a common class of unsupervised classification algorithms widely used in virtual screening. Compound classification methods used for correlation of molecular properties with specific activities play a significant role in modern virtual screening strategies. The most typical application of classification algorithms includes the identification of compounds with desired target-specific activity, which constitutes an essential part of the virtual screening ideology. Such methods can be effectively applied to process the results of high-throughput screening or known literature data, to generate annotated and targeted libraries and develop different neural models to predict a wide spectrum of key pharmacologically relevant features including biological activity (e.g., target-specific activity), pharmacokinetic and ADME/Tox profiles (e.g., blood-brain barrier (BBB) permeability, half-life time and volume of distribution in human blood plasma, cell and organ-specific toxicity), various physicochemical properties (e.g., water and DMSO solubility or melting point). Thus, we have successfully applied Self-organizing Kohonen maps (SOMs) for the analysis of nontrivial space of clinically validated therapeutic agents and approved drug compounds. In particular, the developed models can further be used for selection of screening candidates from virtual databases. The applied virtual screening technology is focused solely on the small molecular level, as opposed to target structure-based design or docking methodology. A leitmotif of the method used is a ligandbased strategy realized in the context of self-organizing mapping. In the framework of chemogenomics, this concept represents a consistent and valuable approach toward both the rational drug design and gathering information from the simultaneous biological evaluation of many compounds on multiple biological targets.
2. Materials 2.1. Databases
Initially, a comprehensive knowledge database should be collected for subsequent neural-net modeling. As a rule it represents a set of compounds with experimentally defined features (such as activity against a target of interest, BBB permeability, toxicity,
Compound Library Design for Target Families
23
cytochrome P450 (CYP450) substrate affinity, etc.). Currently, several commercially available pharmaceutical databases, such as Prous Ensemble (1), WOMBAT (2) or Beilstein (3) databases, as well as proprietary knowledge databases can be easily used as the separate or joint source of information about structures and their specific activities. Among these sources Prous Ensemble database, which is a licensed database of known pharmaceutical agents compiled from the patent and scientific literature, seems to be one of the most convenient and experimentally validated sources. Thus, based on this database we have recently developed a unique model for the prediction of G-protein-coupled receptor (GPCR)-specific activity (4). The overall objective was to investigate differences between various groups of GPCR-specific ligands based on their physicochemical properties (for details see Subheading 4). The main characteristics of Prous Ensemble database are listed as follows: • More than 285,000 therapeutic agents and bioactive compounds including macromolecules, peptidomimetics, small-molecule organic compounds as well as many rare substances (e.g., unique metal-coordinated or metal-containing complexes) • 3,128 launched drugs • 146 preregistered compounds • 8,355 agents in different clinical trials (Phases I–III) • 25,300 compounds in preclinical evaluation • 249,457 compounds currently evaluated in early biological tests • 1,900 precedented targets with key signaling pathways • 7,400 genomics records with various gene-related studies • 90 biomarkers records with uses/techniques • 17,000 synthetic schemes, including more than 70,000 intermediates and reagents • 2,400 companies and research organizations, including sales information on more than 300 It also includes more than: • 650,000 data values from experimental pharmacology studies that delineate drug/receptor and enzyme/target cell interactions • 340,000 data values on pharmacokinetics/metabolism for parent compounds and active metabolites • 80,000 references to clinical trials of compounds currently under study and/or in use in humans • 785,000 references to the current literature, abstracts and proceedings from congresses and symposia, and company communications • 100,000 patent families from 11 leading sources
24
Balakin, Ivanenkov, and Savchuk
Principal information sources are the patent literature, biomedical literature and congresses, company communications, as well as Internet monitoring. Ensemble database covers more than 1,500 journals and 300 conferences annually in the areas of medicinal chemistry, organic synthesis, experimental pharmacology, clinical pharmacology, biomarkers and genomics, as well as tracking the activity of 2,500 pharmaceutical and biotechnology companies. The main focus is on products in discovery or development since approximately 1988 to the present date. 2.2. Experimental Dataset
All structures were selected from the Ensemble database. In addition to approved therapeutic agents these particularly include a set of lead compounds entered in advanced clinical/preclinical trials (a total of 16,540 compounds). Structures were extracted according to the assigned activity class, where the class indicates a common target-specific group such as GPCRs, kinases and proteases, nuclear receptors, and ion channels as well as more than 150 subclasses (for example, serotonin, tachykinin and dopamine receptors, tyrosine, Abl, Aurora and serine/threonine kinases, cysteine and serine proteases, etc.). Prior to the statistical experiments, the molecular structures should be filtered and normalized in order to fulfill certain criteria (see Subheading 3.5 and 4).
2.3. Software
Over the past decade the amount of data arising from various medicinal chemical disciplines especially from biological screening and combinatorial chemistry has literally exploded and continues to grow extremely at a staggering pace. Scientists are constantly being inundated with all types of chemical and biological data. However, the computational tools for integrating and analysis of such data have largely failed to keep pace with these advances. The majority of computer programs targeted for dimensionality reduction, mapping, and throughput data analysis have roughly been realized in simple, often inconvenient console format, or as an external module installed under the different pilot platforms, such as Microsoft Excel and MATLAB computing language; these include, but not limited, to SOM_PAK (console DOS-based version) (5), Ex-SOM (excel-based interface) (6), and SOM Toolbox (Matlab-based interface) (7). To date, several novel powerful Windows-based programs operating in the field of dimensionality reduction and multiparametric data analysis are currently available from different commercial and academic sources. Among these software InformaGenesis (8), NeuroSolutions (9), and NeurOK (10) are typical examples of neural-based computational programs running under Windows and particularly targeted for Kohonen and Sammon mapping. However, there is a relatively small number of such software specialized for chemical data analysis. Among these computational programs, SmartMining (8), which is originally developed and scientifically validated as the
Compound Library Design for Target Families
25
specific calculation module fully integrated into the master computing engine of InformaGenesis platform, is a powerful software primarily based on Kohonen SOM algorithm (see Subheading 3) and additionally supported by many advanced modifications and complex-specific modalities. It should be particularly noted that the program has specifically been designed to work under Windows operating system. In addition to basic Kohonen settings and learning parameters, it includes significant algorithmic-based improvements, such as “Neural Gas,” “Duane Desieno,” “Noise Technique,” “Two Learning Stages and 3D-architecture,” as well as several unique algorithms and specific methods, for instance “Corners,” “Gradient,” and “Automatic Descriptor Selection Algorithm (ADSA)” (8). SmartMining was completely adapted for the analysis of large sets of chemical data of different types and dimensionality. It calculates more than hundred fundamental molecular descriptors that are generally divided into several logical and functional categories, including the basic specific physicochemical features, such as LogP, number of H-bond donors, H-bond acceptors, and rotatable bonds; topological and electrotopological descriptors, such as Zagreb, Wiener and E-state indexes; as well as quasi-3D descriptors, such as Van der Waals volume and surface. All descriptors are directly calculated by using well-known common models and approximations borrowed from the scientific literature (11). In addition, several algorithms have been progressively modified to obtain more exact feature prediction or/and calculation, for example Van der Waals parameters are calculated fairly accurately considering the overlapped volumes and/or surfaces. Consequently, this program represents a real practical tool for enhancement of informational content of virtual compound selections and can be effectively used for developing the neural model describing a target-specific activity.
3. Methods 3.1. Som 3.1.1. The Main Concept of SOM
One of the difficult challenges in data analysis is to be able to represent whatever complexities might be intrinsic to the data in a simple and intuitive form. Traditional methods of data visualization, such as property distribution histograms, are often inadequate to represent the extremely large, high-dimensional datasets common to statistical analyses of large virtual databases. In order to minimize the complexity and reduce number of individual plots needed to visualize this sort of data, one must attempt to reduce the dimensionality of the representation. Several different techniques were proposed to achieve dimensionality reduction, while preserving the topology of the original space. That is, points near
26
Balakin, Ivanenkov, and Savchuk
each other in the high-dimensional space are also near each other in the low-dimensional space. Among these algorithms Kohonenbased SOM’s and Sammon maps are the most widely used techniques for dimensionality reduction with different conceptual basis. SOMs (12) belong to a class of neural networks known as competitive learning or self-organizing networks which in turn are based on unsupervised learning rule (see Subheading 4). They were originally developed to model the ability of the brain to store complex information as a reduced set of salient facts without loss of information about their interrelationships. High-dimensional data are mapped onto a two-dimensional rectangular or hexagonal lattice of neurons in such a way as to preserve the topology of the original space. Each object, or molecule, can be represented as a vector, the components of which are variables with a definite meaning (molecular descriptors). The Kohonen neural network automatically adapts itself to the input data in such a way that similar input objects are associated with the topologically close neurons in the neural network. In the Kohonen approach, the neurons learn to determine the location of the neuron in the neural network that is most “similar” to the input vector. This means that objects on the 2-D map located physically close to each other have similar properties. Kohonen SOM’s can be very effective for visualizing, comparing and filtering chemical libraries. In the last decade, Kohonen maps became popular for comparative analysis and visualization of datasets (13). A study on comparison of benzodiazepine and dopamine datasets was performed with an implementation of a Kohonen network (14). In another study, a dataset of 31 steroids binding to the corticosteroid binding globulin (CBG) receptor was modeled (15). SOMs were used for distinguishing between drugs and nondrugs with a set of descriptors derived from semi-empirical molecular orbital calculations (16). Kohonen map-based algorithm was recently used for clustering and visualization of the National Cancer Institute’s publicly available antitumor drug-screening data (17). This analysis identified relationships between chemotypes of screened agents and their effect on four major classes of cellular activities: mitosis, nucleic acid synthesis, membrane transport and integrity, and phosphatase- and kinase-mediated cell cycle regulation. In our laboratories, we developed an effective classification scheme for segregation of human CYP450 substrates/nonsubstrates using Kohonen SOMs (18). The same methodology was applied for discrimination between BBB well- and poorly permeable drugs (19). Several important preparatory procedures are required prior to initiation of any knowledge-based statistical data mining experiment. Two main steps usually precede the develop ment of a classification model: (1) collection and processing of the knowledge database aiming at generation of quality training datasets; (2) calculation of molecular descriptors and selection of an appropriate subset of descriptors for further modeling.
Compound Library Design for Target Families
27
The detailed procedure of developing the target neural-based model is successively described in the following subsections. 3.1.2. Import From Database
In the first step, the selected dataset including 16,540 structures (see Subheading 2.2) was exported from the Ensemble database into the corresponding SDF file, then it was imported into the SmartMining software; thus, the internal database was fully formed except 36 structures with unrecognized structures. The import procedure was completed in less than 2 min.
3.1.3. Descriptor Calculation
At the second step, the physicochemical and topological properties (molecular descriptors) of compounds should be calculated and analyzed; then a minimal set of key parameters adequately describing the selected dataset should also be determined. Physicochemical properties have long been used to develop structureactivity relationships. They quantify a large number of molecular features known to determine the pharmacokinetic and pharmacodynamic properties of compounds. Among them are molecular weight (MW), octanol-water partition coefficient (logP), molar refractivity, Van der Waals volume (VDWvol) and surface area (VDWsurf), the number of filled orbitals, HOMO and LUMO energies, partial atomic charges and electron densities, dipole moment, ionization potential, and many others. Molecular connectivity or topological indices are numerical values calculated from certain invariants (characteristics) of a molecular graph (20) which encodes features such as branching, ring positions, and bond order. They are attractive for quantifying molecular diversity because they are inexpensive to compute and have been validated through years of use in the field of structure-activity correlation. The available programs calculate indices based on connectivity, shape, subgraph counts, topological equivalence, and electrotopological state (E-State indexes). In addition, several other descriptors encoded specific molecular properties such as number of free-rotatable bonds (RBN), radius of gyration, and whole flexibility, and they can also be included in the same cate gory. Finally, there is a large class of structural descriptors consisting of several minor subclasses including formal, simple structure determinants, such as number of atoms (heteroatoms), rings, or different functionalities (amide fragment, carbonyl group, etc.); key functional motives, such as number of structural fragments with known physicochemical properties (H-bond acceptors and donors). The applicability and use of various topology indices is discussed in several recent papers (21, 22). A thorough overview of different molecular descriptors can be found in a fundamental edition presenting a comprehensive collection of molecular descriptors and a detailed review from the origins of this research field up to the present day (11). Molecular property descriptors have also been extensively reviewed in several excellent reviews (23, 24). Using the internal module for descriptor calculation
28
Balakin, Ivanenkov, and Savchuk
originally integrated in the SmartMining software, more than 100 different molecular descriptors including physicochemical properties, such as LogP, VDWvol/surf and MW; topological descriptors, such as Zagreb, Winner, and E-state indexes; as well as various structural descriptors, such as number of H-bond acceptors/ donors and RBN, were immediately calculated. 3.1.4. Descriptor Selection
After the calculation a feature reduction stage should be performed (for details see Subheading 4). In the modeling studies described here, for reduction of the number of input variables, we have used a unique algorithm, named Automatic Descriptors Selection (ADS), implemented in SmartMining software. The main concept of ADS is briefly described in Subheading 4. In addition to ADS, several well-known and fully validated methods for dimensionality reduction can be also used, for example Principal Component Analysis (PCA). The principles of PCA have been described many times in scientific literature (25, 26) and are not described here. As a result of the performed selection procedure, at the output, an experimental set consisted of seven molecular descriptors including Zagreb index, E-state indexes for the following structural fragments: >C–, –CH2–, –CH3, the number of H-bond donors, HB2 (a structural descriptor which encodes the strength of H-bond acceptors following an empirical rule), and LogP was determined. After all the preparatory procedures were complete, the reference database with selected molecular descriptors was used for development of in silico model with the most appropriate architecture and learning strategy (see Subheading 3.6). Key examples cited in Subheading 4 represent real computational filtering technologies developed at ChemDiv, Inc. for enhancement of knowledge-based content of exploratory chemical libraries for biological screening at the stage of combinatorial synthesis planning. In particular, several methodological pathways toward the design of target-specific combinatorial libraries using different computational-based approaches are also described in Subheading 4. Prior to the statistical experiments, the molecular structures should be filtered and normalized in order to fulfill certain criteria.
3.1.5. Database Preprocessing
The filters described herein represent simple structural and descriptor limitations mainly targeted for excluding the obvious error and outlet structures (outliers) as well as structures with descriptor values lying far beyond a normal distribution criteria, for example a classical Gauss distribution with single/double dispersion threshold. The preprocessing algorithm was easily performed by the following scheme: 1. Remove structures with obvious errors. 2. Remove counterions and solvent molecules in order to obtain single-compound records.
Compound Library Design for Target Families
29
3. Where possible, neutralize charges at acidic and basic groups by adding or removing protons. 4. Remove duplicates within the reference database. 5. Remove redundant tautomeric compound forms, such as tautomers. 6. Remove compounds that do not pass a rejection filter (specific for each particular task). 7. Remove compounds with extremely high/low values of MW (MW < 60 and MW > 700). 8. Remove compounds with very high/low values of LogP (LogP < −6 and LogP > 14). Point 6 needs some additional explanations. For many practical tasks, it is required that the compounds pass a rejection filter that removes chemically reactive or otherwise not suited compounds. Filtering criteria depend on a particular task. For example, compounds can be filtered based on the presence of chemically reactive or toxicophoric fragments, such as alkylating or acylating groups, strong electrophiles, etc. Care should be taken when using a standard set of reactive fragments for exclusion of hypothetically hazardous compounds. For some specific classes of pharmaceutical chemicals, such as oncolytic or protease-active agents, the chemically reactive “warheads” can be necessary elements of the structure. The rejection filter can also include a number of criteria that ensure the general druglikeness (27) or leadlikeness (28) of compounds. In addition, it is usually required to filter molecules based on atom type content, because many standard programs for calculation of molecular descriptors correctly work only with C, N, O, H, S, P, F, Cl, Br, and I atom-containing structures. As a result of implementation of all the preprocessing procedures listed, at the output, the final dataset consisting of 16,000 structures was completely organized and prepared for computational modeling. The following procedure should be carried out for Kohonen network training and map generation. 3.1.6. Kohonen Map Generation
The formal procedure for Kohonen SOM’s generation includes the following stages: 1. Identify and label molecular descriptors (seven descriptors) and training set compounds, which will be used for modeling. 2. Set learning parameters: the number of learning iterations = 3,000, the starting adjustment radius = 8, the initial learning rate = 0.3. In many cases, a unique algorithm, named “Corners,” distributed as additional optionality to the parental SmartMining package can be effectively used to achieve the best results of sample separation. Thus, the algorithm was applied to the training dataset (number of corners = 4).
30
Balakin, Ivanenkov, and Savchuk
3. Normalize descriptor values. 4. Set a proper map size to provide the studied molecules with a sufficient distribution space. For most applications, an optimal map contains 10–100 objects (molecules) per node. A map resolution of 14 × 14 (a resolution that presumably would provide a satisfactory distribution within the constructed Kohonen map with random threshold = 16,000/196~82 compounds per node) was chosen. 5. Determine cell architecture (tetragonal cell) and map dimension (2D). 6. Run the learning process. After the training is accomplished the resulting Kohonen map can be readily formed, the model can be saved and further used for testing and visualizing other objects on the same map. The whole SOM of 16,000 pharmaceutical leads and drugs generated as a result of the unsupervised learning procedure is depicted in Fig. 1. It shows that the studied compounds occupy a wide area on the map, which can be characterized as the area of druglikeness. Distribution of various target-specific groups of ligands in the Kohonen map demonstrates that most of these groups have distinct locations in specific regions of the map (Fig. 2a–l).
Fig. 1. Property space of 16,000 pharmaceutical leads and drugs visualized using the Kohonen map. The data have been smoothed.
Compound Library Design for Target Families
Fig. 2. Distribution of twelve large target-specific groups of pharmaceutical agents within the Kohonen map: (a) G-protein-coupled receptors (GPCR) agonists/antagonists (5,432 compounds); (b) matrix metalloproteinase inhibitors (120 compounds); (c) tyrosine kinase inhibitors (175 compounds); (d) caspase inhibitors (50 compounds); (e) NMDA receptor agonists/antagonists (150 compounds); (f) potassium channel blockers/activators (302 compounds);
31
Fig. 2 (continued) (g) reverse transcriptase inhibitors (160 compounds); (h) serine protease inhibitors (531 compounds); (i) p38 MAPK inhibitors (100 compounds); (j) histamine receptor antagonists (168 compounds); (k) lipoxygenase inhibitors (114 compounds); (l) serine/threonine kinase inhibitors (120 compounds).
32 Balakin, Ivanenkov, and Savchuk
Compound Library Design for Target Families
33
A possible explanation of these differences is in the fact that, as a rule, receptors of one type share a structurally conserved ligand-binding site. The structure of this site determines molecular properties that a receptor-selective ligand should possess to properly bind the site. These properties include specific spatial, lipophilic, and H-binding parameters, as well as other features influencing the pharmacodynamic characteristics. Therefore, every group of active ligand molecules can be characterized by a unique combination of physicochemical parameters differentiating it from other target-specific groups of ligands. Another explanation of the observed phenomenon can be related to different pharmacokinetic requirements to drugs acting on different biotargets. The described algorithm represents an effective procedure for selection of target-biased compound subsets compatible with high-throughput in silico evaluation of large virtual chemical space. Whenever a large enough set of active ligands is available for a particular receptor, quantitative discrimination function can be generated allowing selection of a series of compounds to be assayed against the target. Once a Kohonen network is trained and specific sites of location of target-activity groups of interest are identified, the model can be used for testing any available chemical databases with the same calculated descriptors. The Kohonen mapping procedure is computationally inexpensive and permits real-time calculations with moderate hardware requirements. Thus for a training database consisting of 16,000 molecules with seven descriptors using 3,000 iterations, approximately 1 h is required for a standard PC (Pentium 3-GHz processor) on a Windows 2000/XP platform to train the network. The time increases almost linearly with the size of the database. After the Kohonen network is trained, the 2D map can be created in a short time. It is important to note that focusing on physicochemical rather than structural features makes this approach complementary to any available ligand structure similarity technique. Our own experience and literature data demonstrate that SOMs are an efficient clustering, quantization, classification, and visualization tool very useful in the design of chemical libraries. Possible limitations of this approach are related to the fact that the SOM algorithm is designed to preserve the topology between the input and grid spaces; in other words, two closely related input objects will be projected on the same or on close nodes. At the same time, the SOM algorithm does not preserve distances: there is no relation between the distance between two points in the input space and the distance between the corresponding nodes. The latter fact sometimes makes the training procedure unstable, when the minor changes in the input
34
Balakin, Ivanenkov, and Savchuk
parameters lead to serious perturbation in the output picture. As a result, it is often difficult to find the optimal training conditions for better classification. Another potential problem is associated with the quantization of the output space. As a result, the resolution of low-sized maps can be insufficient for effective visualization of differences between the studied compound categories. 3.2. Focus on GPCR Target Classes
Because of specific cluster structure determined by the internal activation (neuron) function originally realized in the Kohonenbased SOMs it is very difficult to obtain a fully scalable and, at the same time, adequate map with the preservation of all the distances observed among all input samples. Fortunately, using the constructed map it is quite possible to “set the zoom” into the GPCR area. Thus, compounds acting specifically on different GPCR subclasses including a/ b-adrenoceptors, dopamine D1–D4 receptors, tachykinin NK1/NK2, serotonin and chemokine receptors can also be successfully separated within the same map (Fig. 3a–i). As shown in Fig. 3, small molecule compounds targeted against different GPCR subclasses are commonly located separately in different areas within the Kohonen map with minor overlapping. Since a key objective of our research is to analyze chemokine receptor superfamily, generally, in the context of chemogenomic approach adopted specifically for compound library design we have also studied the distribution of compounds within the Kohonen map acting against different chemokine subclasses (Fig. 4a–f). Thus, Fig. 4 clearly shows that, in general, the studied pharmaceutical agents occupy different areas within the obtained map, for example the location of CXCR4 antagonists differs significantly from CCR1/2 position while it is conceptually similar to CCR3/5.
3.3. Similarity Across the Chemokine Receptor Superfamily
During the past decade, the main paradigm in medicinal chemistry has been turning gradually from traditional receptor-specific studies and biological assays to a novel crossreceptor vision. Currently, such approach becomes increasingly applied within the whole pharmaceutical research to enhance the efficiency of modern drug discovery. Following the fundamental principle of chemogenomics, receptors are no longer viewed as single entities but grouped into sets of related proteins or receptor families that are explored in a systematic manner. This interdisciplinary approach aimed primarily to find the links between the chemical structures of bioactive molecules and the receptors with which these molecules interact. Chemogenomics is based on a paradigm originally introduced by Klabunde (29) who has formulated the basic principle – “similar receptors bind similar ligands.” In other words, for a receptor as drug target of interest, known drugs and ligands of similar
Compound Library Design for Target Families
35
Fig. 3. Distribution of several G-protein-coupled receptors (GPCR)-specific groups of pharmaceutical agents on the Kohonen map: (a) chemokine receptors agonists/antagonists (1,212 compounds); (b) dopamine D1–D4 agonists/ antagonists (320 compounds); (c) endothelin ETA/ETB antagonists (121 compounds); (d) CCKA/B agonists/antagonists (77 compounds); (e) bradykinin agonists/antagonists (12 compounds); (f) muscarinic M1 agonists (121 compounds); (g) serotonin receptors agonists/antagonists (477 compounds); (h) tachykinin NK1/NK2 antagonists (103 compounds); (i) b-adrenoceptor agonists/antagonists (556 compounds).
receptors, as well as compounds similar to these ligands, can serve as a convenient starting point for drug discovery. However, the obvious question is: “How can receptor similarity be defined?” A recent review by Rognan (30) provides a comprehensive overview
36
Balakin, Ivanenkov, and Savchuk
Fig. 4. Distribution of six chemokine-specific groups of pharmaceutical agents within the Kohonen map: (a) CXCR4 antagonists (80 compounds); (b) CXCR1/2 antagonists (442 compounds); (c) CCR5 antagonists (238 compounds); (d) CCR3 antagonists (182 compounds); (e) CCR1/2 antagonists (180 compounds); (f) CCR4 antagonists (13 compounds).
on how chemogenomic approaches define receptor and/or ligand similarity and presents case studies on how this knowledge has been applied to rational drug design. The main receptor similarity principles formulated by Rognan are listed as follows: • Receptor class (e.g., GPCRs) • Receptor subclass (e.g., Chemokine receptors) • Overall sequence homology (phylogenetic tree) • Similarity of active binding site (3D structure or 1D sequence motifs) It should be particularly noted that numerous chemogenomic approaches merely apply the classification of target families (such as ion channels, kinases, proteases, nuclear receptors, GPCRs, etc.) or protein subfamilies (such as tyrosine kinases, chemokine receptors, serine proteases, etc.) without taking into account similarities of the determined or assumed ligand-binding sites. However, there are strong evidences that the complex analysis of receptors which includes a formal receptor classification, sequence homology, 3D-similarity, and active binding site construction
Compound Library Design for Target Families
37
provides a more relevant and adequate strategy toward the modern concept of drug design and discovery. The chemokine superfamily includes a large number of ligands that bind to a smaller number of receptors (31, 32), at that multiple chemokine ligands can bind to the same receptor and vice versa. Whereas the perceived complexity and promiscuity of receptor binding introduces an additional challenge in understanding the common mechanism of chemokine ligand binding, with respect to chemogenomics they provide a valuable starting point to investigate key interrelationships across chemokine receptor subfamily. Chemokines (chemotactic/chemoattractant cytokines) are highly basic small secreted proteins consisting on average 70–125 amino acids with molecular masses ranging from 6 to 14 kDa which mediate their effects through binding to seven transmembrane domain (7-TMS) of the specific family of GPCR located on target cell membrane. Since chemokine receptors are members of the common GPCR family the two first similarity criteria (see earlier) are being fulfilled successfully. Currently, there are more than 20 functionally signaling chemokine receptors and more than 45 corresponding chemokine ligands in humans (33). The chemokine ligands and receptors have been divided into several major groups based on their expression patterns and functions. In addition, their genomic organization also provides an alternative chemokine classification. This is apparent from the phylogenetic trees presented in Fig. 5a, b. The chemokine receptor CXCR4 possesses multiple funda mental functions in both normal and pathologic physiology. CXCR4 is a GPCR receptor that transduces signals of its endogenous ligand, the chemokine CXCL12 (stromal cell-derived factor-1, SDF-1, previously SDF1-a). The interaction between CXCL12 and CXCR4 plays a critical role in the migration of progenitors during embryologic development of the cardiovascular, hemopoietic, central nervous systems, and so on. This interaction is also known to be involved in several intractable disease processes, including HIV infection, cancer cell metastasis, leukemia cell progression, rheumatoid arthritis (RA), asthma, and pulmonary fibrosis. Unlike other chemokine receptors, CXCR4 is expressed in many normal tissues, including those of the central nervous system, while it is also commonly expressed by over 25 different tumor cells including cancers of epithelial, mesenchymal, hematopoeitic origin, etc. (35). Since CXCR4 is the most actively studied chemokine receptor and a number of small molecule compounds are currently known to modulate its basic functions it is quite reasonable to investigate similarity links between this and other chemokine receptors based on the formulated criteria (see earlier). Thus, as shown in phylogenetic dendogram, CXCR4 is located closely to CXCR1, CXCR2, as well as CXCR3. This means primarily that these receptors possess a similar genotype and based on this observation they
38
Balakin, Ivanenkov, and Savchuk
Fig. 5. Sequence relationship analysis of the human (h) and mouse (m) (a) chemokines and (b) chemokine receptors (34). In (a), the GRO and IP10 groups of CXC chemokines and the MCP and MIP groups of CC chemokines are circled.
Compound Library Design for Target Families
39
can be logically grouped into the common CXCR family differed genetically from CCR subclass but not significantly. Prima facie it seems to be perfectly reasonable to investigate small molecule space around whole CXCR subclass; however, the last similarity criterion is still not considered. A binding site composition and corresponding space cavity jointly play a key role in the ligand binding process. Furthermore, the majority of ligand-receptor complexes are not static structures; they can change dynamically upon ligand binding. In addition, enforced conformational changes across the active binding site can also be achieved by ligand partial binding followed by internal cavity formation fitted appropriately for deep embedding. There are several scientific reports highlighted the partial sequence homology (25–30%) and high binding sites’ similarity between CCR5 and CXCR4 (36, 37). For instance, using MembStruk methods to develop 3D protein structures for CXCR4 and CCR5, and the HierDock protocol to define the binding site for both these receptors it was clearly shown that the two binding sites, even though being on different sides of their receptors, have similar characteristics (37). In both cases, CCR5 and CXCR4 MembStruk structures are also used to correctly identify the binding sites regions according to mutational studies. In addition, a high degree of similarity was also determined for CCR5 and CCR3 (38). Therefore, from the chemogenomics point of view, it is of practical relevance to test the agents acting against CXCR4 also on activity toward CXCR1–3 and CCR3/5. Thus, compounds are profiled against a set of receptors and not tested against single targets. Returning to Fig. 4, it is certainly interesting that the ligands that bind to CCR3 and CCR5 are located closely to CXCR4 on the Kohonen map with significant overlapping. Combining the results of our computational modeling and theoretical analysis it can be reasonably concluded that the applied mapping technique represents a useful approach to filtering combinatorial libraries for selection of target-specific subsets including those acting against chemokine receptor superfamily. It permits to reduce the size of initial multidimensional chemistry space up to two orders of magnitude, and can be recommended as an efficient classification and visualization tool for practical combinatorial design. It is important that this property-based method is complementary to other target- and ligand structure-based approaches to virtual screening. In addition, Kohonen-based SOMs are fully compatible with both the high-throughput virtual screening protocols and the analysis of small-to-medium-sized combinatorial libraries. The principal limitation of this statistics-oriented technique is that prior to experiment one should have a large enough dataset of compounds active against the target of interest. 3.4. Internal Database Analysis
The described algorithm is quite an effective tool for synthesis planning of de novo chemical libraries. Due to a series of specific filters, the properties of a virtual chemical space to be synthesized
40
Balakin, Ivanenkov, and Savchuk
can be modulated in a wide range of possibilities in order to optimize them according to the purposes of a particular bioscreening program. Usually, the practical design of target-specific combinatorial libraries also includes elements of other virtual screening approaches, such as selection by structural similarity to known selective ligands (including bioisosteric, topologic, heterocyclic, and substructure similarity), 3D pharmacophore search, flexible docking, etc. After synthetic feasibility assessment, the combinatorial libraries focused toward particular biotargets are synthesized and used in primary screenings. This general strategy is applicable for generating the focused libraries toward several protein target classes, such as GPCRs, protein kinases, nuclear receptors, and ion channels. Thus, using the constructed Kohonen map, we have tested an internal set of diverse representative compounds obtained from ChemDiv chemical database (39) (these libraries are available as commercial products at ChemDiv, Inc.). The corresponding procedure is described in the following subsections. 3.4.1. Import from Database
Initially, a set of compounds consisted of 20,000 structures of high diversity (see Subheading 4) was exported from ChemDiv database as an SDF-file with a unique ID number for each structure. Subsequently, it was imported into the SmartMining software; thus, the experimental internal database was successfully formed. The import procedure was fully completed in less than 3 min.
3.4.2. Descriptor Calculation and Mapping
Just after the import stage was finished, the previously saved neural model was loaded and the appropriate descriptors were automatically calculated. After the descriptor calculation procedure was completed, the location of the tested structures was determined using the Kohonen algorithm. The corresponding maps are shown in Fig. 6a–c.
Fig. 6. Distribution of the tested compounds (dotted line) within the Kohonen map: (a) the overlap with G-protein-coupled receptors (GPCR) agonists/antagonists area; (b) the overlap with chemokine receptor antagonist areas; (c) the selection of compounds which can be regarded as potential agents acting against CXCR4 chemokine receptor (shaded area).
Compound Library Design for Target Families
41
3.4.3. Export Results
The compounds which were formally classified by the algorithm as potential CXCR4 agents (5,130 structures) were then exported into an external SDF file containing two principal fields: a unique ID number and the corresponding score value depended solely on “privileged” factor calculated individually for each Kohonen neuron except not-active units. Across the neurons occupied by CXCR4 agonists/antagonists and directly classified as CXCR4 area the maximum “privileged” factor was 2.5 while the minimum one was 1.1; also, the average value was calculated to be 1.3. The last one means that among the neurons assigned to CXCR4 area the average “privileged” index calculated as (CXCR4 agents in % per neuron)/(other pharmaceutical agents in % per neuron) is equal to 1.3. Therefore, the developed in silico model can be reasonably regarded as a predictive system for chemogenomicsbased compound library design.
3.5. Conclusion
At the present drug discovery technologies are undergoing radical changes due to both amazing progress in the genomic research and massive advent of combinatorial synthesis and high-throughput biological screening. Among these approaches, chemogenomics, as an alternative route to innovative drug discovery, provides novel insights into receptor–ligand interaction and molecular recognition by the analysis of large biological activity datasets. Furthermore, a rational drug design which is based primarily on the fundamental concept of this approach often complements high-throughput screening for finding chemical starting points for novel drug discovery projects. The greatest impact of the chemogenomic approaches can be expected for targets with no or sparse ligand information as well as for targets lacking structural 3D data. For these targets, classical drug design strategies like ligand-based and structure-based virtual screening and/or de novo design cannot be applied. Considering poor productivity and high production cost of the method described the key question still remains: how could a rational compound selection be achieved? One solution lies in the integration of advanced computational-based approaches, such as neural modeling, into the drug discovery. In combination, these approaches provide excellent results in the field of both rational “in silico” drug design and “new-age” bioscreening technologies.
4. Notes 1. Databases. The key to success of any statistics-oriented predictive modeling is the availability of a large set of quality data used as a training set. Usually, at least several tens of structures
42
Balakin, Ivanenkov, and Savchuk
belonging to a defined activity category are required for generation of a robust classification model, though this number can vary in a wide interval depending on the task. Sometimes, for an optimal statistical experiment one needs up to hundreds of thousands of compounds in the training set. 2. Dimensionality reduction (descriptor selection). The highdimensional data representations that are commonplace in statistical modeling applications pose a number of problems. Firstly, as the number of variables used to describe data increases, the likelihood that some of the variables are correlated dramatically increases. While certain applications are more sensitive to correlation than others, in general, redundant variables tend to bias the results. Secondly, the amount of the computational effort needed to perform the analysis increases in proportion to the number of dimensions. The latter fact is particularly significant in virtual screening programs, where the possibility of real-time calculations is a crucial problem. Therefore, to simplify the analysis and representation of the data, it is often desirable to reduce the dimensionality of the space by eliminating dimensions that add little to the overall picture. Several techniques were developed to perform the dimensionality reduction, such as PCA (25, 26), multidimensional scaling (40, 41), genetic algorithm (42), sensitivity analysis (43). It should be noted, however, that none of the existing methods guarantees to extract the optimal set of important features for the application at hand. Moreover, the underlying molecular features that influence the biological activities of drugs are usually unknown, and this fact makes a priori feature selection problematic in many cases. It can be concluded that selection of variables for QSAR applications is difficult and, despite many different statistical criteria for the evaluation of the resulting models, a highly subjective and ambiguous procedure (44). This is why in many practical experiments, particularly those associated with the use of nonlinear learning approaches, computational chemists have to make intuitive decisions upon selecting molecular descriptors. In our study we have successfully applied a unique algorithm named “Automatic Descriptor Selection Algorithm” to reduce the dimensionality of the original input space consisting of more than 100 molecular descriptors. The fundamental concept of this method lies generally in the preorganization of Kohonen neurons and assigned weight coefficients based on several common principles. Conceptually, the method resembles a sensitivity analysis widely used in computational modeling. Gradually adding the next descriptor it painstakingly attempts to find the optimal positions of input objects with a maximum degree of dissimilarity between each other following the corresponding metric distances. Starting from any corner
Compound Library Design for Target Families
43
of the Kohonen map, each subsequent vector of descriptor values passing straight through the map walks step by step across the perimeter until the best separation among the input objects is achieved. The algorithm can be effectively performed using both the supervised and unsupervised logic. During each cycle it can also be amplified by a minor learning procedure to estimate the total sensitivity of temporary fixed vector net. As a rule, the selection procedure is continued until the predefined number of descriptors is achieved. 3. Learning strategy. In this study, we have successfully applied the unsupervised learning strategy to design a target-specific library. At the same time, in the most of the reported classification strategies in drug discovery, an alternative supervised learning strategy was used. Generally, the choice between the supervised or the unsupervised learning approach depends directly on the problem and the available data. In both cases, the objects with known answers are needed. In supervised learning, the answers are directly used to influence the learning system; in unsupervised learning, the answers are needed to identify and label the output neurons. Whereas with supervised learning, the system adapts itself to a selected representation of classes, an unsupervised learning method is more flexible due to its many possible outputs. Using the supervised learning, the multivariate objects should be split into three sets (the training, the control, and the test set). In unsupervised learning, the control set is not required, since the learning continues until the network stabilization. It should also be emphasized that Kohonen or Sammon map-based classification methods do not depend on the definition of a negative set, and, therefore, the virtual search for compounds belonging to a particular category of interest can be conducted more objectively. This feature of unsupervised learning strategies is particularly important in many practical tasks when it is hard to define the negative training set correctly. 4. Learning parameters. There are several key program settings that should be manually determined before Kohonen-based learning begins. The first setting is the map size or map resolution. Following an empirical rule, it should be chosen considering the probability of normal, statistically relevant distribution of the estimated objects across the whole map. With respect to a prediction accuracy of the unsupervised neural algorithms such as Kohonen or Sammon mapping there are some methodologies allowing users to calculate the index of separation among the tested objects located on the map using a simple criterion, mathematical equation or advanced techniques such as Support Vector Machine. Whereas the last technique can be effectively applied in Sammon algorithm a simple statistical criterion is more suitable for Kohonen maps.
44
Balakin, Ivanenkov, and Savchuk
Usually, an optimal map contains 10–100 objects (molecules) per node. For achieving a satisfactory statistical outcome it is of utmost importance to consider a random threshold; the assumed average occupancy rate among all the Kohonen neurons should be not less than a random distribution, i.e., in our case, the random threshold = 16,000/196~82 compounds per node. The obtained results have shown that the average occupancy rate significantly exceeds the random threshold in 90% of the active Kohonen neurons. The number of learning epochs (iterations) should be selected considering an initial learning rate. As a rule, a small number of epochs (100–500) forced users to choose a large value of the initial learning rate (0.7–0.5) and vice versa to achieve an appropriate and, at the same time, fast convergence of the algorithm. It is important to note that in the first case the learning step is too large to avoid distortions; many weight coefficients are changed discontinuously to provide an inadequate separation, while in the second one the global convergence of the algorithm would not be achieved as well. In turn, a starting adjustment radius should be chosen considering the map size selected previously. Usually, during the initial iterations this setting should provide a whole neuron activity and gradually decreases it for subsequent learning epochs finally tending to a value that is close to zero. Thus, in our study we have selected the optimal algorithm settings: the number of learning iterations = 3,000, the starting adjustment radius = 8, and the initial learning rate = 0.3.
References 1. http://www.prous.com. 2. Olah, M., Mracec, M., Ostopovici, L., Rad, R., Bora, A., Hadaruga, N., Olah, I., Banda, M., Simon, Z., Mracec, M., and Oprea, T. I. (2004) WOMBAT: World of molecular bioactivity. In: Oprea, T. I. (ed.) Cheminformatics in Drug Discovery. Wiley-VCH, Weinheim, pp. 223–239. 3. Vanco, J. (2003) The Beilstein CrossFire Information System and its use in pharmaceutical chemistry. Ceska Slov. Farm. 52, 68–72. 4. Ivanenkov, Y. A., Balakin, K. V., Skorenko, A. V., Tkachenko, S. E., Savchuk, N. P., Ivachtchenko, A. A., and Nikolsky Y. (2003) Application of advanced machine learning algorithm for profiling specific GPCR-active compounds. Chem. Today 21, 72–75. 5. http://www.cis.hut.fi. 6. http://www.geocities.com. 7. http://www.cis.hut.fi.
8. 9. 10. 11.
http://www.informagenesis.com. http://www.nd.com. http://www.neurok.ru. Todeschini, R., Consonni, V., Mannhold, R., Kubinyi, H., and Timmerman, H. (2000) Handbook of Molecular Descriptors. Wiley, New York. 12. Kohonen, T. (1990) The self-organizing map. Proceedings of the IEEE 78, 1464–1480. 13. Anzali, S., Gasteiger, J., Holzgrabe, U., Polanski, J., Sadowski, J., Teckentrup, A., and Wagener, M. (1998) The use of selforganizing neural networks in drug design. In: Kubinyi, H., Folkers, G., and Martin, Y. C. (eds.) 3D QSAR in Drug Design. Kluwer/ESCOM, Dordrecht, pp. 273–99. 14. Bauknecht, H., Zell, A., Bayer, H., Levi, P., Wagener, M., Sadowski, J., and Gasteiger, J. (1996) Locating biologically active compounds in medium-sized heterogeneous datasets by topological autocorrelation
15.
16.
17.
18.
19. 20. 21.
22.
23.
24.
25. 26. 27.
Compound Library Design for Target Families vectors: Dopamine and benzodiazepine agonists. J. Chem. Inf. Comput. Sci. 36, 1205–1213. Anzali, S., Barnickel, G., Krug, M., Sadowski, J., Wagener, M., Gasteiger, J., and Polanski, J. (1996) The comparison of geometric and electronic properties of molecular surfaces by neural networks: Application to the analysis of corticosteroid binding globulin activity of steroids. J. Comput. Aided Mol. Des. 10, 521–534. Brűstle, M., Beck, B., Schindler, T., King, W., Mitchell, T., and Clark, T. (2002) Descriptors, physical properties, and drug-likeness. J. Med. Chem. 45, 3345–3355. Rabow, A. A., Shoemaker, R. H., Sausville, E. A., and Covell, D. G. (2002) Mining the National Cancer Institute’s tumor-screening database: Identification of compounds with similar cellular activities. J. Med. Chem. 45, 818–840. Korolev, D., Balakin, K. V., Nikolsky, Y., Kirillov, E., Ivanenkov, Y. A., Savchuk, N. P., Ivashchenko, A. A., and Nikolskaya, T. (2003) Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem. 46, 3631–3643. Savchuk, N. P. (2003) In silico ADME-Tox as part of an optimization strategy. Curr. Drug Discov. 4, 17–22. Kier, L. B., and Hall, L. H. (1986) Molecular Connectivity in Structure-Activity Analysis. Wiley, New York. Basak, S. C., Balaban, A. T., Grunwald, G. D., and Gute, B. D. (2000) Topological indices: Their nature and mutual relatedness. J. Chem. Inf. Comput. Sci. 40, 891–898. Bonchev, F. (2000) Overall connectivities/ topological complexities: A new powerful tool for QSPR/QSAR. J. Chem. Inf. Comput. Sci. 40, 934–941. Kubinyi, H. (1993) QSAR. Hansch Analysis and Related Approaches. In: Manhold, R., Krogsgaard-Larsen, P., and Timmermann, H. (eds.) Methods and Principles in Medicinal Chemistry, vol. 1. VCH, Weinheim, pp. 21–36. Livingstone, D. J. (2000) The characterization of chemical structures using molecular properties. a survey. J. Chem. Inf. Comput. Sci. 40, 195–209. Jolliffe, I. T. (1986) Principal Component Analysis. Springer-Verlag, New York. Cooley, W., and Lohnes, P. (1971) Multivariate Data Analysis. Wiley, New York. Clark, D. E., and Pickett, S. D. (2000) Computational methods for the prediction of ‘druglikeness’. Drug Discov. Today 5, 49–58.
45
28. Oprea, T. I., Davis, A. M., Teague, S.J., and Leeson, P. D. (2001) Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41, 1308–1315. 29. Klabunde, T. (2006) Chemogenomic approaches to ligand design. In: Rognan, D. (ed.) Ligand Design for G-proteinCoupled Receptors. Wiley-VCH, Weinheim, pp. 115–135. 30. Rognan, D. (2007) Chemogenomic appro aches to rational drug design. Br. J. Pharmacol. 152, 38–52. 31. Zlotnik, A., and Yoshie, O. (2000) Chemokines: A new classification system and their role in immunity. Immunity 12, 121–127. 32. Yoshie, O., Imai, T., and Nomiyama, H. (2001) Chemokines in immunity. Adv. Immunol. 78, 57–110. 33. Balakin, K. V., Ivanenkov, Y. A., Tkachenko, S. E., Kiselyov, A. S., and Ivachtchenko, A. V. (2008) Regulators of chemokine receptor activity as promising anticancer therapeutics. Curr. Cancer Drug Targets 8, 299–340. 34. Zlotnik, A., Yoshie, O., and Nomiyama, H. (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 7, 243. 35. Allavena, P., Marchesi, F., and Mantovani, A. (2005) The role of chemokines and their receptors in tumor progression and invasion: Potential new targets of biological therapy. Curr. Cancer Ther. Rev. 1, 81–92. 36. Pérez-Nueno, V. I., Ritchie, D. W., Rabal, O., Pascual, R., Borrell, J. I., and Teixidó, J. (2008) Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking. J. Chem. Inf. Model. 48, 509–533. 37. Spencer, E. H. (2005) Development of a Structure Prediction Method for G-Protein Coupled Receptors, Thesis. California Institute of Technology, Pasadena, CA. 38. Efremov, R., Truong, M. J., Darcissac, E. C., Zeng, J., Grau, O., Vergoten, G., Debard, C., Capron, A., and Bahr, G. M. (2001) Human chemokine receptors CCR5, CCR3 and CCR2B share common polarity motif in the first extracellular loop with other human G-protein coupled receptors. Eur. J. Biochem. 263, 746–756. 39. http://www.ChemDiv.com. 40. Torgerson, W. S. (1952) Multi-dimensional scaling: I. Theory and method. Psychometrika 17, 401–419. 41. Kruskal, J. B. (1964) Non-metric multidimensional scaling: A numerical method. Psychometrika 29, 115–129.
46
Balakin, Ivanenkov, and Savchuk
42. Goldberg, D. E. (1989) Genetic Algorithms in Search, Optimization, and Machine Learning. Addison-Wesley, Reading. 43. Bigus, J. P. (1996) Data Mining with Neural Networks. McGraw-Hill, New York. 44. Kubinyi, H. (1994) Variable selection in QSAR studies. I. An evolutionary algorithm. Quant.
Struct.-Act. Relat. 13, 285–294.1.Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23, 3–25.
Chapter 3 Targeting the Purinome Jeremy M. Murray and Dirksen E. Bussiere Summary Purines are critical cofactors in the enzymatic reactions that create and maintain living organisms. In humans, there are approximately 3,266 proteins that utilize purine cofactors and these proteins constitute the so-called purinome. The human purinome encompasses a wide-ranging functional repertoire and many of these proteins are attractive drug targets. For example, it is estimated that 30% of modern drug discovery projects target protein kinases and that modulators of small G-proteins comprise more than 50% of currently marketed drugs. Given the importance of purine-binding proteins to drug discovery, the following review will discuss the forces that mediate protein:purine recognition, the factors that determine druggability of a protein target, and the process of structure-based drug design. A review of purine recognition in representatives of the various purine-binding protein families, as well as the challenges faced in targeting members of the purinome in drug discovery campaigns will also be given. Key words: ATP-binding proteins, Drug design, Drug discovery, Purinome
1. Introduction The discovery of adenosine triphosphate (ATP) was first reported by Karl Lohmann at the Kaiser Wilhelm Institute of Biology in Berlin, as well as by Yellapragada SubbaRow and Cyrus Fiske at Harvard Medical School in Boston, in 1929 (1, 2). Both groups isolated the molecule from muscle as adenosine monophosphate (AMP) and inorganic pyrophosphate (PPi) due to the protocols utilized and the general reactivity of the molecule. At the time, neither group had elucidated the chemical structure, instead referring to ATP as “adenylpyrophosphate.” The energetic potential contained within ATP was revealed in later work by Lohmann and Otto Meyerhof, which showed that a considerable amount of heat was generated by the hydrolysis of ATP to AMP (DH), Edgar Jacoby (ed.), Chemogenomics, Methods in Molecular Biology, vol. 575 DOI 10.1007/978-1-60761-274-2_3, © Humana Press, a part of Springer Science + Business Media, LLC 2009
47
48
Murray and Bussiere
a
NH2 N O
O
O
N
O P O P O
-O P −
O
O−
O
O−
b
O N
N O N
O
O
O P O P O
-O P −
O
−
O
−
O
d
O N
N
N
N
O
O
O
O P
O P
O−
O OH
cAMP
NH2
GTP
NH2
N
N
OH OH
ATP N
N O
O
OH OH
c
N
O−
N N
NH2
O OH
cGMP
Fig. 1. Chemical structures for (a) ATP, (b) GTP, (c) cAMP, and (d) cGMP.
approximately 25 kcal/mol by their measurements at the time (3). The determination of the proper chemical structure would take until 1935, when both Katashi Makino, an investigator at the Dailen Hospital in Manchuria, and Karl Lohmann, separately proposed the correct structure (Fig. 1) (4, 5). The work of these and other investigators revealed the molecule that serves as the common currency in energy conversions within all organisms on the planet. Hydrolysis of ATP to ADP and inorganic phosphate (Pi) produces a free energy of hydrolysis of approximately −7.7 kcal/mol, equivalent to the free energy of hydrolysis of ATP to AMP and pyrophosphate. The hydrolysis of ADP to AMP and Pi produces a slightly lower free energy of hydrolysis of −6.6 kcal/ mol. The phosphoanhydride bonds in ATP are high energy due to the electrostatic repulsion between the phosphate groups, which are negatively charged at physiological pH; cleavage of the bond between the a- and b-phosphate or the b- and g-phosphate relieves this strain. In 1958, Ted Rall and Earl Sutherland at Washington University in St. Louis discovered that a chemical permutation of AMP was the intermediary in many hormonal functions (6, 7). This intermediary, or “second messenger,” was cyclic adenosine monophosphate (cAMP; Fig. 1). Unlike ATP, they discovered that cAMP was heat stable as it lacks the high-energy bonds presented by the b- and g-phosphates. This discovery was of critical importance for understanding the mechanism of action of many hormones (8). Further investigation into the role of cAMP as a second messenger led to the discovery of another essential purine. In a series of experiments between 1969 and 1971, Lutz Birnbaumer, Martin Rodbell, and colleagues at the National Institute of Arthritis and Metabolic Disease in Bethesda showed that hormone-stimulated cAMP production requires guanosine
Targeting the Purinome
49
triphosphate (GTP; Fig. 1), which led to the postulation of a transducer which links the receptor and the cyclase which subsequently produces cAMP (9–22). We now know that G proteins play the role of this transducer. Like ATP, GTP contains two high-energy bonds with free energies of hydrolysis similar to that of ATP. As is the case with ATP and cAMP, a cyclic analog of GTP also exists: cyclic guanosine monophosphate (cGMP; Fig. 1). cGMP was discovered in 1963 by Donald Ashman and T. Price at Columbia University in New York as one of the main phosphate-containing molecules in animal urine (23). In the 1980s, it was discovered that nitric oxide, a readily diffusible gas, was the hormone responsible for triggering cGMP production in smooth muscle, which leads to activation of cGMP-dependent protein kinase and smooth muscle relaxation (24–26). It is highly likely that cGMP plays additional as-of-yet unidentified roles in vivo. In addition, as shown by Phoebus Levene and coworkers at the Rockefeller University in New York in a series of studies in the early decades of the twentieth century, the two purine bases also comprise half of the genetic code (27, 28, see Note 1). Given the roles and importance of these purines to all living organisms as the barometer of the energy content of both the cell and the organism as a whole, as well as comprising half of the genetic code, it is not surprising that a significant percentage of the human genome codes for purine-binding proteins (29). As shown in Fig. 2, this “purinome” is estimated to consist of a total of 3,266 genes. Assuming that the human genome comprises approximately 25,000 genes, approximately 13% of the human genome is used to code for proteins that use purines as either cofactors or substrates (30). The two predominant purinebinding protein classes are involved in cell signaling: the small G-proteins (comprising 3% of the genome), which use GTP as a substrate, and protein kinases (2.1% of the genome), in which ATP acts as a phosphate donor. The remaining purine-binding proteins are divided between 12 classes, from dehydrogenases (1.8% of the genome) to purinergic receptors (<0.1% of the genome). Because of the wide-ranging functional repertoire encompassed by purine-binding proteins, it is not surprising that these proteins are attractive drug targets. For example, it is estimated that 30% of modern drug discovery projects target protein kinases (31). Likewise, modulators of small G-proteins comprise more than 50% of currently marketed drugs (32). Given the importance of purine-binding proteins to drug discovery, in the following review, we will briefly discuss the forces that mediate protein:purine (or target:ligand) recognition, the factors that determine druggability of a protein target, and the process of structure-based drug design. We will also review purine recognition in representatives of the various purine-binding protein families, as well as the challenges faced in targeting members of the purinome in drug discovery campaigns.
50
Murray and Bussiere Motor Proteins (ATP): 22 / 0.67% /0.09% Caboxylases (ATP): 26 / 0.80% / 0.10% CTK (ATP): 34 / 1.04% / 0.14% Sulfotranferases (ATP): 40 / 1.22% / 0.16% Lipases (ATP): 78 / 2.39% / 0.31% Deaminases (ATP): 85 / 2.60% / 0.34%
Purinergic Receptors (Adenosine): 6 / 0.18% / 0.02% Purinergic Receptors (ATP): 11 / 0.34% / 0.04%
Small G Proteins (GTP): 750 / 22.96% / 3.00%
Synthetases (ATP): 213 / 6.52% / 0.85% Helicases (ATP): 217 / 6.64% / 0.87%
Non-conventional purine-utilizing proteins (HSP90): 357 / 10.93% / 1.43% Protein Kinases (ATP): 518 / 15.86% / 2.07%
ATPases (ATP): 453 / 13.87% / 1.81% Dehydrogenases (NAD/NAPD): 456 / 13.96% / 1.82%
Fig. 2. Breakdown of the functional classes of the human purinome. The functions of human purine-binding proteins were assigned via homology searches using the FASTA sequence alignment algorithm by Haystead (29). The chart gives the total number of proteins in that functional class (the first value given after the class designation), the percentage of the human purinome comprising that functional class (the second value given), and the percentage of the human genome devoted to coding for that functional class (the third value given; the reported percentage assumes 25,000 genes in the human genome).
2. Thermodynamics of Ligand Binding The binding of a ligand – whether it be a purine cofactor or a pharmaceutical compound – to an active site or suitable pocket is driven by the decrease in the free energy of the target:ligand complex in comparison to the free energy of both the ligand and the target separately in solution (33). The change in free energy between the target:ligand complex and the unbound state obeys the following relationship at equilibrium: DG ° = DH ° − TDS ° = − RT ln K eq = RT ln K d
where DH ° is the difference in enthalpy between the two states in kcal/mol, DS ° is the difference in entropy between the two states in kcal/mol.K, R is the Universal Gas Constant (or Boltzmann’s constant multiplied by Avogadro’s number, which allows the calculation to proceed in units of kcal/mol), T is the absolute temperature in kelvin (K), Keq is the equilibrium constant, and Kd is the disassociation constant of the ligand. As shown by
Targeting the Purinome
51
this equation, the spontaneous binding of a ligand to its target is accompanied by favorable changes in either or both the enthalpy and entropy of the system. The tighter the binding of the ligand to the target, the greater the difference in the free energy between the bound and unbound states, with the bound state being the lowest in free energy (spontaneous binding must be an exoergic process). This difference in free energy is known as the binding energy of the ligand, DGbind, and can comprise changes in enthalpy and/or entropy, and can be further segregated into various component free energies. The cause(s) of the change in enthalpy are easily understood, as these are due to the direct energies of interaction between the ligand and the target, as well as any perturbations to intramolecular interactions within the ligand and/or the target between their bound and unbound states (34). Table 1 lists common molecular interactions. Changes in entropy are caused by changes in the order (or the total number of states sampled) of the system. Usually, the binding of the ligand to the target is associated with a decrease in entropy (DS ° is thus negative), as the conformations sampled by both the ligand and the target decrease upon the binding event. This decrease is often offset by the displacement of water molecules from the surfaces of both the ligand and the target. Because of this, most drug discovery efforts optimize the number and strength of the enthalpic interactions between the ligand and the target while attempting to minimize the entropic “penalty” that is subjected upon binding. For example, by stabilizing the bioactive conformation of the ligand in solution, the decrease in entropy is minimized. A more detailed consideration of the thermodynamics of ligand binding can be found in Knapp et al. (35).
3. Antitarget and Selectivity Considerations
In addition to binding affinity, selectivity remains a paramount challenge in drug discovery, as potent ligands must have a high degree of selectivity to prevent the ligand from exhibiting toxicities when administered in vivo. The high degree of sequence homology and the resulting three-dimensional structural similarity seen within families of purine-binding proteins often make attaining a high degree of selectivity a challenge. Most protein targets will typically have one or more “antitargets”: a protein that has a similar enough active site or binding pocket to which the ligand can bind with significant affinity. While in most cases an antitarget will be a protein with significant sequence and structural homology to the target, it should be noted that relevant antitargets frequently depend on the ligand’s chemical structure and
Asymmetry in the charge distribution of a molecule or a molecular fragment creates a permanent dipole. These dipoles can be modeled as partial point charges at the nuclear centers. Dipole–dipole interactions occur between two such polar molecules or fragments.
The strength of dipole–dipole interac- The alignment of the dipoles such that the positive pole of the second tions is diminished (approximately dipole is adjacent to negative pole 2.5–5 kcal/mol) because they of the first dipole provides the involve only partial charges. most stabilization. Conversely, an arrangement such that the poles of like charge are facing each other would be destabilizing. The strength of the interaction is inversely proportional to the cube of the distance (1/r3).
The magnitude of the charges, the distance between the charges, and dielectric constant of the continuum between the two charges are key factors. The strength of the interaction falls off linearly with distance (1/r).
The point charges obey Coulomb’s Molecules are often made up of elelaw: An interaction of a positively ments that have varying electronegacharged group with a negatively tivities. Depending on the bonding charged is stabilizing, while the arrangements, these molecules will interaction of two like charges is have asymmetric charge distribution, destabilizing (raises free energy). which can often be effectively modA typical value for a stabilizing eled as point charges centered on interaction is 4–5 kcal/mol. the nuclear centers.
Charge–charge (Electrostatic) interactions (176–178)
Dipole–dipole interactions (179)
The nature of the solvent and the temperature of the system are key factors.
The hydrophobic effect contributes The primary contribution to the between 25 to 50 cal/mol. Å2 of hydrophobic effect comes from the favorable increase in system entropy nonpolar surface area that is freed upon the release of ordered firstfrom water. shell waters from nonpolar surface areas on both the macromolecule and the ligand upon ligand binding; there are also secondary enthalpic contributions.
Geometric and environment factors
Hydrophobic effect (Interactions) (171–175)
Energetics of interaction
Physical basis of interaction
Type of interaction
Table 1 Energetics of molecular interactions. The interactions are presented in order of physical complexity with fundamental interactions presented first and the more complex, multifaceted interactions presented subsequently
52 Murray and Bussiere
The minimal distance between the heavy-atom (non-hydrogen) positions is approximately 1.6 Å and the strength of the hydrogen-bonding falls off rapidly as the distance increases, falling to a negligible value at a distance of 5 Å. The interaction is strongest at an angle of 180° between the hydrogen of the donor and the free lone pair of the acceptor. The strength of the hydrogen bond decreases as this angle deviates from the ideal angle.
Hydrogen bonds contribute between An interaction between a group that 2 and 5 kcal/mol of binding contains a hydrogen atom attached energy. to an electronegative atom (known as the donor) and a functional group with a strongly electronegative atom with a free lone pair(s) of electrons (the acceptor). At first approximation this interaction can be considered a form of electrostatic interaction between the partially positively charged hydrogen atom and the negatively charged electron lone pair.
Hydrogen bonding (181, 182)
(continued)
Attractive: The dispersive interactions are long-range (several Å). The strength of the interaction falls off rapidly with distance (1/r6). Repulsive: The repulsive effect begins when the distance between nuclear centers is less than the sum of the centers’ van der Waal radii (known as the collision diameter). Collisions are extremely unfavorable energetically and grow rapidly as the distance between nuclear centers diminishes (1/r12).
Oscillations in the electron distribution Attractive: The interaction contributes approximately 0.25–0.5 kcal/ of a molecule or a fragment create mol of binding energy for each temporary dipoles. In turn, these atom involved. dipoles induce temporary stabilizing Repulsive: An extremely large dipoles in the electron distribution energetic penalty can be incurred in nearby molecules or fragments. (orders of magnitude greater than Induced dipole–induced dipole interthe attractive force) depending on actions are always stabilizing and the distance between the atomic attractive. This attraction becomes centers and thus the severity of the repulsion when two atoms are sepacollision. rated by less than the sum of their van der Waal radii and the electron fields coincide.
van der Waals forces (Induced dipole–induced dipole interactions) (180)
The strength of dipole-dipole interac- Dipole–induced dipole interactions are always stabilizing. The strength of tions is diminished (approximately the interaction falls off rapidly with 0.5–1 kcal/mol) because they distance (1/r4). involve only partial charges.
Asymmetry in the charge distribution of a polar molecule or molecular fragment with a permanent dipole induces a dipole in an adjacent molecule or fragment with a polarizable electron field.
Dipole–induced dipole interactions (179)
Targeting the Purinome 53
Physical basis of interaction An interaction between two aromatic groups arising from numerous forces, primary of which are attractive van der Waals forces. There are also contributions from electrostatics, induction, and exchangerepulsion. An interaction arising between an aromatic group (Phe, Tyr, Trp, or ligand functional group) and a cation (Arg, Lys, or ligand functional group). His residues can participate in such an interaction as either an aromatic group or cation depending on its protonation state. The interaction is electrostatic in nature, occurring between the positively charged cation and the negatively charged, electron-rich pi-cloud.
Type of interaction
Pi–pi stacking interactions (183–185)
Cation–pi interactions (186– 188)
Table 1 (continued) Geometric and environment factors The interaction is observed occurring in two primary geometries: “offcenter parallel displaced,” has two aromatic rings positioned parallel to one another; “T shaped” has the edge of one ring positioned perpendicular to the face of the other, with their geometric centers coinciding. The cation must lie perpendicular to the plane of the aromatic ring and the cation’s van der Waals surface is less than 2.8 Å from the aromatic ring’s van der Waals surface. If the cation lies further away from the aromatic group, the strength of the interaction will be significantly attenuated by the screening effect provided by solvent molecules.
Energetics of interaction Pi–pi stacking interactions contribute between 1 and 5 kcal/mol.
Cation–pi interactions typically contribute between 2 and 6 kcal/mol.
54 Murray and Bussiere
Targeting the Purinome
55
on the interactions that it can form with the antitarget. Because of this, antitargets are usually chemical scaffold dependent. As such, potential antitargets should be confirmed experimentally and not inferred in silico based on only sequence and structural homologies. The challenges of engineering selectivity can best be appreciated by outlining the thermodynamics involved. Using the equation presented below, it can be shown that given a ligand with a disassociation constant of Kd,t for a target and a disassociation constant of Kd,a for an antitarget, the difference in free energy needed to achieve selectivity is: DDGt − a = DGbind,t − DGbind,a = RT ln (K d,t / K d,a )
where (Kd,t/Kd,a) is the ratio between the disassociation constants for the same ligand bound to the target and antitarget. From this equation it can be shown that at physiological temperatures, approximately 1.4 kcal/mol of additional binding energy between the target and the ligand is required to establish tenfold selectivity. To achieve a 100-fold selectivity, approximately 2.8 kcal/mol of binding energy is required, and a 1000-fold selectivity requires 4.2 kcal/mol of additional binding energy. Thus, exploiting a single strong hydrogen bond present in the target:ligand complex, but not present in the antitarget:ligand complex, would be sufficient to yield a 100-fold selectivity between the target and the antitarget. However, one must bear in mind that relying only on enthalpic interactions such as hydrogen bonds will make it quite difficult to gain selectivity between highly homologous proteins. In these cases, a more successful approach is to target both the differences in opportunities for enthalpic interactions within the respective binding pockets and the differences in the shape and steric complementarity of the respective binding pockets between the target and the antitarget. The energetic cost of a “steric clash” (the so-called repulsive effect outlined under van der Waals forces in Table 1) is so prohibitive that if one is capable of introducing a functional group in the ligand that is accommodated by the shape of the pocket in the target, but is not accommodated by the shape of the pocket in the antitarget, the subsequent steric clash should prevent the ligand from binding optimally to the antitarget. Typically, in drug discovery projects, selectivities of a 100-fold to a 1000-fold are desirable between a highly homologous target and antitarget. Several subtleties exist around target/antitarget issues when targeting purine-binding proteins. The ligand in question will also be competing with endogenous purine molecules for the binding pocket. The purine molecules will likely be present in much higher concentrations in the cell than the ligand itself. Purine concentrations
56
Murray and Bussiere
(predominately ATP and GTP) within a normal cell range from 0.5 to 3.0 mM (36). In a cancer cell, the levels are approximately four times higher (36). Competition from endogenous purines will increase the IC50, which represents the concentration of the ligand at which 50% of the target or antitarget activity is inhibited, as shown by Cheng–Prusoff equation (37):
(
)
IC50 = K d 1 + [Purine] / K m,purine
where [Purine] is the concentration of the endogenous purine within the cell and Km,purine is the Michaelis constant of the endogenous purine. Given this and assuming that the ligand is nonselective with an equivalent Kd for both the target and the antitarget, and is also below saturating levels in the cell, the ligand will preferentially bind to the protein with the higher Km,purine as there is less competition for its binding pocket. To further complicate matters, expression levels of a target and an antitarget may differ significantly within a cell, and are often not present at equimolar concentrations. It is possible that there are several orders of magnitude difference between the concentrations of a target and an antitarget in a cell. While data are limited for human cells, a study of protein expression levels in yeast revealed that kinases, for example, were expressed at concentrations from 1 to 240 nM, with a median protein concentration across all the proteins measured of approximately 54 nM and a maximum concentration of 38 mM for a single protein (38, 39). The limited data available from studies on human cells agree with these ranges (39–41). Additionally, the phenotypic threshold, the percentage of target activity that must be modulated to see a biological effect, may differ significantly between a target and an antitarget. Because of this, antitarget considerations can become quite complex and the selection of antitargets should be made with as many data as possible in hand. Given these considerations, a mechanistic cellular assay may provide more relevant selectivity information than a biochemical assay. A final note regarding antitargets bears mentioning: A drug’s profile does not have to be pristine in regard to specificity to be efficacious. In many therapeutic areas, such as oncology, it can be advantageous to have a drug with activity for more than one target, as long as toxicity does not arise from the inhibition of multiple targets.
4. “Druggability” of Targets While genomics and bioinformatics readily allow the identification of all purine-binding proteins within the human genome, not all these proteins will be suitable as drug targets. To encompass
Targeting the Purinome
57
this idea, the term “the druggable genome” was coined in 2003 to encapsulate those proteins that would be suitable as targets for the development of small-molecule therapeutic compounds (42). To rephrase this, the druggable genome consists of proteins to which a small molecule with appropriate chemical properties will bind with sufficient binding affinity to serve as a therapeutic agent. The use of “druggable” in this context should not be confused with its use in describing a small-molecule compound, where it literally means that the compound is “drug-like” (43). Importantly, a protein being druggable is not sufficient to make a protein a drug target. The primary selection of an individual protein or a protein family as a drug target(s) depends primarily on its biological role(s) in a disease state (44). One must be assured that modulation of a particular protein activity will be disease modifying before it being selected as a drug target (45). Of course, once a drug target is selected, it must also be druggable. To be druggable, a protein or a protein complex (see Note 2) must have one or more concave invaginations on its surface that are chemically featured enough in terms of available sidechain and mainchain functional groups to serve as a binding site for a suitable ligand. This is not to say that these pockets must be highly polar; apolar pockets can also suffice. In the case of an enzyme, the active site usually provides such a pocket, but suitable binding pockets can be identified quite distal to an active site. These are known as “allosteric” sites or “cryptic” sites and can be identified on proteins with no enzymatic activity; an example of such a cryptic binding site will be shown in a later section (see Subheading 5). Most importantly, the binding of ligand to the identified binding pocket must modulate the activity of the protein in the desired manner. The surface of a protein is usually not suitable to serve as a binding site for a ligand due to the screening effect exerted by water, endogenous anions and cations, and endo genous small molecules, all of which serve to screen the interactions required for ligand binding. A concave indentation within the protein provides sufficient shelter from this effect and also allows full exploitation of available van der Waals interactions. Several computational tools have been developed to identify suitable pockets. These include computational techniques that rely on geometry-based algorithms, such as APROPOS (46), CAST (47), LIGSITE (48), PASS (49), POCKETFINDER (50), and SURFNET (51). Scanning of proteins with these algorithms readily identifies natural ligand-binding sites (such as enzymatic active sites) and reveals that these natural ligandbinding sites tend to be the most geometrically complex and/ or the largest binding pocket on the surface of the protein. In addition, energy-based algorithms such as GRID (52) and computational solvent mapping (53, 54) incorporate a more
58
Murray and Bussiere
rigorous physical framework to identify pockets by estimating the binding energies of small probe molecules for these areas. To supplement the computational techniques, biophysical methods exist to scan for suitable pockets, such as the use of NMR-based screening (55). Given this plethora of techniques, it is not surprising that druggability analysis of a potential target is now routinely done by a project team prior to a target being selected, which is a vast improvement over the state of affairs 10–15 years ago when a target would often be selected based only on its biological role only to be proven to be undruggable by months to years of effort. Purine-binding proteins are usually quite druggable by such analyses. Typically, they tend to bind their purine cofactors within well-defined highly featured concave pockets, and tend to have a relatively low affinity for the relevant cofactor, often in the range of mM–mM, as the high concentrations of purines in the cell alleviate the necessity to have a high affinity. Of course, there are notable exceptions. Ras, for example, binds GTP and GDP incredibly tightly with a Kd of 10−11 M (see section that follows). As we shall discuss, this has a direct and detrimental effect on its druggability.
5. Structure-Based Drug Design In the sections that follow, many macromolecular structures will be discussed. But of what use are these structures for drug discovery? Structure-based drug design techniques facilitate the optimization of the ligand in question by utilizing the understanding of the ligand-binding pose, the forces that guide ligand binding, and the three-dimensional coordinates of the target:ligand complex. When this information is combined with knowledge about the druggability of the ligand-binding pocket and applicable antitargets, the rationale for improved binding is easily deciphered (35). The exact structure-based drug design process will vary between research groups and often between projects, but a prototypical structure-based drug design cycle is illustrated in Fig. 3. The cycle begins with elucidation of the three-dimensional structure of the target under investigation – or a suitable fragment thereof – either as an apostructure or in complex with the ligand of interest (lead compound, natural ligand, etc.). The structure can also be an in silico structure that was approximated via comparative modeling. However, the value of the structural information will be dependent on the overall resolution of the technique used for structural determination; X-ray crystallography currently affords the highest resolution of all the available methods, with a typical X-ray crystal structure of 2.6 Å
Targeting the Purinome
59
Fig. 3. Flowchart of the structure-based drug design cycle. The process, as well as technologies employed, varies between projects and between companies.
resolution having a coordinate error of approximately 0.4 Å. Other methods, such as Nuclear Magnetic Resonance (NMR), have much a lower resolution (higher coordinate error) associated with their structures (56). However, NMR analyses can provide insights into the dynamics of the target. Assuming that a druggability analysis has already been completed, and that a target:ligand costructure has been determined either through modeling or by direct experimental determination, the cycle is initiated by examining the existing target:ligand costructure and vetting it against existing structure–activity relationships (SAR), as most projects have established limited chemistry efforts prior to the start of the cycle. If the established binding mode is validated by available SAR, the cycle can proceed: chemical intuition, molecular modeling, as well as other computational techniques can be used to generate new “virtual” lead compounds with optimized features (the factors under optimization are determined by the project team). The first stage of the cycle is to evaluate the ligand’s potential. Do the binding mode and chemical structure of the ligand allow for optimization? Does the ligand have high ligand efficiency? Not surprisingly, often this is not the case. Such ligands should be removed from further consideration. Thus, ligands are rationally evaluated for optimization potential. Once appropriate chemical scaffolds have been selected, the iterative phase of the cycle begins. This process is typically accomplished by coupling in silico computational analyses such as molecular
60
Murray and Bussiere
modeling followed by the synthesis and testing of the designed compounds. Early in the optimization process, the focus is on improving the interaction of the ligand with the target and destabilizing its interactions with antitargets. Improving the ligand’s interaction with the target typically involves building in additional interactions between the target and the ligand by modification of the ligand’s chemical structure. Later in the optimization process, this focus often shifts to improving the physicochemical and absorption, distribution, metabolism, elimination and toxicity (ADMET) properties, as well as the selectivity of the ligand, without compromising its potency. Not all the compounds generated during an iteration of the cycle will show improvement or promise. Many will show no optimization at all and should be discarded from further consideration. The ligands that show improvement go through the cycle again until optimization of the desired features is complete.
6. The Diversity and Druggability of Purine-Binding Proteins
6.1. Phosphodiesterases – an Accessible, Readily Druggable Active Site
As mentioned previously, the purinome consists of a wide variety of proteins with different folds, functionalities, and cofactor binding pockets. The diversity within the purinome is so great, there are only two common features shared by ATP-binding proteins: the P-loop (an important structural element that will be introduced) and the presence of an alpha–beta structural fold consisting of beta-strands alternating with alpha-helices. To illustrate this, the following section will present short vignettes meant to provide an overview of some important representatives of the purine-binding protein families in regard to overall fold and structure, mode of purine recognition, and druggability. The representatives are as follows: readily druggable targets, illustrated by phosphodiesterases (PDEs) and kinases, targets druggable through cryptic binding sites, represented by the kinesin motor proteins such as Eg5, and difficult-to-drug targets, represented by the small G proteins such as Ras. These examples are far from comprehensive, but are meant to give the reader a sampling of the challenges faced in developing therapeutics when targeting purine-binding proteins. They are also selected to show the reader the diversity inherent within the purinome. Since the discovery of cAMP by Rall and Sutherland in 1958 (6) and cGMP by Ashman in 1963 (23), considerable work has been done to show that these nucleotides mediate the intracellular effects of many first messengers such as hormones, neurotransmitters, paracrine and autocrine factors. An important early discovery
Targeting the Purinome
61
concerning the mechanism of action of cyclic nucleotides was the identification of cyclic nucleotide-dependent protein kinases in virtually all phyla in the animal kingdom (57, 58). This culminated in the elucidation of the pathway from hormone (adrenaline) to glycogen breakdown, which is mediated by a kinase cascade, the first enzyme being cAMP-dependent protein kinase (PKA) (59–62). The fundamental importance and of cAMP and cGMP to the functioning of the organism is underscored by the observation that very diverse environmental stimuli, such as photons for vision (63–65) and chemicals for taste, cause changes in the intracellular levels of these cyclic nucleotides (66, 67). Many first messengers control the intracellular levels of cAMP and cGMP by affecting their synthesis, catalyzed by adenylyl cyclase and guanylyl cyclase, respectively, and via their degradation, catalyzed by the cyclic nucleotide PDEs. Since the report of the initial characterization of the first PDE enzymes in 1962 (68), the human genome has been found to encode for 21 PDEs. These 21 PDEs are typically divided into two classes. Class I PDEs contain 11 different subfamilies (PDE1–11). Each of these subfamilies contains between one and four distinct gene products that are designated by a capital letter (A–D). Furthermore, there are over 60 splice variants of these gene products that are designated by a subsequent Roman numeral (69). For example, the designation PDE5A1 denotes PDE family 5, gene A, splice variant 1. The class II PDEs share no recognizable sequence similarity with the class I members and will not be discussed further. To date, there is structural information available for PDE1B, PDE2, PDE3, PDE4, PDE5, PDE7, PDE9, and PDE10 (70–81). The structures of these enzymes contain an N-terminal regulatory domain and a C-terminal catalytic domain. The catalytic domain is formed by 16 helices and can be divided further into three conserved helical subdomains: an N-terminal cyclin-fold region, a linker region, and a C-terminal helical bundle (Fig. 4) (75). The active site is contained within a deep hydrophobic pocket that is formed at the interface of the three subdomains. The active site is highly conserved between class I members and contains 12 of the invariant 19 residues. In PDE5, this pocket is approximately 10 Å deep, with a narrow opening and a wide inner cavity with a volume of over 900 Å3(82). The 11 class I PDEs exhibit intriguing substrate specificity: PDE4ABCD, PDE7AB, and PDE8AB are cAMP specific; whereas PDE5A, PDE6ABC, and PDE9A are cGMP specific. The remaining family members (PDE1ABC, PDE2A, PDE3AB, PDE10, and PDE11A) can act on both cAMP and cGMP to varying extents (69, 83). PDEs contain four key active site interactions that affect substrate specificity and catalysis. First, the purine base is held in the active site by a hydrophobic clamp,
62
Murray and Bussiere
Fig. 4. (a) Ribbon representation of the crystal structure of PDE5A in complex with 5¢GMP (PDB code 1T9S). GMP and the conserved Asn817 are shown as sticks, the hydrogen bond interactions between Oe and Ne of Gln817 and the N1 and O6 of 5¢GMP are represented as black dashes, the divalent cations are represented as spheres. (b) Conserved secondary structure of PDEs illustrated using PDE5A1. Helices are represented as rectangles with corresponding numbers. The H- and M-loops (660–683 and 788–811, respectively) are shown in italics. Gln817 in H15 is highlighted in bold italics. (c) Close up of the active site of the PDE5A GMP complex (PDB code 1T9S) indicating the Q, S, and M subpockets, metal ions are represented as spheres, and the hydrogen-bonding interactions between Gln817 and GMP are represented as dashes.
which in PDE5 is formed from Phe820, Val782, Phe786, and Ile768. All these residues are either invariant (such as Phe820) or semiconserved across the PDE family. Second, nucleotide recognition is mediated by an invariant active site glutamine residue (Gln817 in PDE5). This invariant glutamine residue forms critical hydrogen bonding interactions that facilitate the ability for the different PDEs to discriminate between cGMP and cAMP (75, 79). In the crystal structure of PDE5 in complex with the low affinity product, 5¢-GMP, the sidechain of Gln817 participates in hydrogen-bond interactions with the N1 and O6 atoms of the purine base of guanine (84). Third, the C1¢, O4¢, C4¢, and C5¢ atoms of the ribose group are contacted by Phe820, Leu725, and Leu765. Fourth, the phosphate group interacts with the hydrolysis center containing two divalent cations (M1 and M2) that are held by the conserved metal-binding motif (–HDXXHXXXXN–), common to all mammalian PDEs (85). The enzymes likely share a common catalytic mechanism in which an enzyme-activated water molecule serves as a nucleophile hydrolyzing the phosphorus– oxygen bond in the substrate, a cyclic phosphate ester nucleotide, to produce a nucleoside monophosphate (81). Given their critical role in regulating cyclic nucleotide levels in the cell, PDEs are of considerable interest as drug targets. Inhibitors of PDE5 activity are used in the treatment of erectile
Targeting the Purinome
63
dysfunction and pulmonary hypertension. It is also becoming increasingly clear that the PDE superfamily serves a physiological role in the spatiotemporal control of cyclic nucleotide signaling. For example, PDE5 exists as a homodimer and is found in epithelial and endothelial tissue including vascular and tracheal smooth muscle, gastrointestinal epithelial cells, platelets, kidney, spleen, prostate gland, as well as the Purkinje cells of the cerebellum (see Note 3). Clearly, a review of all the research on small-molecule inhibitors PDE enzymes is beyond the scope of this chapter. Instead the general mechanism of PDE inhibition will be introduced using PDE5 as an example, and the reader is referred to recent excellent reviews with broader coverage of the field (86–89). The discovery and the development of inhibitors of PDE5 have been vigorously pursued by multiple organizations. Structural analyses have led to the identification of three key subpockets adjacent to the active site that are important for inhibitor binding and selectivity (82). The first, the M-pocket, representing the metal-binding site, is made up of residues His613, His617, His653, Asp654, His657, Asn662, Met681, Glu682, Asp724, Leu725, Asp764. The second subpocket, comprising the Q-switch and P-clamp regions, is formed by residues Tyr612, Leu765, Ala767, Ile768, Gln775, Ile778, Ala779, Val782, Ala783, Leu804, Ile813, Met816, Gln817, and Phe820. The third subpocket is a solvent-filled side pocket formed by residues Gly659, Asn661, Glu785, Phe786, Gln789, Thr802, and Met805. The largest class of small-molecule PDE5 inhibitors incorporates a modified purine core which is found in cGMP and other natural products such as caffeine, theophylline, and theobromine (Fig. 5).
O
a
N
N
O
N
O
b
N
H N
N
O
N
O
c
N
N
HN
O
N
O
d
N
N
N
O
N
N H
Fig. 5. Chemical structures of naturally occurring PDE inhibitors highlighting the pyrimidinone heterocycle as a naturally occurring pharmacophore for PDE inhibition. (a) Caffeine (1,3,7-trimethylpurine-2,6-dione). (b) Theophylline (1,3-dimethyl7H-purine-2,6-dione). (c) Theobromine (3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione). (d) IBMX (3-isobutyl-1-methyl-7Hpurine-2,6-dione).
64
Murray and Bussiere
Although these natural products are generally weak and nonselective inhibitors of PDEs, they have helped establish the pyrimidinone heterocycle as an important pharmacophore for PDE inhibition. The prototypical synthetic inhibitor, isobutyl methyl xanthine (hereafter, IBMX), is also weak and nonselective. IC50s of IBMX for PDE1, PDE2, and PDE4 was determined to be 7 mM, >10 mM, and 10 mM, respectively (90). Examination of costructures of IBMX bound to both PDE4D2 (a cAMP-specific PDE) and PDE5A1 (a cGMP-specific PDE) demonstrates that in both enzymes, IBMX binds in the active site pocket, mainly interacting with the conserved residues. In PDE5, the xanthine ring stacks against Phe820 on one side, and with Val782 and Phe786 on the other side. A bidentate hydrogen bond interaction is observed between the O6 and N7 of IBMX and the sidechain of Gln817 (91). Interestingly, the orientation of the pyrimidinone core in IBMX observed in the costructure with PDE5 is flipped relative to the binding mode of the pyrimidinone core of 5¢-GMP as observed in the PDE5 5¢-GMP cocrystal structure (84). The binding mode of IBMX orients the five-membered imidazole ring on top of the six-membered pyrimidinone ring of 5¢-GMP (Fig. 6). This binding mode provides the rationale for increased PDE5 potency of IBMX analogs substituted with hydrophobic substituents at the C8 position. For example, 8-(norbornylmethyl)-IBMX has an IC50 of 1.5 nM against PDE5 and improved selectivity against PDE1 (IC50 of 30 nM) and PDE4 (IC50 of 10 mM) (92, 93). Among the first-generation PDE5 inhibitors to make it to the clinic are purine isosteres represented by sildenafil and vardenafil. Comparison of the chemical structures of sildenafil and vardenafil illustrates that these retain the bicyclic guanine core, but differ in the arrangement of nitrogen atoms (Fig. 7).
Nε
Q817 O6 Oε N1
Fig. 6. Flipped binding mode of IBMX compared to 5¢-GMP. 5¢-GMP is represented as sticks (PDB ID 1T9S) and IBMX is represented as ball and sticks (PDB ID 1RKP). The interaction with the conserved Gln817 is shown.
Targeting the Purinome
a
b
O N O
N S
O N
N
HN
N
N N
O
O
HN
S
N
O
O
Q817
65
N
N
O
Q817
Fig. 7. Comparison of the chemical structures of (a) sildenafil (5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one) and (b) vardenafil (2-[2-ethoxy-5-(4-ethylpiperazin-1-yl) sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one) illustrates that these retain the bicyclic guanine core, but differ in the arrangement of nitrogen atoms. Comparison of the cocrystal structures of PDE5 in complex with sildenafil (PDB ID 2H42) and vardenafil (PDB ID 1UHO) shows that the binding mode of both sildenafil and vardenafil is similar to the binding mode of the guanine ring in the 5¢-GMP complex. The interaction with the conserved Gln817 is shown.
Comparison of the cocrystal structures of PDE5 in complex with sildenafil and vardenafil shows that the binding mode of both sildenafil and vardenafil is similar to the binding mode of the guanine ring in the 5¢-GMP complex. Thus, the C8 position of IBMX maps onto the C5 position of sildenafil (Fig. 7). The cocrystal structure of sildenafil in complex with PDE5 demonstrates that the pyrazolopyrimidine core and the substituted ethoxyphenyl bind similarly in all PDE5 costructures, with Gln817 making a bidentate hydrogen-bond interaction with the N6 and O7 atoms of the pyrazolopyrimidinone core of sildenafil (77, 82, 84, 94). The ethoxyphenyl group extends into a hydrophobic pocket made up of Val782, Ala783, Phe786, Leu804, and Ile813. There are intriguing conformational differences in the sulfonyl and the methylpiperazine groups observed in the three different PDE5 sildenafil costructures (PDB ID 1DUT, 2H42, and 1TBF). This
66
Murray and Bussiere
is thought to be due to the conformational change in the H-loop that moves up to 24 Å compared to the conformation observed in unliganded PDE5 (Fig. 4) (94). In contrast to these purine isosteres, tadalafil uses a novel tetracylic hexahydro-2-methyl-diketopiperazine-indole core. The cocrystal structure of tadalafil with PDE5 indicates that the indole nitrogen is involved in a single hydrogen bond interaction with the e-oxygen of Gln817 (Fig. 8) (77). This interaction orients the rest of the diketopiperazine core toward the mobile H-loop where it forms a pi-stacking interaction above and below the plane of the ring with Phe786 and Phe820, respectively. The interaction with Gln817 orients the benzodioxol substituent into the same hydrophobic pocket utilized by the ethoxyphenyl of sildenafil and vardenafil. A recent review of the SAR of a large number of PDE5 inhibitors from
HN
O N O
O
O N
Oε
Q817
Fig. 8. Chemical structure of tadalafil (6-benzo[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12, 12a-hexahydro-pyrazino[1¢,2¢:1,6]pyrido[3,4-b]indole-1,4-dione). Cocrystal structure of PDE5 and tadalafil (PDB ID 1UDU) with the interaction with the conserved Gln817 is shown.
Targeting the Purinome
67
various scaffolds suggests that drug discovery campaigns against this target class will benefit from the groundwork done in the development of PDE5 inhibitors (95). 6.2. Protein Kinases – Achieving Selectivity in a Family with High Homology
Protein kinases are essential regulators of cellular signaling cascades. As was outlined in the introduction, ATP is the energy currency of the cell. However, it also serves a role as a substrate in the post-translational modification by phosphor ylation. The phosphorylation of proteins has an important role in virtually all cellular and metabolic signaling pathways (57) and protein kinases are ubiquitous in the cell. Eukaryotic protein kinases can be split into two broad groups: conventional protein kinases (ePKs) and atypical protein kinases (aPKs). Using the sequence similarity within the kinase domain, the presence of accessory domains and the mechanism of regulation, 518 individual ePKs have been identified representing approximately 1.7% of the human genome. These can be further clustered into eight families (96). The aPKs constitute a smaller set of protein kinases that do not display sequence similarity with the ePKs. The catalytic domain of an ePK is constructed from approximately 250 amino acids, comprising two domains connected by a flexible linker or hinge. The smaller N-terminal domain has a mainly beta-sheet secondary structure (b1–b5) with one conserved helix, the aC helix. The secondary structure of the C-terminal domain is composed of two beta-strands (b7 and b8) and seven conserved helices (aD, aE, aEF, and aF-aI). The active site is located at the interface between these two domains. Within this active site, the adenine ring of ATP interacts with the hinge region, donating a hydrogen bond from the exocylic amine to the backbone carbonyl of residue n (the numbering of this residue will depend on the kinase under consideration) in the hinge and the N1 nitrogen accepting a hydrogen bond from the backbone amide of hinge residue n + 2 (Fig. 9). Hydrophobic residues lie above and below the plane of the adenine ring, thereby enforcing the strong tendency of this site to bind flat aromatic rings. The ribose-binding site is located close to the start of the aD helix. The triphosphate group is held in place by the glycine-rich phosphate-loop (P-loop) that contains the Walker-A motif (–GXXGXGK[T/S]–). The Asp from the conserved DFG motif generally coordinates to a Mg2+ ion which in turn contacts the b- and g-phosphate oxygen atoms. In regard to substrates, approximately 80% of protein kinases are Ser/Thr kinases, and despite possessing highly similar folds, protein kinases recognize and phosphorylate a wide range of protein substrates. The ePKs catalyze the transfer of the g-phosphate of ATP to the hydroxyl group of Ser, Thr, or Tyr residues. Phosphotransfer is metal-ion dependent and proposed to occur by an inline attack of the lone-pair electrons of the substrate hydroxyl group on
68
Murray and Bussiere
Fig. 9. Adenine ring of ATP interacts with the hinge region, donating a hydrogen bond from the exocylic amine to the backbone carbonyl of residue n (the numbering of this residue will depend on the kinase under consideration) in the hinge and the N1 nitrogen accepting a hydrogen bond from the backbone amide of hinge residue n + 2. The side chain of the gatekeeper is shown (in this picture Met). The Mg2+ ions are shown as small spheres; the catalytic residues and the XDFG motif are shown as sticks. This illustration is based on the high-resolution crystal structure of the ternary complex of PKA (PDB ID 1RDQ).
the g-phosphorous of the ATP with the Mg2+ ion reducing the electrostatic repulsion of the incoming nucleophile (97). The phosphorylation site specificity of a kinase is largely determined by the substrate’s localization, unique surface charge, and hydrophobicity. In general, four residues to either side of the residue to be phosphorylated (the P-site residue) provide the first level of substrate specificity (98). Protein kinases are highly validated drug targets with over 30 distinct kinase targets being developed to the stage of Phase I clinical trials (99). The importance of kinase inhibitors is further underlined by the finding that in oncology, the success rate for kinase inhibitors is higher compared to all other drugs (100). The identification of potent ATP-competitive kinase inhibitors is not usually a problem in a kinase drug discovery campaign, instead achieving the desired selectivity profile against other kinases, particularly those within the same family, remains one of the biggest challenges. As explained in the introduction, there is often a correlation between the selectivity of an inhibitor for the kinase of interest and the sequence similarity of the kinase antitargets (101, 102). Large-scale selectivity profiling of available kinase inhibitors provides insight into not only selectivity of inhibitors, but also which kinases are easy or difficult to inhibit by the currently available chemical matter. However, there may be potential biases in large-scale selectivity analyses, introduced
Targeting the Purinome
69
by for example kinases that are difficult to express and assay. Nevertheless, knowledge about compound selectivity at the kinome level also provides an important indication of whether certain kinases and/or compounds are inherently more promiscuous than others. When the selectivity profile is coupled with cocrystal structures it facilitates the application of structure-based design techniques to rationally probe the interactions that provide selectivity, or lack thereof, for a specific compound and kinase. Furthermore, it facilitates the identification of new interactions in the context of different scaffolds, enabling scaffold hopping, scaffold morphing, and target hopping techniques to be employed. Sequence analyses in concert with the wealth of structural information that is available for protein kinases and their inhibitors suggest there are key features of the active sites of protein kinases that can be exploited to gain more selectivity for the kinase of interest versus kinase antitarget(s). The choice of which features are exploited is generally scaffold and kinase specific. This section will describe five such features that can be rationally targeted using structure-guided drug design techniques to both improve the potency and/or increase the selectivity of ATP-competitive inhibitors against a kinase antitarget(s). These features are as follows. 6.2.1. The Gatekeeper Residue
The gatekeeper residue is so named for its ability to restrict access to the hydrophobic DFG pocket as it is situated midway in the hinge region connecting the N- and C-terminal domains (103–105). This gatekeeper residue is constrained to be a threonine or larger residue and is an important determinant of inhibitor selectivity in kinases (106, 107). Sequence comparison coupled with data on inhibitor selectivity indicates that there is a fairly good correlation between the size of the gatekeeper residue and the SAR seen between particular kinases (101). Furthermore, ATP-competitive kinase inhibitors can be classified according to whether any substituents access the DFG pocket and impose an inactive, “DFG-out” conformation on the kinase as do the Type II kinase inhibitors, or whether the compound binds solely in the ATPbinding pocket and does not require a change in the conformation of the kinase, as do the Type I kinase inhibitors (108). In addition, mutational data from gleevec resistant forms of Bcr–Abl, together with structural understanding of the binding mode of gleevec, suggest that the mutation of the gatekeeper residue plays an important role in acquired resistance to gleevec (109). Drug discovery campaigns directed against a specific kinase are often able to exploit a single gatekeeper residue difference to achieve the desired selectivity for the target and decrease activity against antitargets. An example of the importance of the gatekeeper residue on selectivity has been demonstrated through work on p38 isoforms. The triarylimidazole inhibitor, SB203580 (Fig. 10), is a type I p38 inhibitor that is selective for the p38a
70
Murray and Bussiere
a
b
F CF3 N
N
N
S N H
O
NH
HN
N
HN O
Fig. 10. Chemical structures of kinase inhibitors. (a) p38 inhibitor SB203580 (4-[5-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-3H-imidazol-4-yl]pyridine). (b) EGFR inhibitor (N-(3-(6-(3-(trifluoromethyl) phenylamino) pyrimidin-4-ylamino) phenyl) cyclopropanecarboxamide). The dashed line indicates hydrogen-bonding interactions with the hinge.
and p38b isoforms of p38 (IC50 of 48 and 50 nM, respectively) in comparison to the closely related p38g and p38d isoforms (IC50 of greater than 10 mM for both isoforms) (110). The selectivity can be rationalized to a single difference in the gatekeeper residue, which is a threonine in p38a and p38b, and a methionine in p38g and p38d (110–112). The crystal structure of p38a in complex with SB203580 (PDB ID 1A9U) demonstrates that the pyridine N accepts a hydrogen bond amide from the backbone amide of the hinge, and this orients the trisubstituted imidazole so that the fluorophenyl group projects toward the hydrophobic pocket located beyond the Thr gatekeeper residue in p38a (112). The presence of a Methionine would most likely result in a steric clash and therefore a loss in potency in p38g and p38d. Another example of how the gatekeeper residue can be exploited to enhance the selectivity of compounds is provided by the rational design of EGFR inhibitors (113). Researchers at the Genomics Institute of the Novartis Research Foundation were able to convert the generally promiscuous diaminopyrimidine scaffold to a selective EGFR inhibitor by the design of compounds that hydrogen bond with the sidechain of the Thr766 gatekeeper residue in EGFR. The selectivity of the resultant 4,6-dianilinopyrimidines was rationalized by docking, SAR, and mutagenesis of the gatekeeper. The hydrogen bond interaction with the gatekeeper of EGFR likely contributed to the selectivity observed for these compounds (113). 6.2.2. The XDFG Motif
As stated previously, kinase inhibitors can be classified as type I and type II binders based on their ability to access the hydrophobic DFG
Targeting the Purinome
71
pocket (108). Although the DFG motif is generally well conserved across ePKs, the residue preceding this motif is generally not conserved. Instead, a range of different amino acids with physicochemical properties is tolerated in the position N-terminal to the DFG, hereafter referred to as the X position (Fig. 9). Analysis of protein structures that display an inactive, DFG-out conformation suggests that the X residue in the XDFG motif is most frequently a small side chain such as Ala or Gly (114). Furthermore, no kinase crystal structures with a DFG-out conformation have been reported for kinases that contain large residues in the X position of the XDFG motif and the gatekeeper position (114, 115). 6.2.3. The Selectivity Region on the aD Helix
The aD helix is a conserved structural element that is located at the mouth of the ATP-binding site. Many kinases possess a conserved acidic residue at the N-terminus of this helix that interacts with the hydroxyl groups of the ribose sugar. In numerous crystal structures of the kinase domain, one face of the helix is solvent exposed. Despite this, residue differences on the solvent exposed face of the helix have been exploited to achieve selectivity against kinase antitargets. An excellent example of how residue differences on the aD helix can be used to achieve selectivity against antitargets is illustrated by the rational design of selective CDK4 inhibitors. In this study, structure-based drug design techniques were used to identify residue differences close to the active site that could be exploited to convert a pyrroloisoindol-9-urea core that had equipotency for CDK2 and CDK4 into a selective CDK4 inhibitor (116). In this particular case, a threonine residue on the aD helix that is specific to CDK4 was targeted. The equivalent residue in CDK2 (the antitarget) is a lysine and therefore substitution with bulky groups directed toward this residue difference provided the required steric hindrance to favor CDK4 binding over CDK2 binding by approximately 190-fold; the IC50s against CDK4 and CDK2 are 2.3 nM and 440 nM, respectively (116).
6.2.4. The Span of Residues Between the Gatekeeper and the Ribose-Binding Site
The hinge region of ePKs can be subdivided into an upper and a lower hinge region. The upper hinge region contains the gatekeeper and the lower hinge region contains the ribose-binding site. There is low sequence conservation among kinases in the hinge region, and approximately 60% of kinases contain a glycine insertion in this region. For example, CDKs have seven residues between the gatekeeper residue (Phe80) and the ribose-binding residue (Asp86) present at the N-terminus of the aD helix. In contrast, AKT2 kinase contains eight residues between the gatekeeper (Met229) and the ribose-binding residue (Glu236). Depending on the specific antitarget for the compound of interest and the vectors provided for substitution from the compound core, introduction of bulkier chemical groups adjacent to this region will provide selectivity through steric occlusion.
72
Murray and Bussiere
6.2.5. Inhibitor-Specific Conformations
A confounding feature of many drug discovery campaigns directed against a specific target is the ability of the target to change conformation in an unpredictable manner in the presence of certain compounds (117). Conformational flexibility is a welldocumented feature of certain kinases (118). However, there are examples in which an inhibitor selects for a conformation beyond the DFG-in and DFG-out conformations observed for type I and type II kinase inhibitors (119–121). The binding of lapatinib to EGFR provides a good example of this phenomenon. In contrast to the crystal structure of the EGFR:OSI-774 complex, which resembles the active conformation (122), the crystal structure of the EGFR:lapatinib complex reveals that the binding results in the rotation of the N-terminal lobe by ~12° and the movement of the N-terminal end of the aC-helix by over 9 Å. Furthermore, it seems probable that this inhibitor-specific conformation may also contribute to increased selectivity against other members of the kinome (102, 119). The design and development of compounds in this class is generally through empirical observation of the phenomena, However, computational approaches are also being developed (123). A common theme of each of these selectivity determinants is the exploitation of favorable sterics in the kinase target of interest. As was described in the introduction, steric clash provides a large energetic penalty to binding and therefore should prevent the ligand from binding optimally to the antitarget.
6.3. Eg5 (Motor Protein and Mitotic Kinesin) – Accessible Active Site, More Amenable Cryptic Binding Site
Biological functions such as chromosome segregation, vesicular transport, and organelle transport require the generation of motile force. The cell’s ability to execute these processes relies heavily on a class of proteins known as motor proteins. The motor proteins utilize the energy derived from ATP hydrolysis to generate and transduce motile force in an efficient manner (124, 125). It is estimated that these molecular motors operate at an efficiency that varies from 70 to 100% depending on the motor protein involved (126). To put this in perspective, a high-efficiency engine from a racing car only has an efficiency of approximately 35%. Each motor protein consists of an N-terminal motor domain, or head, a connective stalk or tether, which is often nanometers long and comprises a coiled-coil structure, and terminate in a C-terminal tail domain (126, 127). The motor proteins comprise three superfamilies: the kinesin superfamily, the dynein superfamily, and the myosin superfamily. Members of the kinesin superfamily and the myosin superfamily share structural homology as well as a moderate sequence homology of between 20 and 50% amino acid identity; the dynein superfamily shares no homology with the other two superfamilies (128). The kinesin superfamily is diverse, with hundreds of members that can be grouped into 14 families based on sequence similarity. A subset of the kinesin superfamily,
Targeting the Purinome
73
the mitotic kinesins, mediate a wide range of functions including mitotic spindle assembly and chromosome movement. The proposed mechanism for kinesin function is as follows. At rest, a kinesin exists in an ADP-bound state. Upon the binding of ATP, the affinity of the kinesin motor domain for microtubules increases, leading to the docking of the kinesin on the microtubule. The kinesin undergoes a directed series of conformational changes that causes the motor domain to “walk” along the microtubule. This “step” positions the kinesin onto the next suitable binding spot of the microtubule. During the motion, the ATP hydrolyzes to ADP through a currently unknown mechanism. At this point, the kinesin either binds another molecule of ATP, releasing the ADP, and undergoes the cycle again, or reverts to its ADP-bound state that has a low affinity for microtubules, and is released from the microtubule. Kinesin-related motor protein Eg5, which is also known as Kinesin Spindle Protein (KSP) or Kinesin Family Member 11, is a member of the kinesin superfamily. Eg5 is localized to the mitotic spindle and is only found in cells undergoing mitosis; it is not found in other cells and appears to have no role outside of mitosis. It is necessary for both the formation of the bipolar mitotic spindle and for the proper segregation of the replicated DNA in the resulting daughter cells. Eg5 is considered a prime target for the development of antimitotic therapeutics. Current antimitotic agents disrupt mitosis by interfering with microtubule function and stability, which leads to severe toxicity and onerous side effects, such as peripheral neuropathy and other neurotoxicities. A therapeutic targeting Eg5 would not affect microtubules, avoiding these toxicities. However, as an Eg5 antimitotic would target rapidly dividing cells whether or not they are malignant, there would still be an effect on rapidly dividing healthy cells such as neutrophils (see Note 4). The structure of Eg5 comprised a central fold possessing an eight-stranded beta-sheet, which is flanked by three alphahelices on each side (129). The a2 helix, which is positioned on the opposite side from the microtubule-binding site, has a loop insertion of unknown function. This loop is present in all kinesins and varies in length depending on the particular family. The ATP-binding pocket is well conserved within the kinesin superfamily and has four major structural components: the P-loop, the Switch I region, the Switch II region, and the adenosine selective domain (Fig. 11). In kinesins, the P-loop shares the signature motif observed in other P-loop containing folds (–GXXXXGK[T/S]–) and is responsible for donating hydrogen-bonds to the b-phosphate from the backbone amide groups of Gly108, Gly110, Lys111, and Thr112. The last amino acid of the P-loop (a serine or threonine) also coordinates to the divalent Mg2+ cation. The two switch regions
74
Murray and Bussiere
a
b
Switch I a6 a4
ADP
Switch II a3 Mg2+
Mg2+
b1
b4
Loop 5 Trp127 a2
b7 b6
Fig. 11. Conformational changes in Eg5 upon binding of monastrol leading to the formation of the allosteric pocket. (a) KSP:ADP cocrystal structure(PDB ID 1II6) with key secondary structure marked. (b) KSP:ADP:monastrol costructure (PDB ID 1Q0B) showing the movement of Loop 5 and the translocation of Trp127 by approximately 10 Å; the monastrol molecule is circled.
form hydrogen bonds with the g-phosphate of ATP and also with each other (130, 131). Because of this, it is hypothesized that significant structural changes occur when the bound ATP hydrolyzes to ADP. Within the adenosine selective domain, pi-stacking forms the basis for recognition of the adenine ring. The adenine ring stacks against the conserved Pro27 on one face and forms a pi-stacking interaction with Phe113 which immediately precedes the C-terminus of the P-loop (Fig. 12). Because of this limited number of interactions, kinesins have a moderate affinity for ATP: Eg5 has a Km of approximately 21 mM for ATP (132). While the ATP-binding pocket has a reasonable volume of approximately 1,980 Å3 and significant chemical and structural features to define it as a druggable binding site, empirical evidence suggests that it is not the most amenable site on the macromolecule for drug discovery. In 1999, a virtual screening campaign using the structure of Kinesin K560 and targeting the ATP-binding site and the putative microtubule-binding site led to the identification microtubulecompetitive compounds, but no ATP-competitive compounds (133). Building on this work, in 1999, a small-molecule phenotypic screen for compounds that affected mitosis was executed. This screen identified a compound, monastrol, that arrested mitosis in mammalian cells and was specific for Eg5 (134). Further characterization revealed that the (S)-enantiomer was the
Targeting the Purinome
75
Gly 108 Pro27 ADP ? 12 Å ~12
Mg2+ Phe113
a3
Asp265 Thr112 Arg221 Glu116
Asp130
monastrol Arg119 Tyr211 Trp127
Fig. 12. Location of the allosteric pocket in relation to the ATP-binding pocket using the KSP:ADP:monastrol costructure (PDB ID 1Q0B). Key interactions between the ADP and the protein and the monastrol and the protein are shown with dashed line. Due to the complexity of the figure, distances are omitted.
active species and that the compound was a weak binder, with an IC50 of 22 mM (Fig. 13) (135). Kinetic studies revealed that monastrol was non-ATP competitive and suggested that it was an allosteric inhibitor which bound to a cryptic binding site separate and distinct from the ATPbinding pocket (135, 136). The determination of the cocrystal structure of Eg5 with monastrol confirmed this (137). Upon the binding of monastrol, a series of conformational changes occur that lead to the formation of a novel binding pocket approximately 12 Å from the ATP-binding pocket. This cryptic binding site is situated between the a3 helix and the a2 insertion loop. Upon compound binding, Trp127 and the insertion loop (Loop 5) flip in toward the protein, leading to the translocation of Trp127 by approximately 10 Å. Trp127 creates the “top” of the pocket along with the sidechains of Arg119 from a2 and Tyr211 from a3 helix. The a3 helix unwinds partially to allow entry of an aromatic ring from the compound. Thus, the pocket displays considerable plasticity, which can be both a boon and a curse for drug discovery (see Note 5). The pocket has a volume of approximately 2,250 Å3 and is mostly hydrophobic in nature as its surface is formed from aliphatic and aromatic sidechains. However, the pocket provides key opportunities for hydrogen bonding and electrostatic interactions through available main-chain amide and carbonyl groups, as well as proximal glutamic acid (Glu116) and arginine (Arg221) residues (Fig. 12). Concurrent with the discovery of this pocket, numerous pharmaceutical companies executed drug discovery and design programs targeting Eg5 and other kinesins. In 2004, the first paper
76
Murray and Bussiere
a
b O
OH
N O
N
Cl
O HN
N
O
N H
S
N
Monastrol
Br
CK-106023
c
d
e
O
Cl N
Cl
N
N
N O
S
S
N
NH2
N
N
CK-238273 (Ispinesib)
Fig. 13. Chemical structures for allosteric and ATP-competitive Eg5 inhibitors. (a) Monastrol ((S)-ethyl 1,2,3,4-tetrahydro4-(3-hydroxyphenyl)-6-methyl-2-thioxopyrimidine-5-carboxylate), the first compound discovered which bound to the allosteric pocket; the compound has an IC50 of 22 uM. (b) CK-106023 (N-((R)-1-(3-benzyl-7-chloro-3,4-dihydro-4oxoquinazolin-2-yl)propyl)-4-bromo-N-(3-(dimethylamino)propyl) benzamide), which binds to the same allosteric pocket as Monastrol and has a Ki of 12 nM. (c) CK-238273 N-(3-aminopropyl)-N-((R)-1-(3-benzyl-7-chloro-3,4-dihydro-4oxoquinazolin-2-yl)-2-methylpropyl)-4-methylbenzamide), an optimized analog of CK-106023 which is in phase II and has a Ki of 1.7 nM. (d) 4-(2-(1-phenylethyl)thiazol-4-yl)pyridine, an ATP-competitive thiazole compound which was an initial hit from the Merck compound collection; the compound has an IC50 of 11 uM. (e) 4-(2-(1-(4-chlorophenyl)cyclopropyl)thiazol-4-yl)pyridine, an optimized ATP-competitive thiazole compound with an IC50 of 290 nM.
announcing the development of a novel, non-ATP competitive inhibitor with a quinazoline core, CK-106023 (Fig. 13), was published by Sakowicz and coworkers (125). This compound has a Ki of 12 nM and is 200-fold specific for Eg5 over other members of the Kinesin superfamily. It was also shown to be efficacious against two ovarian cancer cell lines (SKOV3 and A2780) with 50% growth inhibition and GI50 values of 126 nM and 191 nM, respectively. A similar compound, CK-238273, also known as ispinesib, has a Ki of 1.7 nM and has progressed to clinical trials (132). Detailed kinetic experiments have shown that both monastrol and ispinesib slow the release of ADP in the absence and in the presence of microtubules, in essence stabilizing Eg5 in the resting state (132). In addition, the binding of ispinesib also
Targeting the Purinome
77
favors transition to the ADP-bound state by accelerating the rate of Pi release (an indirect measure of ATP hydrolysis). The costructure of CK-238273 demonstrates that the compounds bind to the same allosteric pocket as monastrol (138). In comparison to monastrol, CK-238273 has a 65% increase in hydrophobic interaction area and a superior fit in the allosteric pocket. In addition, a key hydrogen bond is made between the primary amine of the compound and Glu116 and the 8-chloro group on the quinazoline ring forms a stabilizing interactions with Arg221 (138). The additional interactions and superior fit lead to the nanomolar Ki. In addition to these compounds, the number of published non-ATP competitive compounds targeting Eg5 has increased dramatically. The available chemotypes include, but are not limited to, monastrol analogs, dihydropyrroles, dihydropurazoles, tetrahydrocarbolines, tetrahydroisoquinolines, and thiophenes (139). A recent survey of 25 available chemical structures of non-ATP competitive inhibitors has led to the development of a three-dimensional pharmacophore model, which distills the common features of these compounds. The resulting model consists of one hydrogen-bond acceptor, one hydrogen-bond donor, one aromatic ring, and one hydrophobic group suitably arranged in space (140). Like any binding pocket, the allosteric pocket of Eg5 can mutate when put under the selective pressure generated by exposure to compounds in such a way as to acquire resistance to those compounds. It has been possible to generate a colorectal tumor cell line resistant to quinazolinone Eg5 inhibitors. The resistance was conferred via a D130V mutation in the loop 5 region (141, 142). It is possible that an allosteric pocket might be more or less susceptible to the selective pressure mediated by compound exposure. If the pocket has a critical biological role or is immutable due to structural constraints, it will be less susceptible to selective pressure. If the pocket is fortuitous in nature, it will be more susceptible to selective pressure. Thus, the resistance profile of a compound targeting an allosteric pocket is unlikely to be superior to that of an ATP-competitive inhibitor, but it will likely be different. The biological role of the allosteric pocket in Eg5, if any, is currently unknown. The discovery of ATP-competitive inhibitors has lagged significantly behind the discovery and development of compounds targeting the allosteric-binding site, but there have been publications discussing compounds that have all the hallmarks of ATP-competitive inhibitors. For example, the thiazole-containing compound shown in Fig. 13a was identified from a highthroughput screen from the Merck compound collection, has a modest IC50 of 11 uM, and has shown to be competitive for ATP and uncompetitive with microtubules in steady-state ATPase assays (143). Further elaboration of this thiazole scaffold by substituting the methyl group on the benzylic methylene with a
78
Murray and Bussiere
1,1-substituted cyclopropane, as well as introduction of chloro group at the 4-position of the benzyl ring yielded the most potent analog, with this compound reaching an IC50 of 290 nM (Fig. 13). Despite the enticing kinetic data, the exact binding site of these compounds has yet to be determined and no costructure is available. Other ATP-competitive compounds have also been reported (144). Why is it so difficult to discover and optimize ATP-competitive inhibitors of kinesins and yet relatively straightforward to discover inhibitors which target an allosteric site? There is no simple answer, but consider the following: The ATP-binding site of Eg5 is modest in terms of both size and its affinity for ATP. In fact, Eg5 only recognizes the purine based by interacting with the basest of chemical features (the phosphates and the shape and charge of the aromatic ring) and does not make any direct hydrogen bonds with the purine base itself. The high concentration of ATP in the cell abrogates the necessity for this. Thus, the ATP-binding site may indeed not be highly featured enough or large enough to bind a compound significantly different chemically from ATP. In addition, Eg5 exists at “rest” in its ADP-bound form. As shown, the binding of compounds to the allosteric site stabilizes the ADP-bound form of Eg5. Thus, enzymatic screens will tend to favor the discovery of allosteric inhibitors as they are typically run at ATP levels that are below the saturation level, when the ADP-bound form will be more prevalent. This affinity for ADP will also interfere in subsequent costructure determination, preventing the possibility of a drug design campaign. Alternatively, the allosteric site may simply be more highly featured in terms of shape and available interactions and therefore more likely to yield attractive, drug-like hits. Regardless of the explanation, Eg5 serves as an example of a target where the most amenable site for drug discovery is separate and distinct from the ATP-binding pocket, which would serve as the “traditional” active site. Such allosteric sites have also been discovered in other members of the purinome, such as kinases (145, 146). 6.4. Ras (Small G Protein) – Theoretically Druggable, but Difficult in Practice
Ras proteins were originally identified as the gene products of oncogenes capable of inducing cell transformation. Ras is the most frequently mutated oncogene in both solid and soft tumors and is arguably the most highly validated oncology drug target available today. The human genome codes for three RAS genes that give rise to four proteins: H-Ras, K-Ras4A, K-Ras4B, and N-Ras; the K-Ras4A and K-Ras4B isoforms arise from differential splicing of the KRAS gene (147, 148). K-Ras is most mutated in solid tumors, while N-Ras is most frequently mutated in leukemias (149–151). The Ras proteins are part of a superfamily of proteins known as small G proteins. The superfamily can be further divided into the Ras, Rab, Ran, Rho, Sar1/Arf, and Ran
Targeting the Purinome
79
families. The Ras and Rho families regulate gene expression, the Rab and Sar1/Arf families help regulate vesicular transport, and the Ran family regulates the cell cycle as well as nuclear transport. The superfamily of G-proteins is monomeric with molecular weights spanning from 20 to 40 kDa with primary sequence conservation between members running from approximately 30 to 55% homology. Within the Ras family, the homology is much higher at approximately 50%. The cellular localization and biological function of small G-proteins depends on posttranslational modification, which can include attachment of lipid groups, proteolytic cleavage, or methylation. H-Ras and N-Ras are palmitoylated and farnesylated and their C-terminal Cys residue is carboxymethylated, K-Ras is farnesylated, and all Ras isoforms have a small C-terminal peptide removed via proteolysis by an endopeptidase. These modifications ensure their localization to the lipid membrane. Small G proteins are classified as enzymes, functioning as GTP hydrolases. Their enzymatic function is quite poor with kcat in range of 0.03/min (Ras family) to 0.003/min (152). This low level of activity underlies their true cellular function, which is to serve as a readily diffusible switch that can exist in two and only two possible states: ON (or active; GTP-bound form) and OFF (inactive; GDP-bound form). The hydrolase activity exists to ensure that the “switch” function does not become trapped in a permanent ON state, but instead cycles to OFF automatically at a regular interval. To ensure this binary (ON/OFF) mode of function, small G-proteins have an extremely high affinity for their cofactor. For example, Ras’ affinity for GTP (Kd) is estimated to be 10−11 M (153, 154). The affinity for GDP is approximately ten-fold lower (153). This high affinity and high cellular levels of GTP ensure that Ras practically never exists in a purine-free form. It also has another consequence, in that it has allowed for the evolution of mechanisms for exquisitely precise positive and negative regulation of small G-proteins. An example of a typical and simplified activation cycle for Ras is as follows (note that this cycle varies slightly between family members): In response to a signal, guanine nucleotide exchange factor (GEF) proteins interact with Ras and stimulate the exchange of GDP to GTP, thus activating Ras (148, 155). Ras activation is reversed by GTPase-activating proteins (GAPs), which stimulate the intrinsic GTPase activity of Ras, thereby completing the cycle (148, 155). In regard to tertiary structure, Ras shares a unique 20-kDa catalytic domain with the entire small G-protein superfamily. This domain comprises five a-helices (denoted a1–a5), six b-strands (b1–b6), and five loops (G1–G5) (153). Typically, within a particular protein fold, primary sequence is most highly conserved within the secondary structure elements. The opposite is true for this protein fold, where the loops are more highly conserved
80
Murray and Bussiere
between family members (152, 156). The reason for this conservation is functional in nature. The G1 loop (also known as the P-loop), which connects B1 and A1, interacts with the a- and b-phosphates of the GTP through mainchain interactions as well as with the sidechain of Lys16 (numbering as per Ras structures). The G2 loop connects a1 and b2 and contains a critical Thr residue (Thr35) responsible for coordinating to the Mg2+, which is directly coordinated to the GTP via the a- and g-phosphates and also presents Phe28 which forms a distant pi–pi interaction with the guanine base. The G2 region, also known as the effector loop, is highly conserved in GTPases. The G3 loop, which connects b3 and a2, interacts with both the g-phosphate of GTP and the Mg2+, via a water-mediated interaction with Asp57. This region is conserved in all GTPases. The purine base is recognized by two loops, G4 and G5. The G4 loop, which connects b5 and a4, contains a consensus sequence -NKXD- in which Lys117 forms a hydrogen bond to the ribose sugar and Asp119 forms two hydrogen bonds with the guanine base. The G5 loop, which connects b6 and a5, also serves as a recognition sequence for the guanine base by interacting with the exocyclic oxygen via the mainchain amide of Ala146; this interaction would be lacking in ATP and loss of this interaction weakens the affinity by approximately three orders of magnitude, as one would expect from the loss of a strong hydrogen-bond (see Note 6). This, as well as the pi–pi interaction with Phe28 –an interaction specific to Ras– and additional mainchain interactions allow for exclusion of ATP binding (see Fig. 14): G-proteins bind GTP with sevens orders of magnitude higher affinity than ATP (157). In fact, it is possible to alter this specificity via judicious point mutations with serious biological consequences (158, 159). Small G proteins exploit virtually every enthalpic interaction possible with GTP and GDP, thereby explaining their high affinity for these cofactors. This level of interaction between protein and cofactor is atypical for purine-binding proteins. GTP hydrolysis occurs via an SN2 mechanism in which a water molecule is activated by Gln61, which serves as the catalytic base (160–162). GAPs stimulate this activity by positioning an arginine residue into the GTP/GDP-binding site, placing the positively charged guanidino-group proximal to the g-phosphate, thereby stabilizing the negatively charged transition state and promoting the hydrolysis reaction (163). Removal of the g-phosphate leads to pronounced conformational changes in a few distinct regions, revealing the difference between the active and inactive forms. These conformational changes occur in the switch I (G2) and switch II regions (comprising a2 and G3; also known as the effector loop because of its role in effector protein binding) (164–167). These changes are shown in Fig. 15.
Targeting the Purinome
81
Lys117 Asp119
Gly13
Lys16
Gly15
Gly60 Ala18 Mg2+
Thr35
Phe28
Fig. 14. The Ras guanine nucleotide-binding pocket. The figure is in approximately the same orientation as the figure that follows. Important mainchain and sidechain interactions are indicated by dotted lines and distances (in Å) and the pertinent residues are labeled. The Ras:GTP complex is approximated by the cocrystallization of a nonhydrolyzable GTP analog containing a methylene linkage between the b- and g-phosphates (PDB ID 5P21).
The binding of GEFs to Ras requires the P-loop, switch I, and switch II regions to be in the inactive or the GTP-free conformations. Likewise, the active conformation of the switch I and II regions is required for binding to effector proteins and GAPs. The most prevalent activating mutations in Ras are G12D and G12V. The activation occurs primarily through two mechanisms. First, the mutation of the small glycine residue to a bulkier residue leads to a shielding of the nucleophilic water from the g-phosphate. Second, the mutation prevents proper placement of the catalytic arginine residue from GAPs (168). The combined effect is a drastic decrease in GTP hydrolysis. The complexities of developing a GTP-competitive therapeutic for Ras do not lie in its druggability. The active site of Ras is suitable for the isolation and optimization of such a compound. The first barrier is structural in nature: A GTP/GDP-competitive inhibitor of Ras must necessarily promote the formation the inactive conformation of the protein or another conformation that is not recognizable to proteins which interact with Ras. A compound that stabilizes the formation of the active form of Ras would likely be highly oncogenic. The second barrier is thermodynamic: the Kd of Ras for GTP is 10−11 M and the concentration of GTP in the cell is in the mM range. This ensures that Ras will virtually
82
Murray and Bussiere
A4
A3
G4 B6 B5 A5
B4
G1
G3 A2 Switch II
Mg 2+ G5
B3
Switch I
Mg2+ Switch II
B2 Switch I A1
GTP-Bound (‘On’) Conformation
GDP-Bound (‘Off’) Conformation
Fig. 15. Conformational differences between Ras:GTP:Mg2+ and Ras:GDP:Mg2+ (PDB ID 4Q21) complexes. The a-helices are denoted A1–A5, the b-sheets are denoted B1–B6, and the loops are denoted G1–G5. The Ras:GTP complex is approximated by the cocrystallization of a nonhydrolyzable GTP analog containing a methylene linkage between the b- and g-phosphates (PDB ID 5P21). The GTPase activity of Ras prevents crystallization of the complex with GTP. Note the significant conformational differences within the Switch I and Switch II regions between the two structures. The transition between these two states occurs upon GTP hydrolysis.
always be present in the GTP- or GDP-bound forms. To compete successfully with this concentration of cellular GTP, a compound would need bind to Ras with picomolar affinity and be capable of reaching equivalent (or higher) cellular concentrations. While the affinity requirement can be reached with difficulty, the concentration requirement likely cannot be achieved. For example, it has been possible to synthesize GTP analogs that show higher affinity for Ras than either GTP or GDP (190); see Fig. 16. However, it is likely that these compounds would not be specific inhibitors and have unsuitable pharmacokinetic and physiochemical properties given that they are nucleoside triphosphates (189, 190); the triphosphate moiety - or at the very least a disphosphate - is critical for binding. Thus, Ras serves as an example that an amenable binding site is necessary, but not sufficient, for drug discovery. The biochemistry of the system is also of paramount importance. Because of this, considerable work has been undertaken to attempt to develop compounds that inhibit effectors (189, 191). Another possible strategy would be to directly disrupt the interaction of Ras with effectors through a small-molecule therapeutic or to target a yet-unidentified cryptic binding site on Ras to inhibit it allosterically. Given the existing thermodynamic constraints, these two strategies will likely prove more successful than trying to develop a GTP/GDP-competitive drug. For example, there
Targeting the Purinome
a
83
O N
−O
P O−
O
P O−
R
O
O
O
N
O
P
O
N
N
O
O−
N H R=p-FC6H4 p-BrC6H4 p-n-BuC6H4
OH OH
Base Mo dified GTP Analogue
c
O
b
OH
F
O
OH
F
O O
S
Sulindac Sulfide
Optimized Sulindac Analogue
Fig. 16. Chemical structures for Ras inhibitors. (a) GTP analogs with modified bases bind to Ras with up to a Krel (IC50 of Analog divided by the IC50 of GDP) of 3.30. (b) Sulindac sulfide ((3Z)-3-(4-(methylthio)benzylidene)-6-fluoro-3,3adihydro-2-methyl-2H-indene-1-carboxylic acid) disrupts this interaction with an IC50 of approximately 210 mM. (c) An optimized sulindac analog ((3Z)-6-fluoro-3-((furan-3-yl)methylene)-3,3a-dihydro-2-methyl-2H-indene-1-carboxylic acid) has an IC50 of approximately 30 mM. The molecular basis of the compound’s mechanism of action is unknown, but both (b) and (c) are hypothesized to operate by disrupting Ras–Raf interactions.
is experimental evidence that the nonsteroidal anti-inflammatory drug sulindac sulfide inhibits Ras signaling by binding in a noncovalent manner and inhibiting its interaction other proteins with Ras–binding domains, such as Raf (169). The IC50 for the inhibition of Ras–Raf interaction is approximately 210 mM, and analogs have been synthesized that disrupt the Ras–Raf interaction with an IC50 of 30 mM (169, 170) (Fig. 16). As the interaction has no effect on Ras’ GTPase activity, it is necessary that this interaction occur at a site distinct from the active site, although no structural information is available for the nature of the interaction.
84
Murray and Bussiere
7. Conclusion In this chapter, we have strived to expose the reader to the complexities of the purinome, as well as to the methodologies and technologies that can be employed to help in the discovery of new drugs targeting these proteins. As demonstrated, the purinome is a significant and complex component of the human genome. While there are common themes across the purinome, such as positioning of the P-loop to recognize the triphosphate group of ATP and GTP and other such sequence motifs, there is also incredible variation in the exact interactions that are involved with purine recognition, as well as variation in overall protein fold, function, and mechanism. As shown in each of the preceding sections, the druggability and the methodologies used to discover drugs for each selected protein will vary from protein to protein, although it will likely be possible to use common approaches within protein families. Many targets will yield to traditional approaches. Others, such as the small G-proteins represented by Ras will require novel approaches and perhaps even the development novel chemistries to produce compounds occupying a new segment of chemical “space.” In some, the purine-binding pocket and/or active site will be suitable for drug discovery. In others, it will not or there will be a biological or thermodynamic impediment and novel binding pockets will need to be identified. Given this, the work done on targeting the purinome will certainly yield significant scientific discoveries, as well as novel pharmaceutical compounds, over the coming years.
8. Notes 1. The authors recognize that many biologically active purines are not reviewed herein, for example, nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), as well as enzymatically modified analogs of ATP and GTP. These omissions are purposeful and have been instituted to limit the scope of the review. The reader is encouraged to peruse Chapter 4 within this volume for more examples. 2. These complexes can range from homomultimers to supramolecular complexes of multiple proteins such as a virus capsid. In this review, we will focus on single proteins for the sake of simplicity, but the reader should be aware that druggable pockets could exist within these larger
Targeting the Purinome
85
complexes as well. In addition, they can occur at the interfaces between protein and other types of chemical matter, such as RNA or DNA. 3. For example, recent clinical research has been focused on the use of PDE5 inhibitors in the treatment of pulmonary hypertension. See http://clinicaltrials.gov for more information. 4. As one would predict, neutropenia is a demonstrated clinical consequence of treatment with inhibitors of Eg5. 5. In the authors’ experience, a static, immutable binding site makes drug design difficult because opportunities for picking up key contacts for selectivity are limited. In contrast, an active site with high plasticity is likewise difficult to work with as it undergoes some level of structural rearrangement each time it is perturbed, for example, by attaching a novel functional group to a lead compound. 6. Recall from the prior section that a 1000-fold difference in selectivity requires approximately 4.3 kcal/mol difference in binding energy, which is equivalent to a strong hydrogen bond. References 1. Fiske, C.H., and Subbarow, Y. (1929) Phosphorus compounds of muscle and liver. Science 70, 381–2. 2. Lohmann, K. (1929) Über die Pyrophosphatfraktion im Muskel. Naturwissenschaften 17, 624–5. 3. Meyerhof, O., and Lohmann, K. (1932) Über energetische Wechselbeziehungen zwischen dem Umsatz der Phosphorsäureester im Muskelextrakt. Biochem. Z. 253, 431–61. 4. Lohmann, K. (1935) Konstitution der Adenopyrophosporsäure und Adenosindphosphosäure. Biochem. Z. 282, 120–3. 5. Makino, K. (1935) Über die Konstitution der Adenosintriphosposäure. Biochem. Z. 278, 161–3. 6. Rall, T.W., and Sutherland, E.W. (1958) Formation of a cyclic adenine ribonucleotide by tissue particles. J. Biol. Chem. 232, 1065–76. 7. Sutherland, E.W., and Rall, T.W. (1958) Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232, 1077–91. 8. Haynes, R.C. Jr., Sutherland, E.W., and Rall, T.W. (1960) The role of cyclic adenylic acid in hormone action. Recent. Prog. Horm. Res. 16, 121–38. 9. Birnbaumer, L., Pohl, S.L., Michiel, H., Krans, M.J., and Rodbell, M. (1979) The
10.
11.
12. 13.
14.
15.
actions of hormones on the adenyl cyclase system. Adv. Biochem. Psychopharmacol. 3, 185–208. Birnbaumer, L., Pohl, S.L., and Rodbell, M. (1969) Adenyl cyclase in fat cells. 1. Properties and the effects of adrenocorticotropin and fluoride. J. Biol. Chem. 244, 3468–76. Birnbaumer, L., Pohl, S.L., and Rodbell, M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. II. Comparison between glucagon- and fluoride -stimulated activities. J. Biol. Chem. 246, 1857–60. Birnbaumer, L., and Rodbell, M. (1969) Adenyl cyclase in fat cells. II. Hormone receptors. J. Biol. Chem. 244, 3477–82. Pohl, S.L., Birnbaumer, L., and Rodbell, M. (1969) Glucagon-sensitive adenyl cyclase in plasma membrane of hepatic parenchymal cells. Science 164, 566–7. Pohl, S.L., Birnbaumer, L., and Rodbell, M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. I. Properties. J. Biol. Chem. 246, 1849–56. Pohl, S.L., Krans, H.M., Kozyreff, V., Birnbaumer, L., and Rodbell, M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. VI. Evidence for a role of membrane lipids. J. Biol. Chem. 246, 4447–54.
86
Murray and Bussiere
16. Rodbell, M., Birnbaumer, L., Pohl, S.L., and Krans, H.M. (1979) Properties of the adenyl cyclase systems in liver and adipose cells: The mode of action of hormones. Acta Diabetol. Lat. 7(Suppl 1), 9–63. 17. Rodbell, M., Birnbaumer, L., and Pohl, S.L. (1971) Characteristics of glucagon action on the hepatic adenylate cyclase system. Biochem. J. 125, 58P-9P. 18. Rodbell, M., Birnbaumer, L., and Pohl, S.L. (1970) Adenyl cyclase in fat cells. 3. Stimulation by secretin and the effects of trypsin on the receptors for lipolytic hormones. J. Biol. Chem. 245, 718–22. 19. Rodbell, M., Birnbaumer, L., Pohl, S.L., and Sundby, F. (1971) The reaction of glucagon with its receptor: Evidence for discrete regions of activity and binding in the glucagon molecule. Proc. Natl. Acad. Sci. U.S.A. 68, 909–13. 20. Rodbell, M., Krans, H.M., Pohl, S.L., and Birnbaumer, L. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. 3. Binding of glucagon: Method of assay and specificity. J. Biol. Chem. 246, 1861–71. 21. Rodbell, M., Krans, H.M., Pohl, S.L., and Birnbaumer, L. (1971) The glucagonsensitive adenyl cyclase system in plasma membranes of rat liver. IV. Effects of guanylnucleotides on binding of 125I-glucagon. J. Biol. Chem. 246, 1872–6. 22. Rodbell, M., Birnbaumer, L., Pohl, S.L., and Krans, H.M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action. J. Biol. Chem. 246, 1877–82. 23. Ashman, D.F., Lipton, R., Melicow, M.M., and Price, T.D. (1963) Isolation of adenosine 3¢, 5¢-monophosphate and guanosine 3¢, 5¢-monophosphate from rat urine. Biochem. Biophys. Res. Commun. 11, 330–4. 24. Furchgott, R.F., and Zawadzki, J.V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373–6. 25. Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., and Chaudhuri, G. (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84, 9265–9. 26. Ignarro, L.J., Byrns, R.E., Buga, G.M., and Wood, K.S. (1987) Endothelium-derived relaxing factor from pulmonary artery and
27. 28. 29. 30.
31. 32.
33.
34.
35.
36. 37.
38. 39. 40.
vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 61, 866–79. Levene, P.A. (1909) Über die Hefenucleinsäure. Biochem. Z. 17, 120–31. Levene, P.A. (1919) The structure of yeast nucleic acid. IV. Ammonia hydrolysis. J. Biol. Chem. 40, 415–24. Haystead, T.A. (2006) The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6, 1117–27. International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of the human genome. Nature 431, 931–45. Cohen, P. (2002) Protein kinases – the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309–15. Ja, W.W., and Roberts, R.W. (2005) G-protein -directed ligand discovery with peptide combinatorial libraries. Trends Biochem. Sci. 30, 318–24. Marshall, G.R., Head, R.D., and Ragno, R. (2000) Affinity prediction: The sine qua non. In: Di Cera, E. (ed.) Thermodynamics in Biology. Oxford University Press, Oxford, pp. 87–111. Holdgate, G.A., and Ward, W.H. (2005) Measurements of binding thermodynamics in drug discovery. Drug Discov. Today 10, 1543–50. Knapp, M., Bellamacina, C., Murray, J.M., and Bussiere, D.E. (2006) Targeting cancer: The challenges and successes of structure-based drug design against the human purinome. Curr. Top. Med. Chem. 6, 1129–59. Traut, T.W. (1994) Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140, 1–22. Cheng, Y., and Prusoff, W.H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–108. Ghaemmaghami, S., Huh, W.K., Bower, K., et al. (2003) Global analysis of protein expression in yeast. Nature 425, 737–41. Knight, Z.A., and Shokat, K.M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621–37. Arooz, T., Yam, C.H., Siu, W.Y., Lau, A., Li, K.K., and Poon, R.Y. (2000) On the concentrations of cyclins and cyclin-dependent kinases in extracts of cultured human cells. Biochemistry 39, 9494–501.
41. Bhatt, R.R., and Ferrell, J.E. Jr. (2000) Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs. J. Biol. Chem. 275, 32983–90. 42. Hopkins, A.L., and Groom, C.R. (2002) The druggable genome. Nat. Rev. Drug Discov. 1, 727–30. 43. Keller, T.H., Pichota, A., and Yin, Z. (2006) A practical view of ‘druggability’. Curr. Opin. Chem. Biol. 10, 357–61. 44. Walke, D.W., Han, C., Shaw, J., Wann, E., Zambrowicz, B., and Sands, A. (2001) In vivo drug target discovery: Identifying the best targets from the genome. Curr. Opin. Biotechnol. 12, 626–31. 45. Schneider, M. (2004) A rational approach to maximize success rate in target discovery. Arch. Pharm. 337, 625–33. 46. Peters, K.P., Fauck, J., and Frommel, C. (1996) The automatic search for ligand binding sites in proteins of known threedimensional structure using only geometric criteria. J. Mol. Biol. 256, 201–13. 47. Liang, J., Edelsbrunner, H., and Woodward, C. (1998) Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein Sci. 7, 1884–97. 48. Hendlich, M., Rippmann, F., and Barnickel, G. (1997) LIGSITE: Automatic and efficient detection of potential small moleculebinding sites in proteins. J. Mol. Graph. Model. 15, 359–63. 49. Brady, G.P. Jr., and Stouten, P.F. (2000) Fast prediction and visualization of protein binding pockets with PASS. J. Comput. Aided Mol. Des. 14, 383–401. 50. An, J., Totrov, M., and Abagyan, R. (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol. Cell Proteomics 4, 752–61. 51. Laskowski, R.A. (1995) SURFNET: A program for visualizing molecular surfaces, cavities, and intermolecular interactions. J. Mol. Graph. 13, 323–30. 52. Goodford, P.J. (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28, 849–57. 53. Kortvelyesi, T., Dennis, S., Silberstein, M., Brown, L. III, and Vajda, S. (2003) Algorithms for computational solvent mapping of proteins. Proteins 51, 340–51. 54. Silberstein, M., Dennis, S., Brown, L., Kortvelyesi, T., Clodfelter, K., and Vajda, S. (2003) Identification of substrate binding
Targeting the Purinome
55.
56.
57. 58. 59.
60. 61.
62. 63.
64.
65.
66.
67.
68.
87
sites in enzymes by computational solvent mapping. J. Mol. Biol. 332, 1095–113. Hajduk, P.J., Huth, J.R., and Fesik, S.W. (2005) Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48, 2518–25. Brunger, A.T. (1997) X-ray crystallography and NMR reveal complementary views of structure and dynamics. Nat. Struct. Biol. 4 (Suppl), 862–5. Krebs, E.G., and Beavo, J.A. (1979) Phosphorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 48, 923–59. Nestler, E.J., and Greengard, P (1983). Protein phosphorylation in the brain. Nature 305, 583–8. Lohmann, S.M., Walter, U., and Greengard, P. (1980) Identification of endogenous substrate proteins for cAMP-dependent protein kinase in bovine brain. J. Biol. Chem. 255, 9985–92. Langan, T.A. (1968) Histone phosphorylation: Stimulation by adenosine 3¢,5¢-mono phosphate. Science 162, 579–80. Mayer, S.E., and Krebs, E.G. (1970) Studies on the phosphorylation and activation of skeletal muscle phosphorylase and phosphorylase kinase in vivo. J. Biol. Chem. 245, 3153–60. Krebs, E.G., and Stull, J.T. (1975) Protein phosphorylation and metabolic control. Ciba Found. Symp. 31, 355–67. Cobbs, W.H., Barkdoll, A.E. III, and Pugh, E.N. Jr. (1985) Cyclic GMP increases photocurrent and light sensitivity of retinal cones. Nature 317, 64–6. Kurkin, S.A., Kislov, A.N., and Fesenko, E.E. (1982) Conductance of cytoplasmic membrane of photoreceptors by the method of intracellular dialysis. Biofizika 27, 1053–6. Yau, K.W., and Nakatani, K. (1985) Lightsuppressible, cyclic GMP-sensitive conductance in the plasma membrane of a truncated rod outer segment. Nature 317, 252–5. Bruch, R.C., and Kalinoski, D.L. (1987) Interaction of GTP-binding regulatory proteins with chemosensory receptors. J. Biol. Chem. 262, 2401–4. Striem, B.J., Pace, U., Zehavi, U., Naim, M., and Lancet, D. (1989) Sweet tastants stimulate adenylate cyclase coupled to GTPbinding protein in rat tongue membranes. Biochem. J. 260, 121–6. Butcher, R.W., and Sutherland, E.W. (1962) Adenosine 3¢,5¢-phosphate in biological materials. I. Purification and properties of cyclic 3¢,5¢-nucleotide phosphodiesterase
88
69. 70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
Murray and Bussiere and use of this enzyme to characterize adenosine 3¢,5¢-phosphate in human urine. J. Biol. Chem. 237, 1244–50. Beavo, J.A., Conti, M., and Heaslip, R.J. (1994) Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46, 399–405. Wang, H., Liu, Y., Hou, J., Zheng, M., Robinson, H., and Ke, H. (2007) Structural insight into substrate specificity of phosphodiesterase 10. Proc. Natl. Acad. Sci. U.S.A. 104, 5782–7. Wang, H., Liu, Y., Chen, Y., Robinson, H., and Ke, H. (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J. Biol. Chem. 280, 30949–55. Iffland, A., Kohls, D., Low, S., et al. (2005) Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system. Biochemistry 44, 8312–25. Huai, Q., Colicelli, J., and Ke, H. (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42, 13220–6. Huai, Q., Wang, H., Sun, Y., Kim, H.Y., Liu, Y., and Ke, H. (2003) Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 11, 865–73. Xu, R.X., Hassell, A.M., Vanderwall, D., et al. (2000) Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science 288, 1822–5. Lee, M.E., Markowitz, J., Lee, J.O., and Lee, H. (2002) Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 530, 53–8. Sung, B.J., Hwang, K.Y., Jeon, Y.H., et al. (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425, 98–102. Huai, Q., Wang, H., Zhang, W., Colman, R.W., Robinson, H., and Ke, H. (2004) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. U.S.A. 101, 9624–9. Xu, R.X., Rocque, W.J., Lambert, M.H., Vanderwall, D.E., Luther, M.A., and Nolte, R.T. (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J. Mol. Biol. 337, 355–65. Scapin, G., Patel, S.B., Chung, C., et al. (2004) Crystal structure of human phosphodiesterase 3B: Atomic basis for substrate
81.
82.
83. 84.
85.
86.
87.
88.
89.
90.
91.
92.
and inhibitor specificity. Biochemistry 43, 6091–100. Liu, S., Mansour, M.N., Dillman, K.S., et al. (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc. Natl. Acad. Sci. U.S.A. 105, 13309–14. Card, G.L., England, B.P., Suzuki, Y., et al. (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12, 2233–47. Beavo, J.A. (1995) Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 75, 725–48. Zhang, K.Y., Card, G.L., Suzuki, Y., et al. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell. 15, 279–86. Francis, S.H., Colbran, J.L., McAllisterLucas, L.M., and Corbin, J.D. (1994) Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J. Biol. Chem. 269, 22477–80. Rotella, D.P. (2002) Phosphodiesterase 5 inhibitors: Current status and potential applications. Nat. Rev. Drug Discov. 1, 674–82. Haning, H., Niewohner, U., Schenke, T., Lampe, T., Hillisch, A., and Bischoff, E. (2005) Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors. Bioorg. Med. Chem. Lett. 15, 3900–7. Rotella, D.P. (2006) Phosphodiesterases. In: Taylor, J.D., and Triggle, D.J. (eds.) Comprehensive Medicinal Chemistry II. Elsevier, Oxford, pp. 919–57. Haning, H., Niewoehner, U., Bischoff, E. (2003) Phosphodiesterase Type 5 (PDE5) Inhibitors. Progress in Medicinal Chemistry 41, 246–306. Sekhar, K.R., Grondin, P., Francis, S.H., and Corbin, J.D. (1996) Design and synthesis of xanthines and cyclic GMP analogues as potent inhibitors of PDE5. In: Schudt, C. (ed.) The Handbook of Immunopharmacology. Academic Press, New York, pp. 135–46. Huai, Q., Liu, Y., Francis, S.H., Corbin, J.D., and Ke, H. (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem. 279, 13095–101. Kramer, G.L., and Wells, J.N. (1979) Effects of phosphodiesterase inhibitors on cyclic nucleotide levels and relaxation of pig coronary arteries. Mol. Pharmacol. 16, 813–22.
93. Garst, J.E., Kramer, G.L., Wu, Y.J., and Wells, J.N. (1976) Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine. J. Med. Chem. 19, 499–503. 94. Wang, H., Liu, Y., Huai, Q., et al. (2006) Multiple conformations of phosphodiesterase-5: Implications for enzyme function and drug development. J. Biol. Chem. 281, 21469–79. 95. Eros, D., Szantai-Kis, C., Kiss, R., et al. (2008) Structure -activity relationships of PDE5 inhibitors. Curr. Med. Chem. 15, 1570–85. 96. Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912–34. 97. Adams, JA. (2001) Kinetic and catalytic mechanisms of protein kinases. Chem Rev 101, 2271–90. 98. Ubersax, J.A., and Ferrell, J.E. Jr. (2007) Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell. Biol. 8, 530–41. 99. Benson, J.D., Chen, Y.N., Cornell-Kennon, S.A., et al. (2006) Validating cancer drug targets. Nature 441, 451–6. 100. Walker, I., and Newell, H. (2009) Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15–6. 101. Vieth, M., Higgs, R.E., Robertson, D.H., Shapiro, M., Gragg, E.A., and Hemmerle, H. (2004) Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697, 243–57. 102. Karaman, M.W., Herrgard, S., Treiber, D.K., et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–32. 103. Liu, Y., Shah, K., Yang, F., Witucki, L., and Shokat, K.M. (1998) A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg. Med. Chem. 6, 1219–26. 104. Liu, Y., Shah, K., Yang, F., Witucki, L., and Shokat, K.M. (1998) Engineering Src family protein kinases with unnatural nucleotide specificity. Chem. Biol. 5, 91–101. 105. Bishop, A.C., and Shokat, K.M. (1999) Acquisition of inhibitor-sensitive protein kinases through protein design. Pharmacol. Ther. 82, 337–46. 106. Blencke, S., Zech, B., Engkvist, O., et al. (2004) Characterization of a conserved structural determinant controlling protein
Targeting the Purinome
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117. 118.
89
kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691–701. Alaimo, P.J., Knight, Z.A., and Shokat, K.M. (2005) Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg. Med. Chem. 13, 2825–36. Liu, Y., and Gray, N.S. (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358–64. Manley, P.W., Cowan-Jacob, S.W., and Mestan, J. (2005) Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta. 1754, 3–13. Lee, J.C., Kassis, S., Kumar, S., Badger, A., and Adams, J.L. (1999) p38 mitogen-activated protein kinase inhibitors – mechanisms and therapeutic potentials. Pharmacol. Ther. 82, 389–97. Wilson, K.P., McCaffrey, P.G., Hsiao, K., et al. (1997) The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423–31. Wang, Z., Canagarajah, B.J., Boehm, J.C., et al. (1998) Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117–28. Zhang, Q., Liu, Y., Gao, F., et al. (2006) Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinasedirected heterocycle library. J. Am. Chem. Soc. 128, 2182–3. Ghose, A.K., Herbertz, T., Pippin, D.A., Salvino, J.M., and Mallamo, J.P. (2008) Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J.Med. Chem. 51, 5149–71. Bohmer, F.D., Karagyozov, L., Uecker, A., et al. (2003) A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278, 5148–55. Honma, T., Yoshizumi, T., Hashimoto, N., et al. (2001) A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 44, 4628–40. Teague, S.J. (2003) Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2, 527–41. Huse, M., and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275–82.
90
Murray and Bussiere
119. Wood, E.R., Truesdale, A.T., McDonald, O.B., et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor offrate, and receptor activity in tumor cells. Cancer Res. 64, 6652–9. 120. Heron, N.M., Anderson, M., Blowers, D.P., et al. (2005) SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16, 1320–3. 121. Bellon, S.F., Kaplan-Lefko, P., Yang, Y., et al (2008) c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J. Biol. Chem. 283, 2675–83. 122. Stamos, J., Sliwkowski, M.X., and Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265–72. 123. Kufareva, I., and Abagyan, R. (2008) Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J. Med. Chem. 51, 7921–32. 124. Vale, R.D., and Milligan, R.A. (2000) The way things move: Looking under the hood of molecular motor proteins. Science 288, 88–95. 125. Sakowicz, R., Finer, J.T., Beraud, C., et al. (2004) Antitumor activity of a kinesin inhibitor. Cancer Res. 64, 3276–80. 126. Kolomeisky, A.B., and Fisher, M.E. (2007) Molecular motors: A theorist’s perspective. Annu. Rev. Phys. Chem. 58, 675–95. 127. Vale, R.D., and Fletterick, R.J. (1997) The design plan of kinesin motors. Annu. Rev. Cell Dev. Biol. 13, 745–77. 128. Vetter, I.R., and Wittinghofer, A. (1999) Nucleoside triphosphate-binding proteins: Different scaffolds to achieve phosphoryl transfer. Q. Rev. Biophys. 32, 1–56. 129. Turner, J., Anderson, R., Guo, J., Beraud, C., Fletterick, R., and Sakowicz, R. (2001) Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the necklinker. J. Biol. Chem. 276, 25496–502. 130. Sablin, E.P., Kull, F.J., Cooke, R., Vale, R.D., and Fletterick, R.J. (1996) Crystal structure of the motor domain of the kinesin-related motor ncd. Nature 380, 555–9. 131. Kull, F.J., Sablin, E.P., Lau, R., Fletterick, R.J., and Vale, R.D. (1996) Crystal structure of the kinesin motor domain reveals a structural similarity to myosin. Nature 380, 550–5.
132. Lad, L., Luo, L., Carson, J.D., et al. (2008) Mechanism of inhibition of human KSP by ispinesib. Biochemistry 47, 3576–85. 133. Hopkins, S.C., Vale, R.D., and Kuntz, I.D. (2000) Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 39, 2805–14. 134. Mayer, T.U., Kapoor, T.M., Haggarty, S.J., King, R.W., Schreiber, S.L., and Mitchison, T.J. (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286, 971–4. 135. Maliga, Z., Kapoor, T.M., and Mitchison, T.J. (2002) Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem. Biol. 9, 989–96. 136. Luo, L., Carson, J.D., Dhanak, D., et al. (2004) Mechanism of inhibition of human KSP by monastrol: Insights from kinetic analysis and the effect of ionic strength on KSP inhibition. Biochemistry 43, 15258–66. 137. Yan, Y.W., Sardana, V., Xu, B., et al. (2004) Inhibition of a mitotic motor protein: Where, how, and conformational consequences. J. Mol. Biol. 335, 547–54. 138. Zhang, B., Liu, J.F., Xu, Y., and Ng, S.C. (2008) Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity. Biochem. Biophys. Res. Commun. 372, 565–70. 139. Zhang, Y., and Xu, W. (2008) Progress on kinesin spindle protein inhibitors as anticancer agents. Anticancer Agents Med. Chem. 8, 698–704. 140. Liu, F., You, Q.D., and Chen, Y.D. (2006) Pharmacophore identification of KSP inhibitors. Bioorg. Med. Chem. Lett. 17, 722–6. 141. Maliga, Z., and Mitchison, T.J. (2006) Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chem. Biol. 6, 2. 142. Brier, S., Lemaire, D., DeBonis, S., Forest, E., and Kozielski, F. (2006) Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. J. Mol. Biol. 360, 360–76. 143. Rickert, K.W., Schaber, M., Torrent, M., et al. (2008) Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch. Biochem. Biophys. 469, 220–31. 144. Parrish, C.A., Adams, N.D., Auger, K.R., et al. (2007) Novel ATP-competitive kinesin spindle protein inhibitors. J. Med. Chem. 50, 4939–52.
145. Tecle, H., Shao, J., Li, Y., et al. (2009) Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEKpocket exist in kinases other than MEK? Bioorg. Med. Chem. Lett. 19, 226–9. 146. Lewis, J.A., Lebois, E.P., and Lindsley, C.W. (2008) Allosteric modulation of kinases and GPCRs: Design principles and structural diversity. Curr. Opin. Chem. Biol. 12, 269–80. 147. Downward, J. (1998) Ras signalling and apoptosis. Curr. Opin. Genet. Dev. 8, 49–54. 148. Buday, L., and Downward, J. (2008) Many faces of Ras activation. Biochim. Biophys. Acta. 1786, 178–87. 149. Nakao, M., Janssen, J.W., Seriu, T., and Bartram, C.R. (2000) Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 14, 312–5. 150. Burmer, G.C., and Loeb, L.A. (1989) Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc. Natl. Acad. Sci. U.S.A. 86, 2403–7. 151. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549–54. 152. Bourne, H.R., Sanders, D.A., and McCormick, F. (1991) The GTPase superfamily: Conserved structure and molecular mechanism. Nature 349, 117–27. 153. Paduch, M., Jelen, F., and Otlewski, J. (2001) Structure of small G proteins and their regulators. Acta Biochim. Pol. 48, 829–50. 154. Feuerstein, J., Kalbitzer, H.R., John, J., Goody, R.S., and Wittinghofer, A. (1987) Characterisation of the metal-ion-GDP complex at the active sites of transforming and nontransforming p21 proteins by observation of the 17O-Mn superhyperfine coupling and by kinetic methods. Eur. J. Biochem. 162, 49–55. 155. Ahmadian, M.R. (2002) Prospects for antiras drugs. Br. J. Haematol. 116, 511–8. 156. Dever, T.E., Glynias, M.J., and Merrick, W.C. (1987) GTP-binding domain: Three consensus sequence elements with distinct spacing. Proc Natl Acad Sci U.S.A. 84, 1814–8. 157. Scheidig, A.J., Franken, S.M., Corrie, J.E., et al. (1995) X-ray crystal structure analysis of the catalytic domain of the oncogene
Targeting the Purinome
158.
159.
160. 161.
162.
163.
164.
165.
166.
167.
168.
91
product p21H-ras complexed with caged GTP and mant dGppNHp. J. Mol. Biol. 253, 132–50. Zhong, J.M., Chen-Hwang, M.C., and Hwang, Y.W. (1995) Switching nucleotide specificity of Ha-Ras p21 by a single amino acid substitution at aspartate 119. J. Biol. Chem. 270, 10002–7. Schmidt, G., Lenzen, C., Simon, I., et al. (1996) Biochemical and biological consequences of changing the specificity of p21ras from guanosine to xanthosine nucleotides. Oncogene 12, 87–96. Kosloff, M., and Selinger, Z. (2001) Substrate assisted catalysis – application to G proteins. Trends Biochem. Sci. 26, 161–6. Kosloff, M., and Selinger, Z. (2003) GTPase catalysis by Ras and other G-proteins: Insights from substrate directed superimposition. J. Mol. Biol. 331, 1157–70. Frech, M., Darden, T.A., Pedersen, L.G., et al. (1994) Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: An experimental and theoretical study. Biochemistry 33, 3237–44. Nassar, N., Horn, G., Herrmann, C., Scherer, A., McCormick, F., and Wittinghofer, A. (1995) The 2.2 A crystal structure of the Ras-binding domain of the serine/ threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 375, 554–60. Zhang, J., and Matthews, C.R. (1998) Ligand binding is the principal determinant of stability for the p21(H)-ras protein. Biochemistry 37, 14881–90. Zhang, J., and Matthews, C.R. (1998) The role of ligand binding in the kinetic folding mechanism of human p21(H-ras) protein. Biochemistry 37, 14891–9. Spoerner, M., Herrmann, C., Vetter, I.R., Kalbitzer, H.R., and Wittinghofer, A. (2001) Dynamic properties of the Ras switch I region and its importance for binding to effectors. Proc. Natl. Acad. Sci. U.S.A. 98, 4944–9. Geyer, M., Schweins, T., Herrmann, C., Prisner, T., Wittinghofer, A., and Kalbitzer, H.R. (1996) Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Biochemistry 35, 10308–20. Al-Mulla, F., Milner-White, E.J., Going, J.J., and Birnie, G.D. (1999) Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J. Pathol. 187, 433–8.
92
Murray and Bussiere
169. Herrmann, C., Block, C., Geisen, C., et al. (1998) Sulindac sulfide inhibits Ras signaling. Oncogene 17, 1769–76. 170. Waldmann, H., Karaguni, M.I., Carpintero, M., et al (2004) Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway. Angew. Chem. Int. Ed. Engl. 43, 454–8. 171. Kyte, J. (2003) The basis of the hydrophobic effect. Biophys. Chem. 100, 193–203. 172. Ruelle, P., and Kesselring, U.W. (1998) The hydrophobic effect. 1. A consequence of the mobile order in H-bonded liquids. J. Pharm. Sci. 87, 987–97. 173. Ruelle, P., and Kesselring, U.W. (1998) The hydrophobic effect. 2. Relative importance of the hydrophobic effect on the solubility of hydrophobes and pharmaceuticals in H-bonded solvents. J. Pharm. Sci. 87, 998–1014. 174. Ruelle, P., and Kesselring, U.W. (1998) The hydrophobic effect. 3. A key ingredient in predicting n-octanol-water partition coefficients. J. Pharm. Sci. 87, 1015–24. 175. Sharp, K.A., Nicholls, A., Fine, R.F., and Honig, B. (1991) Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. Science 252, 106–9. 176. Honig, B., Sharp, K., and Gilson, M. (1989) Electrostatic interactions in proteins. Prog. Clin. Biol. Res. 289, 65–74. 177. Sharp, K.A., and Honig, B. (1990) Electrostatic interactions in macromolecules: Theory and applications. Annu. Rev. Biophys. Biophys. Chem. 19, 301–32. 178. Sinha, N, and Smith-Gill, S.J. (2002) Electrostatics in protein binding and function. Curr. Protein Pept. Sci. 3, 601–14. 179. Paulini, R., Muller, K., and Diederich, F. (2005) Orthogonal multipolar interactions in structural chemistry and biology. Angew. Chem. Int. Ed. Engl. 44, 1788–805.
180. Israelachvili, J.N. (1973) Van der Waals forces in biological systems. Q. Rev. Biophys. 16, 341–87. 181. Fleming, P.J., and Rose, G.D. (2005) Do all backbone polar groups in proteins form hydrogen bonds? Protein Sci. 14, 1911–7. 182. Perrin, C.L., and Nielson, J.B. (1997) “Strong” hydrogen bonds in chemistry and biology. Annu. Rev. Phys. Chem. 48, 511–44. 183. Kim, K.S., Tarakeshwar, P., and Lee, J.Y. (2000) Molecular clusters of pi-systems: Theoretical studies of structures, spectra, and origin of interaction energies. Chem Rev 100, 4145–86. 184. McGaughey, G.B., Gagne, M., and Rappe, A.K. (1998) pi-Stacking interactions. Alive and well in proteins. J. Biol. Chem. 273, 15458–63. 185. Sinnokrot, M.O., and Sherrill, C.D. (2004) Substituent effects in pi-pi interactions: Sandwich and T-shaped configurations. J. Am. Chem. Soc. 126, 7690–7. 186. Crowley, P.B., and Golovin, A. (2005) Cation–pi interactions in protein–protein interfaces. Proteins 59, 231–9. 187. Cubero, E., Luque, F.J., and Orozco, M. (1998) Is polarization important in cationpi interactions? Proc. Natl. Acad. Sci. U.S.A. 95, 5976–80. 188. Gallivan, J.P, and Dougherty, D.A. (1999) Cation– pi interactions in structural biology. Proc. Natl. Acad. Sci. U.S.A. 96, 9459–64. 189. Wittinghofer, A., and Waldmann, H. Ras – A molecular switch involved in tumor formation. Angew. Chem. Int. Ed. Engl. 39, 4192–214 190. Noonan, T., Brown, N., Dudycz, L., and Wright, G. (1991) Interaction of GTP derivatives with cellular and oncogenic rasp21 proteins. J. Med. Chem. 34, 1302–7. 191. Ahmadian, MR. (2002) Prospects for antiras drugs. Br. J. Haematol. 116, 511–8.
Chapter 4 Cofactor Chemogenomics Ratna Singh and Andrea Mozzarelli Summary Cofactors are organic molecules, most of them originating from vitamins, that bind to enzymes making them able to catalyze defined reactions. A cofactor-based chemogenomics approach exploits the presence of a cofactor-binding domain to develop compound scaffolds tailored to mimic the cofactor and to replace it within target enzyme classes. As a result, a loss of function is observed. An expansion of the cofactor scaffold to include structural/chemical features derived from the substrate, that usually binds at cofactor adjacent sites, increases the specificity of the enzyme fishing. This approach has been so far applied only to NAD(P)+-dependent enzymes. However, it is suitable for all other cofactors, with difficulties, for some of them, originated by very tight binding. In the case of cofactors covalently bound to the enzyme, the competition between the natural cofactor and the cofactor scaffold mimic can only occur during enzyme folding. Key words: Cofactor, Enzyme, Coenzyme, Chemogenomics, Enzyme inhibitor, Coenzyme domain, Catalysis, Protein structure
1. Introduction Chemogenomics aims at mining the chemical space for the identification of interactions between chemical compounds and proteins that, in turn, affect protein function (1). This approach may lead either to identify new proteins or to discover compounds that interfere with biological processes, eventually associated with diseases. A key feature of the chemogenomics approach is the observation that a class of molecules can bind “similar” proteins, suggesting that the identification of ligands for a target can be helpful in the determination of ligands for targets that share some structural or functional feature (2). A compound well profiled for a particular target provides an excellent starting point for Edgar Jacoby (ed.), Chemogenomics, Methods in Molecular Biology, vol. 575 DOI 10.1007/978-1-60761-274-2_4, © Humana Press, a part of Springer Science + Business Media, LLC 2009
93
94
Singh and Mozzarelli
the development of its neighbors in genome space and, possibly, for the subsequent development of drug candidates for related proteins. As a result, the classification of binding pockets based on recognition patterns, active site descriptors, and ligand pharmacophores links the genome/proteome space to the chemical space (3). The chemogenomics approach is particularly powerful when applied to class of proteins that share the same ligands. Therefore, it is not surprising that chemogenomics has been applied to kinases that bind ATP (4), proteases that cleave polypeptide chains (2), GPCRs that bind hormones (5, 6), and oxidoreductases that bind redox coenzymes (7). The former three protein classes are discussed in other chapters. In particular, ATP and ATP analogs have been extensively exploited given the biological involvement of kinases in many diseases and their pharmacological relevance (4). In the present chapter, we will focus on cofactor-binding proteins. A cofactor is a chemical species bound to an enzyme assisting it in performing catalysis. An enzyme without the cofactor is called apoenzyme and is inactive, and an enzyme with bound cofactor is called holoenzyme and is fully active. A cofactor can be a water molecule, a metal ion, and an organic compound. We will only report on chemogenomics studies on organic cofactors, such as coenzymes and prosthetic groups. Coenzymes are the biologically active form of hydrophilic vitamins that bind to the corresponding enzyme with affinities that may vary significantly during the catalytic cycle, even leading to dissociation, whereas prosthetic groups usually are tightly bound to the enzyme. A representative example of a coenzyme-bound enzyme is NAD+-lactate dehydrogenase and of a prosthetic group-bound enzyme is the heme-containing cyclooxygenase 1. The list of coenzymes and prosthetic groups is reported in Table1. The rationale of cofactors chemogenomics is based on the existence for a given class of enzymes of a common binding site for the cofactor, as, for example, the NAD-binding domain in dehydrogenases. This site can be exploited for the design of a library of compounds that, by replacing the natural cofactor in the cofactor domain of dehydrogenases, lead to enzyme inhibition. The ligand-binding specificity can arise from the conjugation of a scaffold bearing structural/chemical feature of the cofactor with a second moiety bearing structural/chemical features defined by the substrate active site that is usually adjacent to the cofactorbinding site. These two structural/functional features will guide the resulting compounds to dock in the enzyme active site. This general strategy might be difficult to apply when the cofactor is tightly bound; thus, the designed compounds should exhibit affinity in the nanomolar or subnanomolar range in order to be able to affect enzyme function. Alternatively, the designed
.
Cofactor Chemogenomics
95
Table 1 Cofactors Vitamins
Coenzyme (abbreviation)
Function
Structure
Thiamin (B1)
Thiaminpyrophosphate (TPP)
Aldehyde two carbons group transfer
Fig. 1m
Riboflavin (B2)
Flavin mono- (FMN) and Flavin adenine dinucleotide (FAD)
Redox with hydride and proton transfer
Fig. 1c,d
Niacin (B3)
Nicotinamide adenine dinucleotide (NAD+)
Redox with hydride transfer
Fig. 1a,b
Pantothenic acid (B5)
Coenzyme A (CoA)
Acyl carrier moiety
Fig. 1h
Pyridoxine (B6)
Pyridoxal 5¢-phosphate (PLP)
Amino acid, amine, and ketoacid modification
Fig. 1i–l
CO2 transfer
Fig. 1s
Biotin (B7) Folate (B9)
Tetrahydrofolate
One-carbon transfer
Fig. 1e
Cobalamin (B12)
Adenosylcobalamin and methylcobalamin
Alkyl/hydride group transfer
Fig. 1u
Heme
Redox
Fig. 1n,o
Lipoamide
Acyl transfer
Fig. 1q
S-adenosylmethionine
Methyl transfer
Fig. 1p
Prosthetic groups
compound can bind to the enzyme during folding. As a result, chemogenomics and chemogenomics-oriented studies have been applied to cofactors that are loosely bound to the enzymes, at some stage of the catalytic cycle, and, therefore, can be displaced by a properly designed compound. NAD(P)+ chemogenomics is reported first as, up to now, it is the only cofactor for which this approach has been successfully applied.
2. NAD(P)+ NAD(P)+ (Fig. 1a) and the reduced form NAD(P)H (Fig. 1b) are the coenzymes of oxidoreductases, enzymes that catalyze the oxidation/reduction of the substrates. The general reaction scheme is:
96
Singh and Mozzarelli
Fig. 1. Chemical structure of cofactors (a) NAD(P)+ and (b) NADH(P), with R = H is NAD+ or NADH, and R = P is NADP+ or NADPH, (c) Flavin mononucleotide (FMN), (d) Flavin adenine dinucleotide (FAD), (e) Tetrahydrofolate, (f) 10-formyltetrahydrofolic acid, (g) 5–10 methylenetetrahydrofolic acid,
.
Cofactor Chemogenomics
97
Fig. 1. (continued) (h) Pantothenate, (i) Pyridoxine, (j) Pyridoxal 5¢-phosphate, (k) pyridoamine 5¢-phosphate, (l) Schiff base between PLP and lysine in the active site forming the internal aldimine, (m) Thiamine pyrophosphate, (n) Iron-porphirin, (o) Protoporphirin IX,
98
Singh and Mozzarelli
Fig. 1. (continued) (p) S-adenosyl methionine, (q) Lipoamide, (r) Lipoamide covalently bound to an enzyme via a carbamide bond, (s) Biotin, (t) Biotin bound to an enzyme via a carboamide bond, (u) Cobalamine derivatives 5¢-deoxyadenosylcobalamin and methylcobalamin.
.
Cofactor Chemogenomics
99
NAD(P)+ + reduced substrate ¤ NAD(P)H E
+ oxidized product + H + The reaction involves the hydride transfer from the substrate to the pyridine C-4 position of NAD(P) +. This transfer is usually stereospecific, being the oxidoreductase either anti or syn, depending on the rotation by 180° of the nicotinamide ring with respect to the ribose moiety. During the catalytic cycle, when formed, NAD(P)H dissociates and is replaced by an incoming NAD(P)+ indicating that NAD(P)H exhibits a weaker enzyme affinity. An oxidoreductase usually consists of two domains, a coenzyme-binding domain, like the Rossmann fold (8, 9), and an adjacent catalytic domain where the substrate binds (Fig. 2). Sem and colleagues used a system-based design approach for identifying specific inhibitors for multiple oxidoreductases (7, 10–12). First, a cluster analysis was performed on cofactors extracted from 288 oxidoreductase crystal structures. Oxidoreductases were classified into 11 subfamilies, termed pharmacofamilies that were related by cofactor geometry, protein sequence, and protein fold. This implies some common features in the cofactor-binding site within each pharmacofamily. As a first attempt for the generation of both general and specific ligands for oxidoreductases, pharmacofamilies 1 and 2 were selected as they are the most populated, both possessing a domain Rossmann fold, with the nicotinamide ring in the anti and syn geometry, respectively.
Fig. 2. Three-dimensional structure of M. tuberculosis dihydropicolinate reductase consisting of the Rossmann-fold domain with bound NAD (stick representation) and the catalytic domain with bound the substrate pyridine-2,6-dicarboxylic acid (stick representation) (100).
100
Singh and Mozzarelli
The inhibitor design strategy parallels the modular design of the oxidoreductase gene family (11) and produces inhibitors across a pharmacofamily(7). The procedure starts by identifying a small molecule that binds to the common ligand site (a common ligand mimic or CLM) for this class of enzymes. CLM candidates are selected computationally by matching the pharmacophore properties of nicotinamide mononucleotide portion of NADH cofactor bound to dihydrodipicolinate reductase (DHPR), an oxidoreductase in pharmacofamily 1, essential for cell wall synthesis in Mycobacterium tuberculosis(13). This ligandbased search employed the icosahedral matching algorithm (14), contained within the THREEDOM software package to identify potential inhibitors. These compounds were tested for binding potency using steady-state kinetic inhibition of DHPR and other dehydrogenases belonging to the same pharmacofamily. A privileged cofactor scaffold CLM is shown in (Fig. 3), with the linker that allows to expand the compound and introduce the specificity ligand (SL). The expansion was carried out using an NMR-based binding site method (NMR SOLVE) to determine where to insert a combinatorial library in order to direct diversity elements into the adjacent substrate site. The NMR SOLVE method (11, 15) maps a binding site relative to a reference ligand, such as the cofactor, and then characterizes the binding mode of a novel ligand, such as a CLM relative to the reference ligand. Key information obtained with NMR SOLVE is where a linker should be placed and which chemical diversity elements can be attached and directed into an adjacent specificity pocket. Although the geometric relationship of the CLM and SL sites is conserved in oxidoreductases, the actual size and electrostatic properties of the SL-binding site will vary in a way that parallels the diversity of substrates used by oxidoreductases. The diversity elements attached to the conserved CLM scaffold were matched to the properties of substrates used throughout the oxidoreductase gene family. Three hundred diversity elements were selected and chemically joined to the CLM-linker construct. The resulting biligand library was then screened against three Rossmann-fold
Fig. 3. CLM (common ligand mimic) with linker to SL (substrate ligand) is prepared by computationally matching the pharmacophore properties of the nicotinamide ring of NADH bound to dihydrodipicolinate reductase (DHPR) (11).
.
Cofactor Chemogenomics
101
enzymes in pharmacofamilies 1 and 2: DHPR, lactate dehydrogenase, and 1-deoxy-D-xylulose-5-phosphate reductoisomerase. It was found that the CLM expansion to include the SL increases, in some cases, the affinity by 1,000-fold (from 55 mM to 42 nM) (7). This study demonstrates that a biligand collection of sufficient size and diversity, built with an appropriately chosen CLM and well-placed linkers is able to produce nM inhibitors for most members of a pharmacofamily. In a very recent paper (12), targets in M. tuberculosis and antitargets in human liver cells were fished using a catechol-rhodamine privileged biligand scaffold, generated from the aforementioned studies. This work consists of three parts: (a) assessment of ligand uptake in E. coli cells as a test for the capability of crossing bacteria walls and in vivo protein labeling with fluorescent biligand conjugated to N-hydroxysuccinamide (NHS) to introduce a moiety reacting with amine residues; (b) isolation of targets and antitargets by catechol-rhodamine functionalized affinity chromatography, and (c) identification of targets and antitargets by SDS gel electrophoresis and nanospray LC/MS/MS. Collected MS